hepat
diseas
often
treatabl
predict
prognosi
definit
diagnosi
made
mani
complex
function
liver
reflect
multitud
pathophysiolog
derang
occur
hepat
diseas
understand
derang
necessari
accur
interpret
laboratori
test
make
clinic
decis
regard
diagnost
test
determin
manag
patient
brief
discuss
import
pathophysiolog
abnorm
includ
begin
chapter
recent
advanc
noninvas
imag
liver
biopsi
method
made
hepat
biopsi
routin
essenti
tool
manag
patient
hepat
diseas
lead
definit
diagnosi
allow
clinician
make
appropri
decis
regard
manag
hepatobiliari
excret
bilirubin
requir
adequ
uptak
conjug
secret
hepatocyt
hepat
failur
lead
hyperbilirubinemia
icteru
bilirubin
form
primarili
breakdown
product
red
blood
cell
hemoprotein
enzym
cytochrom
red
blood
cell
finit
life
span
usual
day
dog
day
cat
remov
circul
bodi
reticuloendotheli
system
especi
spleen
liver
kupffer
cell
liver
senesc
red
blood
cell
degrad
free
hemoglobin
similarli
circul
hemoglobin
bound
sever
carrier
protein
phagocyt
kupffer
cell
enzym
heme
oxygenas
catabol
hemoglobin
biliverdin
convert
bilirubin
enzym
biliverdin
reductas
lipidsolubl
free
bilirubin
cross
cell
membran
releas
circul
bound
albumin
circul
complex
term
unconjug
indirect
bilirubin
eventu
activ
taken
hepatocyt
bilirubin
bound
intracellular
carrier
protein
undergo
conjug
primarili
glucuronid
conjug
bilirubin
also
call
direct
bilirubin
secret
bile
canaliculu
transport
gallbladd
storag
must
consider
hepatocellular
diseas
increas
bilirubin
load
hemolysi
result
hyperbilirubinemia
liver
reserv
capac
bilirubin
process
time
normal
bilirubin
load
therefor
serum
bilirubin
concentr
insensit
indic
hepatocellular
function
increas
sever
hepatocellular
diseas
gener
total
bilirubin
concentr
mgdl
detect
clinic
jaundic
wherea
concentr
mgdl
result
abnorm
bilirubinuria
spun
serum
plasma
visibl
icter
unconjug
bilirubin
circul
plasma
bound
albumin
undergo
glomerular
filtrat
appear
urin
unless
coexist
glomerular
diseas
conjug
bilirubin
howev
freeli
filter
appear
urin
readili
detect
urin
dipstick
dog
low
renal
threshold
conjug
bilirubin
excret
thu
urin
concentr
bilirubin
increas
far
readili
plasma
concentr
normal
find
small
amount
bilirubin
urin
dog
especi
concentr
sampl
therefor
must
consider
increas
bilirubin
load
increas
plasma
concentr
slight
elev
plasma
bilirubin
signific
suggest
hepatobiliari
diseas
cat
renal
threshold
much
higher
find
degre
bilirubinuria
alway
abnorm
renal
tubular
cell
dog
also
possess
limit
abil
convert
hemoglobin
unconjug
bilirubin
appear
urin
thu
account
bilirubinuria
occur
hemolyt
diseas
hyperbilirubinemia
categor
prehepat
intrahepat
posthepat
caus
prehepat
hyperbilirubinemia
occur
product
exce
liver
capac
metabol
secret
caus
includ
immunemedi
hemolyt
anemia
heavi
metal
toxic
lead
copper
methylen
blue
toxic
evid
hemogram
increas
product
bilirubin
notabl
chang
decreas
hematocrit
intrahepat
caus
hyperbilirubinemia
occur
abnorm
hepat
uptak
conjug
secret
bilirubin
hepatocellular
diseas
usual
coexist
impair
bilirubin
uptak
conjug
secret
therefor
usual
mixtur
conjug
unconjug
hyperbilirubinemia
increas
conjug
bilirubin
result
impair
bilirubin
secret
damag
hepatocyt
impair
bile
flow
bile
canaliculi
due
hepatocyt
swell
inflamm
fibrosi
increas
unconjug
bilirubin
result
coexist
impair
hepat
uptak
conjug
deconjug
conjug
bilirubin
lysosom
enzym
releas
injur
hepatocyt
inflammatori
cell
invad
liver
therefor
increas
primarili
unconjug
bilirubin
conjug
bilirubin
mixtur
depend
natur
intrahepat
lesion
intrahepat
extrahepat
biliari
obstruct
caus
posthepat
hyperbilirubinemia
occur
conjug
bilirubin
regurgit
system
circul
primarili
conjug
hyperbilirubinemia
howev
also
concurr
unconjug
hyperbilirubinemia
posthepat
caus
result
deconjug
bilirubin
damag
hepatocyt
lysosom
inflammatori
cell
enzym
bile
hepatotox
cholestasi
result
secondari
hepatocellular
damag
inflamm
conjug
bilirubin
absorb
system
circul
recircul
compet
unconjug
bilirubin
uptak
hepatocyt
caus
extrahepat
biliari
obstruct
list
box
rel
increas
conjug
unconjug
bilirubin
variabl
three
gener
categori
hyperbilirubinemia
therefor
aid
clinician
local
natur
lesion
ultrasonographi
laparoscopi
laparotomi
local
caus
hyperbilirubinemia
deltabilirubin
deltabilirubin
novel
form
bilirubin
first
notic
sum
conjug
unconjug
bilirubin
less
total
bilirubin
concentr
measur
highperform
liquid
chromatographi
differ
attribut
conjug
bilirubin
coval
bound
albumin
subsequ
call
deltabilirubin
form
bilirubin
mainli
seen
cholestat
hepat
diseas
life
span
deltabilirubin
depend
halflif
albumin
approxim
day
strong
coval
bond
albumin
deltabilirubin
appear
urin
signific
hepatocellular
uptak
thu
featur
long
halflif
albumin
deltabilirubin
remain
elev
even
cholestasi
complet
resolv
mark
variabl
amount
deltabilirubin
among
dog
explain
persist
elev
total
bilirubin
concentr
clinic
icteru
follow
surgic
correct
biliari
obstruct
patient
find
increas
total
bilirubin
concentr
without
concurr
hyperbilirubinuria
suggest
presenc
deltabilirubin
exclud
artifact
patient
resolut
bilirubinuria
may
best
marker
resolut
cholestasi
bile
compos
bile
acid
salt
bile
pigment
primarili
bilirubin
cholesterol
phospholipid
primarili
lecithin
hepat
enzym
alkalin
phosphatas
bile
acid
abund
major
solut
bile
constitut
three
fourth
total
solid
synthes
liver
result
cholesterol
metabol
secret
bile
feed
normal
stimulu
bile
acid
secret
enter
intestin
undergo
effici
enterohepat
circul
follow
passiv
activ
absorpt
ileum
unalt
bile
acid
deconjug
dehydroxyl
intestin
bacteria
reabsorb
enter
enterohepat
circul
effici
remov
liver
reconjug
necessari
resecret
bile
hepatocellular
uptak
highli
effici
process
larg
excess
capac
oper
far
satur
physiolog
condit
typic
meal
total
bile
acid
pool
recycl
two
three
time
enterohepat
pathway
small
amount
bile
acid
lost
fece
normal
liver
synthes
enough
bile
acid
compens
fecal
loss
minim
respect
total
bile
acid
pool
although
bile
acid
format
depend
hepat
synthesi
liver
reserv
capac
never
exceed
small
amount
need
physiolog
purpos
fecal
loss
bile
acid
repres
major
pathway
cholesterol
excret
bodi
addit
role
lipid
absorpt
bile
acid
also
stimul
pancreat
enzym
releas
activ
factor
import
govern
bile
acid
metabol
includ
hepat
function
portal
blood
suppli
small
intestin
intestin
bacteria
dietari
factor
pathophysiolog
effect
bile
acid
hepatotox
gastric
hyperacid
diarrhea
abnorm
hepat
function
biliari
excret
portal
circul
interrupt
normal
enterohepat
circul
lead
increas
serum
bile
acid
concentr
occur
mani
hepatobiliari
diseas
liver
parenchyma
diseas
inabl
normal
uptak
conjug
secret
result
decreas
extract
bile
acid
portal
circul
lead
increas
system
concentr
intrahepat
posthepat
cholestasi
bile
acid
diffus
bile
system
circul
manner
similar
bilirubin
portosystem
shunt
either
congenit
acquir
enterohepat
circul
directli
interrupt
bile
acid
fail
extract
bypass
liver
set
hepat
synthesi
bile
acid
continu
order
maintain
normal
bile
acid
pool
result
tremend
increas
system
concentr
especi
follow
feed
discuss
section
laboratori
evalu
hepat
diseas
serum
bile
acid
concentr
repres
sensit
indic
hepat
function
albumin
import
protein
synthes
liver
import
mani
homeostat
function
mainten
plasma
colloid
oncot
pressur
plasma
transport
carrier
mani
electrolyt
hormon
pigment
drug
albumin
repres
approxim
protein
synthes
liver
albumin
rel
high
prioriti
synthesi
synthesi
protein
decreas
albumin
hepatocellular
diseas
proteincalori
malnutrit
albumin
concentr
decreas
sever
hepat
diseas
decreas
synthesi
ammonia
elev
hepat
diseas
inhibit
albumin
releas
hepatocyt
addit
abnorm
insulin
glucagon
concentr
occur
hepat
diseas
also
result
inhibit
albumin
releas
hepatocyt
also
ascit
present
increas
volum
distribut
albumin
liver
respons
synthes
mani
clot
factor
includ
factor
ii
v
vii
ix
x
liver
also
synthes
activ
inhibitor
fibrinolyt
system
antiplasmin
addit
liver
involv
synthesi
catabol
clearanc
procoagul
anticoagul
antithrombin
iii
fibrin
degrad
product
plasminogen
activ
hepat
diseas
derang
process
lead
varieti
hemostat
abnorm
caus
coagulopathi
associ
hepat
diseas
list
box
although
spontan
bleed
patient
hepat
diseas
unusu
excess
bleed
follow
surgic
trauma
liver
biopsi
may
occur
clinic
case
hepat
diseas
may
multipl
abnorm
hemostat
test
prothrombin
time
partial
thromboplastin
time
activ
clot
time
prolong
hepat
failur
lack
synthesi
clot
factor
usual
occur
massiv
acut
hepat
necrosi
cirrhosi
publish
studi
dog
chronic
hepat
die
within
week
present
significantli
prolong
prothrombin
partial
thromboplastin
time
compar
dog
surviv
decreas
absorpt
fatsolubl
vitamin
k
lead
prolong
clot
time
cofactor
necessari
hepat
synthesi
activ
factor
ii
vii
ix
x
chronic
biliari
obstruct
caus
vitamin
k
malabsorpt
howev
intestin
bacteria
synthes
vitamin
k
make
defici
vitamin
less
common
caus
bleed
hepat
diseas
unless
use
longterm
intestin
antibiot
decreas
bacteri
vitamin
k
synthesi
clot
time
prolong
administr
parenter
vitamin
k
follow
normal
clot
time
within
hour
confirm
vitamin
k
defici
contributor
coagulopathi
recent
report
studi
dog
cat
use
pivka
test
protein
induc
vitamin
k
antagonismabs
suggest
test
sensit
detect
coagulopathi
patient
hepat
diseas
studi
pivka
test
twice
sensit
detect
coagulopathi
dog
three
time
sensit
detect
coagulopathi
cat
compar
routin
coagul
test
prothrombin
time
activ
partial
thromboplastin
time
vitamin
k
administr
may
help
certain
situat
one
report
vitamin
k
administr
improv
pivka
time
dog
hepat
diseas
normal
pivka
time
cat
experi
bleed
follow
hepat
biopsi
correl
coagul
find
decreas
synthesi
clot
factor
dissemin
intravascular
coagul
dic
decreas
antithrombin
iii
synthesi
excess
fibrinolysi
decreas
antiplasmin
synthesi
decreas
clearanc
plasminogen
activ
circul
anticoagul
normal
remov
liver
remain
elev
fibrin
degrad
product
fdp
decreas
vitamin
k
avail
increas
tissu
thromboplastin
massiv
hepat
destruct
abnorm
platelet
function
box
includ
pivka
test
patient
coagulopathi
like
bleed
patient
without
coagulopathi
case
signific
bleed
follow
hepat
biopsi
technic
problem
experi
rapid
bleed
andor
necropsi
examin
suggest
larg
vessel
damag
rather
hemorrhag
due
persist
ooz
needl
biopsi
site
except
patient
dissemin
intravascular
coagul
dic
often
signific
hemorrhag
regardless
biopsi
techniqu
use
control
studi
veterinari
patient
necessari
make
final
conclus
regard
postbiopsi
hemorrhag
patient
coagulopathi
dic
common
coagulopathi
occur
hepat
diseas
experi
one
like
result
hemorrhag
follow
hepat
biopsi
thrombosi
hemorrhag
potenti
sequella
dic
dic
result
decreas
hepat
synthesi
antithrombin
iii
decreas
clearanc
activ
clot
factor
increas
releas
tissu
thromboplastin
associ
massiv
hepat
destruct
mechan
may
complic
event
lead
excess
fibrinolysi
latter
situat
occur
excess
activ
fibrinolyt
enzym
plasmin
occur
increas
plasminogen
activ
decreas
antiplasmin
concentr
net
result
excess
fibrinolysi
format
fibrin
degrad
product
fdp
potent
anticoagul
effect
clear
effici
diseas
liver
laboratori
test
result
suggest
presenc
dic
includ
prolong
prothrombin
partial
thromboplastin
thrombin
time
thrombocytopenia
elev
fdp
hypofibrinogenemia
schistocytosi
abnorm
platelet
function
also
occur
hepat
diseas
defect
may
evalu
platelet
aggreg
studi
studi
routin
perform
clinic
patient
lack
equip
avail
platelet
function
defect
may
explain
bleed
tendenc
patient
normal
coagul
test
platelet
function
estim
evalu
toenail
lip
bleed
time
spontan
hemorrhag
unusu
hepat
diseas
except
gastrointestin
gi
hemorrhag
latter
result
increas
gastrin
concentr
due
decreas
hepat
clearanc
gastrin
increas
gastrin
releas
stimul
elev
bile
acid
concentr
caus
increas
gastric
acid
product
addit
dic
lead
abnorm
gi
mucos
microcircul
due
microthrombi
format
thu
decreas
abil
mucosa
withstand
injuri
one
consequ
gi
hemorrhag
exacerb
hepat
encephalopathi
blood
substrat
ammonia
product
larg
intestin
addit
gi
hemorrhag
result
partial
deplet
clot
factor
reduc
hepat
biopsi
massiv
prolong
bleed
result
evalu
patient
hepat
diseas
hemostat
abnorm
clinician
must
awar
rel
insensit
clot
time
time
prolong
coagul
factor
reduc
normal
addit
multipl
defect
may
present
detect
routin
coagul
test
abnorm
platelet
function
excess
fibrinolysi
sudden
demand
clot
factor
would
occur
follow
hepat
biopsi
laparotomi
may
precipit
massiv
prolong
hemorrhag
patient
normal
coagul
test
result
exact
natur
defect
often
unknown
multifactori
treatment
fresh
whole
blood
collect
plastic
blood
collect
bag
preserv
platelet
activ
prevent
activ
factor
xii
usual
indic
treat
patient
possibl
effort
taken
hepat
biopsi
correct
known
coagulopathi
ammonia
long
consid
one
import
encephalopath
toxin
patient
hepat
diseas
import
sourc
ammonia
larg
intestin
intralumin
bacteria
convert
protein
nitrogencontain
compound
ammonia
ammonia
absorb
portal
circul
liver
normal
extract
convert
urea
via
urea
cycl
hepat
failur
result
increas
blood
ammonia
decreas
blood
urea
nitrogen
bun
concentr
gramneg
enter
bacteria
quantit
import
organ
convert
nitrogen
substrat
ammonia
although
certain
anaerob
also
capabl
synthes
ammonia
dietari
protein
import
substrat
ammonia
product
substrat
urea
freeli
diffus
system
circul
colon
slough
intestin
epitheli
cell
gi
hemorrhag
also
quantit
import
therefor
reduct
substrat
larg
intestin
bacteri
number
benefici
effect
ammonia
absorpt
treatment
measur
use
decreas
ammonia
absorpt
discuss
section
manag
hepat
diseas
portal
blood
dog
normal
contain
approxim
ammonia
doubl
cat
higher
dietari
protein
content
speci
liver
normal
abl
extract
approxim
result
system
venou
ammonia
concentr
approxim
liver
larg
capac
ammonia
remov
must
consider
hepat
dysfunct
abnorm
portal
circul
rais
system
plasma
concentr
normal
liver
toler
twice
normal
ammonia
load
degre
toler
sensit
indic
hepat
function
use
clinic
perform
ammonia
toler
test
hepat
encephalopathi
defin
clinic
syndrom
character
abnorm
mental
statu
occur
patient
sever
hepat
insuffici
result
primari
hepatocellular
diseas
portosystem
shunt
blood
away
liver
clinic
sign
patient
condit
includ
wide
varieti
behavior
chang
rang
mild
depress
anorexia
coma
mani
sign
nonspecif
seen
wide
varieti
unrel
disordersthes
includ
depress
anorexia
vomit
diarrhea
polydipsia
polyuria
neurolog
sign
also
common
sign
variabl
often
local
specif
anatom
lesion
occur
natur
neurolog
abnorm
vari
time
hepat
encephalopathi
consid
caus
common
neurolog
manifest
decreas
mentat
respons
often
patient
appear
confus
compuls
pace
wander
appear
transient
blind
patient
abnorm
pattern
urin
defec
appear
longer
housebroken
sign
progress
includ
seizur
sever
dementia
coma
sever
sign
often
wax
wane
sometim
respons
feed
alway
correl
sever
hepat
lesion
sever
factor
implic
contribut
hepat
encephalopathi
factor
relat
accumul
neurotox
substanc
metabol
properli
liver
includ
ammonia
benzodiazepinelik
substanc
amino
acid
mercaptan
fatti
acid
caus
includ
chang
bloodbrain
barrier
abnorm
neurotransmitt
balanc
abnorm
cerebr
metabol
metabol
abnorm
experiment
clinic
evid
hepat
encephalopathi
multifactori
concentr
ammonia
mercaptan
free
fatti
acid
necessari
produc
coma
individu
much
higher
one
elev
mercaptan
free
fatti
acid
increas
ammonia
concentr
likewis
hyperammonemia
contribut
amino
acid
imbal
addit
synergist
effect
encephalopath
toxin
metabol
derang
augment
effect
chang
includ
azotemia
hypoxia
electrolyt
imbal
hypoglycemia
tranquil
alkalosi
hypovolemia
patient
derang
like
develop
encephalopathi
correct
derang
significantli
improv
encephalopath
state
exampl
hypokalemia
frequent
accompani
hepat
failur
one
common
metabol
derang
contribut
depress
anorexiawith
potassium
supplement
often
dramat
clinic
improv
appetit
attitud
factor
precipit
metabol
chang
lead
encephalopathi
includ
increas
dietari
protein
intak
gi
hemorrhag
diuret
administr
sed
administr
uremia
infect
constip
larg
intestin
bacteri
overgrowth
methionin
administr
import
synergist
effect
multipl
interact
encephalopath
factor
help
explain
differ
clinic
present
sever
encephalopathi
vari
blood
concentr
encephalopath
toxin
also
explain
occurr
encephalopathi
absenc
strike
abnorm
singl
factor
includ
ammonia
concentr
therapeut
manipul
factor
repres
cornerston
symptomat
manag
hepat
encephalopathi
discuss
section
manag
hepat
diseas
ascit
accumul
free
fluid
periton
caviti
common
sign
hepat
diseas
occur
result
chronic
portal
hypertens
hypoalbuminemia
increas
renal
salt
water
retent
develop
ascit
occur
alter
starl
forc
includ
increas
venou
lymphat
hydrostat
pressur
decreas
capillari
oncot
pressur
increas
vascular
permeabl
increas
intraperiton
oncot
pressur
portal
hypertens
one
import
factor
lead
develop
ascit
patient
hepat
diseas
portal
hypertens
caus
increas
total
portal
blood
flow
increas
resist
portal
intrahepat
posthepat
blood
flow
combin
chang
common
caus
portal
hypertens
cirrhosi
result
increas
resist
sinusoid
vessel
caus
swell
hepatocyt
fibrosi
around
sinusoid
caus
postsinusoid
outflow
block
combin
increas
portal
pressur
blood
flow
caus
increas
hepat
lymph
formationwhen
excess
ascit
result
anoth
common
effect
chronic
portal
hypertens
develop
acquir
portosystem
shunt
unlik
congenit
portosystem
shunt
acquir
shunt
usual
multipl
extrem
tortuou
variabl
locat
formerli
thought
portal
hypertens
hypoalbuminemia
initi
ascit
format
result
decreas
effect
circul
plasma
volum
compensatori
respons
renal
conserv
fluid
electrolyt
mediat
chang
renal
blood
flow
glomerular
filtrat
rate
activ
reninangiotensinaldosteron
axi
retent
salt
water
perpetu
problem
lead
increas
splanchnic
lymph
portal
blood
flow
howev
recent
evid
contradict
theori
suggest
renal
mechan
lead
retent
water
electrolyt
primari
initi
event
format
ascit
hepat
diseas
set
renal
salt
water
retent
develop
ascit
thu
expand
circul
plasma
volum
contribut
develop
portal
hypertens
eventu
portal
hypertens
lead
develop
ascit
hypoalbuminemia
continu
perpetu
factor
may
initi
renal
salt
water
retent
includ
increas
sensit
aldosteron
failur
releas
respond
natriuret
hormon
respons
expand
circul
plasma
volum
latter
situat
result
inabl
excret
salt
water
load
respons
volum
expans
addit
normal
neg
feedback
system
govern
reninangiotensinaldosteron
system
shut
reduc
aldosteron
secret
presenc
portal
hypertens
ascit
high
concentr
aldosteron
return
effect
circul
plasma
volum
normal
presenc
ascit
despit
retent
sodium
mechan
therapeut
intervent
manag
ascit
includ
salt
restrict
inhibit
reninangiotensinaldosteron
axi
drug
spironolacton
enalapril
benazepril
discuss
section
manag
hepat
diseas
presenc
ascit
act
increas
albumin
volum
distribut
lower
blood
albumin
concentr
lower
plasma
oncot
pressur
exacerb
format
ascit
fluid
presenc
portal
hypertens
necessari
develop
ascit
leakag
albumin
abdomin
caviti
set
ascit
present
plasma
albumin
concentr
higher
ascit
attribut
hypoalbuminemia
alon
normal
portal
pressur
plasma
albumin
concentr
must
approxim
gdl
result
ascit
occur
gi
renal
protein
loss
occur
subcutan
edema
often
predomin
ascit
liver
play
central
role
carbohydr
metabol
primari
organ
glucos
storag
convert
glucos
glycogen
enzym
also
provid
glucos
fast
glycogenolysi
inadequ
store
glycogen
might
occur
hepat
diseas
glucos
need
suppli
catabol
muscl
protein
amino
acid
convers
glucos
via
gluconeogen
pathway
caus
muscl
wast
increas
nitrogen
load
aggrav
hyperammonemia
import
gluconeogenesi
liver
maintain
blood
glucos
concentr
complet
hepatectomi
rapidli
result
death
hypoglycemia
hepat
failur
result
either
preprandi
hypoglycemia
postprandi
hyperglycemia
loss
approxim
hepat
mass
may
caus
fast
hypoglycemia
inadequ
glycogen
storag
gluconeogenesi
addit
caus
hypoglycemia
includ
congenit
defici
glycogenmetabol
enzym
occur
glycogen
storag
diseas
tumor
hypoglycemia
portosystem
shunt
associ
decreas
hepat
mass
lack
tropic
portal
blood
liver
patient
hypoglycemia
associ
hepat
diseas
usual
easi
get
blood
glucos
concentr
normal
rang
intraven
glucos
supplement
contrast
patient
insulinproduc
tumor
difficult
get
blood
glucos
concentr
normal
rang
despit
aggress
intraven
glucos
administr
caus
postprandi
hyperglycemia
hepat
diseas
includ
defici
hepat
enzym
handl
carbohydr
load
lead
inadequ
glycogenesi
increas
plasma
concentr
glucocorticoid
decreas
hepat
clearanc
fibrinogen
protein
synthes
liver
synthesi
fibrinogen
diminish
late
stage
sever
hepat
failur
factor
usual
import
determin
fibrinogen
concentr
rate
hepat
synthesi
factor
commonli
lead
decreas
fibrinogen
concentr
includ
increas
fibrinogen
consumpt
occur
dic
primari
fibrinolysi
factor
result
increas
fibrinogen
concentr
includ
inflammatori
diseas
involv
involv
liver
major
surgeri
set
increas
synthesi
releas
hepatocyt
microsom
enzym
system
liver
import
drug
hormon
metabol
hepat
failur
result
abnorm
delay
drug
metabol
clearanc
addit
drug
highli
protein
bound
increas
biolog
effect
hypoalbuminemia
associ
hepat
diseas
set
less
albumin
bind
drug
therefor
unbound
activ
drug
exert
effect
therefor
drug
undergo
hepat
clearanc
highli
protein
bound
administ
caution
patient
hepat
failur
mani
hormon
metabol
liver
abnorm
elev
hepat
diseas
import
hormon
prolong
clearanc
steroid
hormon
includ
cortisol
estrogen
androgen
progesteron
mani
drug
degre
protein
bind
therefor
concentr
unbound
activ
hormon
alter
hypoalbuminem
state
hormon
undergo
alter
metabol
patient
hepat
diseas
includ
insulin
glucagon
thyroxin
pituitari
hormon
gastrin
aldosteron
mani
alter
discuss
refer
specif
physiolog
effect
reticuloendotheli
system
re
remov
toxic
foreign
substanc
cellular
debri
bacteria
drug
endotoxin
blood
hepat
re
import
rest
bodi
appropri
process
materi
primari
hepatocellular
diseas
portosystem
shunt
either
congenit
acquir
caus
failur
hepat
re
hepat
diseas
tissu
re
activ
partial
compens
diminish
hepat
re
function
defici
specif
role
hepat
re
function
lead
characterist
chang
re
tissu
compens
liver
directli
respons
clear
absorb
gi
product
pass
liver
gain
access
system
circul
product
includ
intestin
bacteria
endotoxin
gi
mucos
antigen
effect
decreas
clearanc
gi
product
system
access
bacteria
toxin
result
potenti
sepsi
andor
endotoxemia
addit
posit
bacteri
growth
hepat
biopsi
specimen
even
underli
caus
chapter
hepat
diseas
bacteri
origin
experi
unusu
cultur
escherichia
coli
enter
bacteria
hepat
biopsi
specimen
obtain
patient
variou
hepat
diseas
one
consequ
abnorm
exposur
gi
antigen
system
circul
develop
hyperglobulinemia
immunoglobulin
produc
nonhepat
tissu
respons
system
antigen
load
anoth
potenti
sourc
hyperglobulinemia
occur
hepat
diseas
releas
antigen
injur
hepatocyt
mani
intracellular
structur
hepatocyt
especi
nucleu
mitochondria
recogn
foreign
elicit
immun
respons
character
influx
lymphocyt
plasma
cell
effect
cellular
infiltr
includ
potenti
hepatocyt
damag
thu
perpetu
viciou
cycl
discuss
section
chronic
activ
hepat
addit
plasma
cell
manufactur
gamma
globulin
lead
hyperglobulinemia
mainten
integr
hepatocyt
membran
import
function
insult
damag
cell
membran
lead
loss
intracellular
content
includ
organel
enzym
antigen
addit
loss
intracellular
content
hepatocyt
function
may
compromis
loss
intracellular
enzym
except
certain
proteas
lead
abnorm
function
clinic
sign
use
laboratori
test
diagnost
purpos
enzym
leak
plasma
follow
increas
hepatocellular
membran
permeabl
includ
alanin
aminotransferas
alt
formerli
glutamicpyruv
transaminas
gpt
aspart
aminotransferas
ast
formerli
glutamicoxaloacet
transaminas
got
arginas
sorbitol
dehydrogenas
sdh
lactic
dehydrogenas
ldh
ornithin
carbamoyltransferas
oct
enzym
activ
increas
biliari
obstruct
includ
alkalin
phosphatas
alp
gamma
glutamyl
transpeptidas
ggt
histor
find
patient
hepat
diseas
often
vagu
nonspecif
patient
toxic
hepatopathi
may
histori
exposur
known
hepatotoxin
includ
corticosteroid
anticonvuls
thiacetarsemid
mebendazol
acetaminophen
certain
chemic
clinic
sign
associ
hepat
diseas
list
box
common
sign
cat
hepat
diseas
nonspecif
includ
lethargi
inappet
patient
manifest
neurolog
sign
sign
may
precipit
eat
especi
highprotein
meal
thu
suggest
hepat
encephalopathi
caus
histor
find
often
absent
howev
even
sever
case
hepat
failur
includ
termin
hepat
cirrhosi
portosystem
shunt
presenc
sign
laboratori
abnorm
suggest
hepat
diseas
certain
breed
may
suggest
diseas
breed
predispos
copperstorag
diseas
bedlington
terrier
west
highland
white
terrier
possibl
doberman
pinscher
physic
examin
find
patient
hepat
diseas
often
variabl
nonspecif
find
suggest
hepat
diseas
includ
icteru
ascit
abnorm
hepat
size
howev
sign
may
seen
diseas
unrel
liver
prehepat
caus
increas
bilirubin
concentr
immunemedi
hemolyt
anemia
result
icteru
jaundic
presenc
icteru
patient
without
anemia
diagnost
hepat
posthepat
biliari
diseas
clinic
manifest
icteru
usual
occur
serum
total
bilirubin
concentr
reach
mgdl
although
vari
individu
mucou
membran
skin
appear
yellow
lower
serum
bilirubin
concentr
present
conjug
state
sclera
soft
palat
area
tongu
peni
usual
sensit
area
look
icteru
magnitud
elev
bilirubin
concentr
alway
correl
intens
icteru
observ
physic
examin
likewis
take
sever
day
icteru
resolv
follow
return
serum
bilirubin
normal
especi
true
follow
resolut
biliari
obstruct
due
presenc
persist
deltabilirubin
see
earlier
section
pathophysiolog
derang
occur
hepat
diseas
portal
hypertens
hypoalbuminemia
renal
retent
salt
water
caus
ascit
patient
hepat
diseas
import
consid
caus
ascit
differenti
diagnosi
includ
rightsid
heart
failur
pericardi
diseas
hypoalbuminemia
result
nonhepat
caus
abdomin
neoplasia
heartworm
diseas
pancreat
increas
lymphat
vascular
permeabl
certain
infecti
diseas
felin
infecti
periton
abdomin
abscess
presenc
ascit
confirm
radiographi
ultrasonographi
abdomin
paracentesi
subsequ
fluid
analysi
help
rule
mani
disord
mention
hepatomegali
may
detect
physic
examin
normal
small
hepat
size
palpat
caus
increas
hepat
size
includ
neoplasia
passiv
congest
secondari
rightsid
heart
failur
increas
corticosteroid
concentr
exogen
endogen
lipid
accumul
diabet
mellitu
felin
hepat
lipidosi
metabol
abnorm
diffus
inflamm
glycogen
storag
diseas
hepat
abscess
hepat
biliari
cyst
liver
lobe
torsion
puppi
kitten
normal
larger
liver
rel
bodi
size
adult
caus
decreas
hepat
size
includ
portosystem
shunt
congenit
acquir
cirrhosi
hepat
necrosi
appar
decreas
hepat
size
may
also
normal
patient
laboratori
test
often
essenti
identifi
hepat
diseas
exist
assess
sever
monitor
progress
understand
pathophysiolog
hepat
diseas
necessari
interpret
laboratori
test
result
make
clinic
decis
regard
diagnost
effort
patient
manag
laboratori
test
identifi
specif
problem
help
determin
specif
therapeut
manag
predict
outcom
differ
diseas
produc
similar
alter
hepat
function
laboratori
test
result
biochem
test
usual
determin
liver
excretori
function
abil
measur
integr
hepatocyt
virtu
leakag
intracellular
enzym
system
biochem
test
identifi
hepat
diseas
exist
diagnosi
must
pursu
morpholog
diagnosi
obtain
biopsi
specimen
analysi
result
laboratori
test
variou
diseas
state
summar
tabl
mani
biochem
test
avail
evalu
liver
anabol
andor
catabol
function
hepat
circul
includ
measur
serum
bile
acid
concentr
plasma
ammonia
concentr
bile
pigment
bilirubin
concentr
abil
excret
organ
dye
hepat
function
markedli
abnorm
despit
mainten
hepatocellular
membran
therefor
normal
serum
activ
hepat
enzym
exampl
includ
portosystem
shunt
termin
cirrhosi
metastat
hepat
neoplasia
likewis
liver
continu
normal
anabol
catabol
function
despit
sever
hepatocyt
leakag
intracellular
enzym
mark
reserv
capac
exampl
situat
occur
certain
case
hepatocellular
necrosi
primari
hepat
neoplasia
trauma
serum
bile
acid
see
earlier
section
pathophysiolog
derang
occur
hepat
diseas
detail
discuss
normal
bile
acid
metabol
chang
occur
hepat
diseas
briefli
bile
acid
synthes
liver
result
cholesterol
metabol
secret
bile
feed
normal
stimulu
bile
acid
secret
bile
acid
enter
intestin
undergo
effici
enterohepat
circul
follow
activ
absorpt
ileum
absorb
remov
portal
circul
liver
reexcret
bile
typic
meal
total
bile
acid
pool
recycl
two
three
time
enterohepat
pathway
small
amount
bile
acid
lost
fece
normal
liver
synthes
enough
bile
acid
compens
fecal
loss
minim
respect
total
bile
acid
pool
although
bile
acid
format
depend
hepat
synthesi
liver
reserv
capac
never
exceed
small
amount
need
physiolog
purpos
thu
measur
bile
acid
concentr
reliabl
test
even
endstag
liver
diseas
abnorm
hepat
function
biliari
excret
portal
circul
interrupt
normal
enterohepat
circul
thu
lead
increas
serum
bile
acid
concentr
occur
mani
hepatobiliari
diseaseswhen
liver
parenchyma
diseas
abnorm
uptak
conjug
secret
bile
acid
result
decreas
extract
portal
circul
lead
increas
system
concentr
intrahepat
posthepat
cholestasi
bile
acid
diffus
bile
system
circul
manner
similar
bilirubin
portosystem
shunt
either
congenit
acquir
enterohepat
circul
directli
interrupt
bile
acid
fail
extract
bypass
liver
set
hepat
synthesi
bile
acid
continu
order
maintain
normal
bile
acid
pool
result
tremend
increas
system
concentr
especi
follow
feed
solidphas
radioimmunoassay
ria
direct
enzymat
spectrophotometr
method
bile
acid
determin
valid
dog
cat
method
made
serum
bile
acid
determin
routin
part
evalu
hepat
function
laboratori
normal
fast
concentr
approxim
dog
cat
twohour
postprandi
concentr
rise
approxim
dog
cat
serum
stabl
measur
sever
day
room
temperatur
sever
artifact
affect
bile
acid
measur
moder
mark
lipemia
artifactu
increas
serum
bile
acid
measur
determin
enzymat
method
artifactu
decreas
measur
determin
ria
method
moder
mark
hemolysi
artifactu
decreas
serum
bile
acid
valu
determin
enzymat
method
probabl
affect
measur
determin
ria
method
bilirubin
littl
effect
measur
bile
acid
concentr
unless
serum
bilirubin
concentr
greater
mgdl
case
may
small
less
decreas
measur
low
bile
acid
concentr
hyperbilirubinemia
due
hepat
diseas
measur
serum
bile
acid
indic
bile
acid
measur
certain
advantag
test
hepat
function
requir
administr
exogen
compound
sulfobromophthalein
bsp
indocyanin
green
icg
dye
oral
ammonium
chlorid
meticul
sampl
handl
requir
plasma
ammonia
determin
indic
measur
serum
bile
acid
concentr
includ
identif
occult
hepat
diseas
enzym
determin
normal
occur
portosystem
shunt
cirrhosi
metastat
hepat
neoplasia
evalu
possibl
portosystem
shunt
patient
suggest
symptomatolog
monitor
hepatobiliari
function
assess
progress
hepat
diseas
identif
abnorm
hepat
function
patient
enzym
activ
elev
may
due
extrahepat
caus
maxim
diagnost
inform
total
serum
bile
acid
measur
fast
postprandi
sampl
obtain
gener
recommend
normals
meal
fed
howev
minimum
amount
food
consum
establish
patient
weigh
lb
less
fed
minimum
tsp
lb
tbsp
food
high
protein
fat
fed
consist
challeng
bile
acid
enterohepat
circul
postprandi
level
inappet
problem
may
necessari
forcefe
patient
cat
special
step
avoid
anorexigen
stimuli
may
necessari
eg
offer
food
quiet
environ
away
dog
owner
hand
feed
privat
area
warm
food
may
help
coax
inappet
cat
eat
patient
encephalopath
tendenc
concern
feed
highprotein
food
lowprotein
meal
may
fed
vomit
problem
frequenc
preclud
feed
initi
test
limit
fast
sampl
result
normal
signific
hepat
disord
remain
consider
howev
fast
sampl
normal
liver
diseas
rule
sever
studi
shown
serum
bile
acid
measur
sensit
specif
indic
hepat
function
dog
cat
dog
fast
serum
bile
acid
concentr
significantli
increas
congenit
portosystem
shunt
glucocorticoidinduc
hepatopathi
hepat
neoplasia
hepat
cholestasi
hepat
necrosi
cirrhosi
diseas
dog
glucocorticoidinduc
hepatopathi
lowest
increas
concentr
serum
bile
acid
therefor
mark
increas
elev
ie
greater
unlik
caus
glucocorticoidinduc
hepatopathi
although
serum
bile
acid
concentr
sensit
indic
hepat
function
distinguish
caus
diseas
process
magnitud
elev
serum
bile
acid
concentr
weakli
correl
histolog
sever
furthermor
dog
intestin
diseas
normal
hepat
function
normal
serum
bile
acid
concentr
import
case
reactiv
hepatopathi
associ
intestin
pancreat
diseas
determin
postprandi
concentr
increas
sensit
test
diseas
done
routin
conjunct
preprandi
sampl
cat
measur
fast
serum
bile
acid
concentr
specif
approach
bile
acid
concentr
also
sensit
test
felin
hepat
diseas
although
approach
valu
serum
bile
acid
detect
hepat
diseas
also
increas
combin
standard
biochem
test
visa
versa
dog
magnitud
elev
help
differenti
diagnosi
hepatobiliari
diseas
detect
portosystem
shunt
serum
bile
acid
concentr
best
diagnost
accuraci
compar
convent
biochem
test
bsp
excret
sensit
equal
ammonia
toler
test
accuraci
improv
postprandi
bile
acid
concentr
measur
conjunct
preprandi
sampl
summari
serum
bile
acid
concentr
sensit
specif
indic
hepatobiliari
function
hepatoport
circul
clinic
use
tool
diagnosi
disord
serum
bile
acid
concentr
especi
valuabl
anicter
hepat
diseas
conveni
measur
blood
ammonia
concentr
specimen
handl
routin
sensit
bsp
retent
requir
inject
foreign
compound
becom
increasingli
difficult
obtain
laboratori
postprandi
concentr
exceed
dog
cat
diagnost
effort
hepat
biopsi
warrant
plasma
ammonia
ammonia
toler
test
ammonia
metabol
primarili
liver
blood
ammonia
concentr
repres
sensit
test
hepat
function
ammonia
produc
bacteri
action
colon
substrat
dietari
protein
slough
intestin
epitheli
cell
urea
freeli
diffus
colon
plasma
absorb
portal
circul
ammonia
extract
liver
convert
urea
urea
cycl
enzym
pathway
normal
extract
process
effici
small
amount
ammonia
escap
system
circul
concentr
ammonia
portal
vein
approxim
dog
approxim
cat
wherea
normal
concentr
system
circul
approxim
abnorm
hepatocyt
function
abnorm
portal
circul
would
occur
portosystem
shunt
liver
effici
extract
portal
ammonia
system
plasma
level
increas
increas
demand
liver
increas
portal
vein
ammonia
concentr
increas
sensit
plasma
ammonia
concentr
detect
abnorm
hepat
function
done
measur
ammonia
concentr
postprandi
state
administ
oral
rectal
ammonia
load
latter
provoc
test
known
oral
ammonia
toler
test
test
perform
take
rest
plasma
ammonia
sampl
administ
oral
ammonium
chlorid
nh
cl
dosag
mglb
bodi
weight
maximum
dose
g
ammonium
chlorid
avail
chemic
reagent
supplier
main
ingredi
urinari
acidifi
dissolv
ml
tap
water
administ
via
orogastr
tube
flush
ml
water
altern
administ
empti
gelatin
capsul
plasma
sampl
obtain
minut
later
ammonia
measur
rectal
ammonia
toler
test
describ
perform
administ
mllb
bodi
weight
solut
nh
cl
follow
cleans
enema
plasma
sampl
obtain
minut
later
theoret
rectal
administr
advantag
vomit
oral
administ
solut
problem
howev
experi
vomit
follow
oral
nh
cl
administr
rare
clinic
problem
especi
solut
dilut
water
describ
invalid
test
occur
often
caus
vomit
hyperammonemia
therefor
ammonia
measur
diagnost
hepat
failur
normal
patient
littl
increment
plasma
ammonia
concentr
follow
administr
ammonium
chlorid
less
increas
sampl
handl
critic
plasma
ammonia
determin
import
venipunctur
rapid
atraumat
prolong
stasi
blood
result
ammonia
gener
sampl
obtain
must
place
ammoniafre
heparin
tube
immedi
place
ice
bath
centrifug
soon
possibl
within
minut
red
blood
cell
elabor
ammonia
contain
two
three
time
much
ammonia
plasma
sampl
separ
prompt
manner
fals
elev
concentr
result
likewis
hemolysi
result
fals
increas
ammonia
concentr
ideal
sampl
assay
ammonia
soon
possibl
within
hour
elimin
artifact
ammonia
concentr
increas
decreas
storag
thu
yield
unpredict
unreli
result
ammonia
concentr
may
increas
deamin
protein
glutamin
breakdown
adenyl
pyrophosph
andor
adenyl
acid
hydrolysi
ammoniogen
substanc
plasma
ammonia
may
decreas
storag
vapor
loss
main
clinic
use
ammonia
toler
test
detect
patient
portosystem
shunt
assess
hepat
function
anicter
hepat
diseas
especi
hepat
enzym
activ
may
normal
assess
role
ammonia
therefor
hepat
function
patient
encephalopath
sign
test
sensit
measur
serum
bile
acid
concentr
assess
hepat
function
sensit
measur
bsp
excret
ammonia
toler
test
shown
virtual
sensit
detect
portosystem
shunt
wherea
approxim
dog
congenit
portosystem
shunt
normal
rest
ammonia
concentr
normal
bsp
retent
main
limit
need
meticul
sampl
handl
need
determin
perform
soon
obtain
sampl
addit
requir
administr
exogen
compound
nh
cl
rare
instanc
worsen
encephalopathi
induc
hepat
coma
latter
complic
anticip
rest
ammonia
determin
perform
first
need
safeti
nh
cl
administr
determin
routin
use
measur
serum
hepat
enzym
activ
indic
hepat
diseas
made
possibl
autom
biochemistri
profil
must
point
enzym
activ
reflect
hepat
function
reflect
either
integr
hepatocyt
membran
patenc
biliari
system
sever
hepat
dysfunct
occur
face
normal
enzym
activ
wherea
hepat
function
may
near
normal
despit
mark
increas
serum
enzym
activ
therefor
limit
use
hepat
enzym
must
appreci
loss
intracellular
enzym
except
certain
proteas
lead
abnorm
function
clinic
sign
use
laboratori
test
diagnost
purpos
enzym
leak
plasma
follow
increas
hepatocellular
membran
permeabl
includ
alt
ast
sdh
ldh
oct
enzym
activ
increas
biliari
obstruct
includ
alp
ggt
serum
alanin
aminotransferas
serum
alanin
aminotransferas
salt
formerli
serum
glutamicpyruv
transaminas
sgpt
liverspecif
enzym
dog
cat
use
detect
hepatocyt
membran
damag
necrosi
enzym
found
chapter
cytoplasm
serum
activ
increas
increas
permeabl
hepatocyt
membran
result
leakag
hepatocyt
extent
enzym
leakag
occur
depend
sever
number
cell
damag
ie
diffus
lesion
indic
revers
injuri
function
statu
liver
activ
salt
mark
chronic
activ
hepat
primari
hepat
neoplasia
hepat
necrosi
see
tabl
often
normal
mildli
increas
salt
activ
portosystem
shunt
cirrhosi
metastat
neoplasia
rare
case
increas
salt
activ
occur
sever
muscl
diseas
although
activ
salt
usual
parallel
degre
hepatocyt
necrosi
often
poor
correl
serum
enzym
activ
degre
morpholog
chang
light
microscop
level
especi
recoveri
phase
likewis
often
poor
correl
serum
activ
salt
degre
hepatocyt
dysfunct
clinic
sign
exampl
sever
increas
salt
activ
follow
automobil
trauma
certain
toxin
yet
patient
often
show
sign
hepat
failur
test
hepat
function
serum
bile
acid
blood
ammonia
concentr
remain
normal
patient
magnitud
increas
salt
activ
reflect
number
hepatocyt
affect
ie
diffus
lesion
although
maintain
abil
perform
intracellular
function
hand
patient
portosystem
shunt
cirrhosi
metastat
neoplasia
often
normal
salt
activ
despit
sever
hepat
failur
patient
normal
enzym
activ
reflect
either
intact
hepatocyt
membran
case
termin
cirrhosi
intracellular
enzym
deplet
often
mild
moder
increas
salt
activ
certain
system
diseas
result
hypoxia
rightsid
heart
failur
secondari
ischem
injuri
hepatocyt
sever
anemia
sever
pulmonari
diseas
endotoxemia
sepsi
also
mild
moder
increas
salt
activ
biliari
obstruct
probabl
result
toxic
effect
bile
acid
diffus
back
hepat
parenchyma
pancreat
inflammatori
intestin
diseas
also
may
result
increas
salt
activ
case
sometim
refer
reactiv
hepatopathi
serum
aspart
aminotransferas
ast
like
alt
high
activ
liver
howev
also
high
ast
activ
muscl
red
blood
cell
serum
aspart
aminotransferas
sast
formerli
serum
glutam
oxaloacet
transaminas
sgot
activ
therefor
less
specif
salt
activ
detect
hepatocellular
leakag
increas
activ
sast
occur
hepatocyt
muscl
damag
well
hemolysi
vitro
vivo
ast
found
free
cytoplasm
within
mitochondria
hepatocytewith
hepat
diseas
sast
activ
usual
parallel
salt
usual
magnitud
increas
salt
activ
exce
sast
activ
may
due
shorter
halflif
sast
sast
also
found
mitochondria
hepatocyt
therefor
sever
insult
requir
caus
mitochondri
damag
thu
releas
sast
site
compar
damag
hepatocellular
membran
activ
sast
exce
salt
muscl
red
blood
cell
rather
liver
consid
sourc
isoenzym
serum
alkalin
phosphatas
serum
activ
alp
usual
increas
biliari
stasi
steroid
hepatopathi
bone
lesion
alp
found
mani
tissu
includ
liver
bone
intestin
placenta
kidney
howev
clinic
situat
isoenzym
found
liver
bone
import
serum
halfliv
isoenzym
minut
wherea
halflif
hepat
isoenzym
day
dog
serum
activ
bone
alp
increas
osteoblast
activ
therefor
elev
young
grow
anim
bone
tumor
osteomalacia
hyperparathyroid
serum
activ
alp
increas
hepat
diseas
primarili
biliari
obstruct
intrahepat
extrahepat
unlik
transaminas
salt
sast
alp
leakag
enzym
associ
increas
hepatocyt
permeabl
rather
product
induc
biliari
obstruct
produc
cell
line
bile
canaliculi
increas
product
accompani
inabl
excret
enzym
biliari
system
thu
result
increas
serum
activ
addit
primari
biliari
obstruct
serum
alp
activ
often
elev
primari
hepatocellular
diseas
mani
caus
due
swell
hepatocyt
eg
associ
inflamm
cloudi
swell
lipid
accumul
neoplast
infiltr
result
intrahepat
cholestasi
see
tabl
diseas
periport
locat
tend
caus
mark
increas
serum
alp
activ
centrilobular
disord
tend
affect
bile
flow
canaliculi
addit
isoenzym
induc
biliari
obstruct
also
steroidinduc
isoenzym
alp
although
isoenzym
also
produc
liver
separ
entiti
induc
biliari
obstruct
dog
sensit
effect
glucocorticoid
regard
oppos
cat
singl
inject
glucocorticoid
increas
serum
activ
steroidinduc
isoenzym
alp
increas
activ
last
sever
week
shortact
prepar
sever
month
longact
prepar
magnitud
increas
depend
dose
administ
durat
rout
individu
sensit
addit
dog
spontan
hyperadrenocortic
cush
syndrom
usual
mark
increas
serum
alp
activ
assay
avail
readili
distinguish
isoenzym
induc
biliari
obstruct
steroidinduc
isoenzym
assay
gener
report
percentag
total
alp
activ
account
steroidinduc
isoenzym
howev
reliabl
test
distinguish
patient
steroid
hepatopathi
hepatopathi
serum
activ
steroidinduc
isoenzym
alp
variabl
increas
mani
type
hepat
diseas
nonhepat
ill
altern
hepat
biopsi
specimen
analysi
dog
readili
distinguish
steroidinduc
hepatopathi
primari
hepatobiliari
diseas
caus
certain
drug
also
induc
increas
serum
alp
activ
common
drug
effect
glucocorticoid
barbitur
anticonvuls
drug
includ
phenobarbit
primidon
phenytoin
drug
result
increas
serum
alp
activ
without
morpholog
chang
liver
alter
hepat
function
document
hepat
function
test
unlik
dog
activ
alp
much
lower
felin
serum
halflif
much
shorter
cat
hour
versu
day
less
felin
alp
produc
secondari
biliari
obstruct
dog
felin
liver
contain
one
third
concentr
alp
per
gram
liver
canin
liver
contain
therefor
even
mild
elev
serum
alp
activ
cat
indic
mark
hepatobiliari
diseas
magnitud
increas
serum
alp
activ
mark
felin
hepat
lipidosi
almost
alway
exceed
magnitud
increas
serum
ggt
activ
syndrom
diseas
cat
result
increas
serum
alp
activ
includ
hepat
malign
lymphoma
felin
cholangiohepat
complex
bile
duct
obstruct
hyperthyroid
gamma
glutamyltranspeptidas
ggt
measur
avail
chemistri
profil
mani
commerci
laboratori
serum
activ
increas
biliari
stasi
steroid
hepatopathi
case
activ
serum
ggt
parallel
serum
alp
measur
occasion
valu
dog
cat
ggt
activ
liver
kidney
pancrea
intestin
howev
halflif
hepat
isoenzym
one
long
enough
account
signific
serum
activ
therefor
elev
serum
ggt
activ
specif
hepatobiliari
diseas
hepat
induct
drug
serum
alp
elev
mark
biliari
obstruct
activ
also
increas
primari
hepatocellular
diseas
result
intrahepat
cholestasi
serum
activ
ggt
may
increas
earlier
biliari
diseas
alp
activ
addit
also
mark
elev
serum
ggt
activ
glucocorticoid
administr
spontan
hyperadrenocortic
drug
anticonvuls
also
increas
serum
ggt
activ
cat
serum
ggt
activ
higher
sensit
lower
specif
serum
alp
activ
detect
hepatobiliari
diseas
felin
hepat
lipidosi
magnitud
increas
serum
alp
activ
gener
exceed
serum
ggt
activ
dog
serum
ggt
activ
gener
specif
less
sensit
serum
alp
activ
detect
hepatobiliari
diseas
thu
serum
ggt
activ
higher
posit
predict
valu
wherea
alp
activ
higher
neg
predict
valu
evalu
hepatobiliari
diseas
diagnost
perform
best
enzym
activ
evalu
togeth
gener
serum
ggt
activ
less
influenc
nonhepat
diseas
enzymeinduc
drug
mani
test
routin
obtain
autom
serum
biochemistri
profil
give
inform
regard
hepat
function
includ
determin
bilirubin
albumin
bun
glucos
see
tabl
serum
urin
bilirubin
hepatobiliari
excret
bilirubin
requir
adequ
uptak
conjug
secret
hepatocyt
well
patent
biliari
system
must
consider
hepatocellular
diseas
increas
bilirubin
load
hemolysi
result
hyperbilirubinemia
liver
reserv
capac
bilirubin
process
time
normal
bilirubin
load
conjug
bilirubin
water
solubl
readili
excret
kidney
dog
low
renal
threshold
bilirubin
excret
thu
find
bilirubinuria
concentr
sampl
normal
therefor
concentr
bilirubin
urin
increas
serum
thu
serum
bilirubin
concentr
insensit
indic
hepatocellular
diseas
serum
concentr
increas
mark
decreas
hepat
function
therefor
slight
elev
serum
bilirubin
concentr
signific
suggest
hepatobiliari
diseas
except
artifactu
increas
serum
bilirubin
concentr
would
occur
lipemia
hemolysi
signific
bilirubinuria
associ
serum
bilirubin
concentr
greater
normal
artifact
consid
cat
high
renal
threshold
bilirubin
excret
bilirubin
urin
abnormalwhen
serum
bilirubin
normal
rang
anicter
hepat
diseas
test
hepat
function
discuss
earlier
need
detect
serum
bile
acid
blood
ammonia
measur
howev
serum
bilirubin
concentr
elev
need
run
addit
function
test
hemolysi
exclud
set
bilirubin
repres
accur
specif
indic
hepat
function
increas
serum
total
bilirubin
concentr
result
prehepat
hemolysi
intrahepat
primari
hepatocellular
diseas
posthepat
biliari
obstruct
caus
rel
amount
conjug
unconjug
bilirubin
variabl
three
gener
categori
hyperbilirubinemia
secondari
event
chang
rel
concentr
two
form
therefor
measur
aid
clinician
local
natur
lesion
magnitud
increas
serum
bilirubin
concentr
also
help
local
natur
lesion
method
local
caus
hyperbilirubinemia
includ
measur
hematocrit
rule
hemolysi
ultrasonographi
laparoscopi
cholecystographi
laparotomi
distinguish
intrahepat
posthepat
caus
gener
serum
bilirubin
concentr
increas
markedli
extrahepat
biliari
obstruct
hepatocellular
diseas
may
result
cholestasi
therefor
hyperbilirubinemia
includ
chronic
activ
hepat
certain
case
primari
neoplasia
felin
cholangiohepat
felin
hepat
lipidosi
cirrhosi
see
tabl
hepat
disord
gener
normal
serum
bilirubin
concentr
includ
portosystem
shunt
hepat
necrosi
steroid
hepatopathi
metastat
neoplasia
see
tabl
gener
disord
involv
periport
area
like
result
increas
bilirubin
concentr
serum
albumin
albumin
repres
approxim
protein
synthes
liver
albumin
rel
high
prioriti
synthesi
sever
hepatocellular
diseas
must
exist
serum
albumin
concentr
fall
hypoalbuminemia
result
hepat
diseas
suggest
chronic
dysfunct
serum
halflif
albumin
day
depend
diseas
state
serum
concentr
must
prolong
hepat
diseas
serum
concentr
decreas
addit
lack
product
occur
hepat
diseas
albumin
concentr
drop
proteincalori
malnutrit
sometim
associ
extrem
low
protein
diet
often
use
therapeut
manag
hepat
diseas
increas
volum
distribut
due
ascit
result
dilut
effect
serum
albumin
concentr
although
serum
albumin
concentr
insensit
nonspecif
test
hepat
function
hypoalbuminemia
may
chang
serum
biochemistri
profil
certain
case
hepat
failur
cirrhosi
portosystem
shunt
presenc
may
justifi
specif
hepat
function
test
eg
serum
bile
acid
assay
may
subsequ
identifi
hepat
failur
one
studi
presenc
hypoalbuminemia
dog
chronic
hepat
predictor
shorter
surviv
time
blood
urea
nitrogen
low
bun
concentr
may
indic
chronic
hepat
diseas
liver
manufactur
urea
extract
portal
vein
ammonia
convert
urea
urea
cycl
enzym
pathway
hepat
failur
process
fail
bun
concentr
fall
howev
mani
factor
influenc
urea
metabol
includ
renal
function
dietari
protein
concentr
catabol
state
system
perfus
hydrat
statu
gi
function
bun
concentr
insensit
nonspecif
test
hepat
function
howev
like
serum
albumin
concentr
low
bun
concentr
may
abnorm
serum
biochemistri
profil
may
import
clue
presenc
hepat
diseas
subsequ
specif
hepat
function
test
would
use
document
hepat
failur
liver
play
import
role
glucos
metabol
hepat
failur
result
either
preprandi
hypoglycemia
postprandi
hyperglycemia
dog
chronic
hepat
presenc
hypoglycemia
accur
predictor
earli
death
abnorm
glucos
concentr
caus
addit
hepat
diseas
must
explor
patient
hypoglycemia
associ
hepat
diseas
usual
easi
get
blood
glucos
concentr
normal
rang
intraven
glucos
supplement
oppos
patient
insulinproduc
tumor
difficult
despit
aggress
intraven
glucos
administr
survey
radiograph
often
inform
evalu
liver
give
inform
size
shape
posit
radiodens
liver
survey
radiograph
also
use
screen
abnorm
includ
ascit
renal
calculi
present
case
portosystem
shunt
thorac
metastasi
abdomin
lymphadenopathi
radiograph
sign
abnorm
hepat
size
list
box
caus
abnorm
hepat
size
list
box
addit
hepat
size
abnorm
hepat
radiodens
also
determin
survey
radiograph
abnorm
includ
calcif
cholelithiasi
parasit
cyst
neoplasia
granuloma
ga
accumul
cholecyst
ga
portal
vein
hepat
abscess
necrot
tumor
inabl
visual
hepat
border
ascit
emaci
radiographi
review
detail
chapter
along
nuclear
scintigraphi
laparotomi
contrast
radiographi
reliabl
method
determin
whether
portosystem
shunt
present
sever
techniqu
evalu
hepat
blood
flow
includ
intraop
mesenter
portographi
percutan
splenoportographi
cranial
mesenter
arteri
portographi
intraop
mesenter
portographi
indic
perform
intraop
mesenter
portographi
confirm
exist
number
locat
portosystem
shunt
box
addit
residu
portoven
flow
liver
assess
prognost
import
portosystem
shunt
identifi
surgic
correct
may
perform
anesthet
procedur
techniqu
intraop
mesenter
portographi
techniqu
readili
perform
gener
practic
special
equip
need
mesenter
jejun
vein
catheter
laparotomi
vessel
eventu
sacrif
select
larg
cathet
possibl
use
cathet
secur
intraven
extens
set
attach
abdomen
temporarili
close
extens
set
exit
abdomin
wall
total
mllb
bodi
weight
iodin
radiograph
contrast
media
inject
rapidli
possibl
extens
set
radiograph
obtain
end
inject
unless
portabl
radiograph
unit
avail
usual
easiest
perform
laparotomi
xray
tablewith
portosystem
shunt
contrast
media
pass
directli
system
venou
circul
bypass
liver
caudal
extent
shunt
cranial
probabl
intrahepat
shunt
caudal
probabl
extrahepat
shunt
percutan
splenoportographi
indic
percutan
splenoportographi
similar
describ
intraop
mesenter
portographi
splenoportographi
often
yield
lesser
qualiti
studi
advantag
requir
laparotomi
especi
import
hypoalbuminem
patient
risk
wound
dehisc
gener
anesthesia
heavi
sedat
requir
splenoportographi
spleen
local
transabdomin
palpat
ultrasound
laparoscopi
use
aid
needl
placement
approxim
mllb
bodi
weight
iodin
radiograph
contrast
media
inject
directli
splenic
pulp
rate
mlsec
radiograph
taken
immedi
approxim
second
end
inject
cranial
mesenter
arteri
portographi
cranial
mesenter
arteri
portographi
excel
method
evalu
entir
portal
system
evalu
hepat
blood
flow
techniqu
less
invas
oper
mesenter
portographi
howev
requir
fluoroscopi
serial
film
special
inject
equip
ultrasonographi
wide
use
evalu
liver
ideal
suit
soft
tissu
imag
give
specif
inform
regard
structur
abnorm
liver
readili
distinguish
fluidfil
structur
solid
soft
tissu
structur
includ
visual
gallbladd
hepat
vessel
adjac
parenchyma
hepat
ultrasonographi
discuss
chapter
also
see
refer
addit
inform
regard
basic
principl
ultrasound
ultrasonograph
appear
liver
main
reason
use
ultrasonographi
evalu
hepat
diseas
distinguish
focal
diffus
diseas
thu
help
determin
appropri
biopsi
method
distinguish
intrahepat
caus
cholestasi
extrahepat
caus
cholestasi
former
potenti
medic
treatabl
problem
latter
surgic
treatabl
problem
addit
indic
ultrasound
evalu
liver
includ
abnorm
hepat
function
size
radiodens
diffus
chang
hepat
echogen
compar
falciform
fat
renal
cortex
spleen
may
suggest
certain
hepat
diseas
diffus
hyperechogen
seen
fatti
chang
steroid
hepatopathi
fibrosi
cirrhosi
hypoechogen
seen
passiv
congest
lymphoma
suppur
hepat
ultrasonographi
also
use
method
obtain
biopsi
specimen
liver
chapter
diseas
liver
hepatobiliari
system
neoplasia
primari
metastat
congest
rightsid
heart
failur
fatti
infiltr
diffus
inflamm
hyperadrenocortic
storag
diseas
abscess
hepat
biliari
cyst
liver
lobe
torsion
puppi
kitten
normal
deep
inspir
normal
use
guid
biopsi
needl
appropri
portion
liver
normal
structur
abnorm
detect
ultrasonographi
list
box
nuclear
scintigraphi
primarili
use
evalu
hepat
blood
flow
aid
detect
portosystem
shunt
scintigraphi
may
case
local
shunt
distinguish
intrahepat
extrahepat
shunt
also
repres
noninvas
method
prove
exist
shunt
may
follow
invas
studi
mesenter
portographi
surgeri
nuclear
scintigraphi
equip
primarili
avail
referr
center
pertechnet
inexpens
avail
radioisotop
absorb
across
colon
mucosa
administ
high
concentr
colon
dynam
imag
first
minut
provid
nuclear
angiogram
portal
system
imag
normal
dog
result
sequenti
visual
portal
vein
liver
sever
second
later
heart
lung
patient
portosystem
shunt
heart
lung
activ
occur
liver
activ
procedur
well
toler
requir
sedat
mani
case
studi
allow
distinct
intrahepat
shunt
singl
extrahepat
shunt
multipl
extrahepat
shunt
although
studi
give
anatom
detail
radiograph
contrast
studi
inform
usual
specif
enough
determin
whether
patient
good
oper
candid
addit
radioisotop
enter
portal
system
caudal
liver
angiograph
studi
distal
caudal
shunt
miss
studi
also
perform
cat
may
requir
higher
imag
frequenc
similar
procedur
also
describ
dog
use
transcolon
iiodoamphetamin
imp
radiolabel
amin
bind
liver
lung
follow
absorpt
colon
imag
within
minut
administr
count
activ
liver
lung
allow
direct
calcul
portal
blood
flow
bypass
liver
method
also
noninvas
accur
howev
disadvantag
compar
transcolon
administr
tc
pertechnet
high
expens
rel
long
halflif
radioisotop
altern
techniqu
involv
analysi
intraven
inject
radiocolloid
radiocolloid
remov
circul
re
bodi
shown
uptak
radiocolloid
liver
reflect
hepat
blood
flow
rather
phagocyt
properti
kupffer
cell
thu
radiocolloid
scintigraphi
sensit
techniqu
screen
portosystem
shunt
procedur
safe
requir
sedat
rel
rapid
radiocolloid
scintigraphi
perform
inject
mci
tc
sulfur
colloid
intraven
subsequ
scan
organ
bodi
gamma
camera
comput
use
plot
activ
lung
liver
time
normal
dog
initi
activ
lung
rapidli
decreas
initi
passag
bolu
second
radiocolloid
clear
circul
spleen
liver
subsequ
gradual
increas
activ
liver
reflect
uptak
radiocolloid
dog
portosystem
shunt
increas
activ
lung
initi
passag
bolu
indic
pulmonari
uptak
rate
hepat
uptak
consider
less
seen
normal
dog
unfortun
mani
indetermin
falseposit
result
method
compar
transcolon
administr
radioisotop
normal
cat
extrahepat
uptak
lung
occur
prevent
adequ
imag
liver
hepat
biopsi
specimen
analysi
way
accur
diagnos
classifi
hepat
diseas
biochem
test
radiograph
ultrasonographi
determin
hepat
diseas
exist
none
test
accur
determin
caus
appropri
treatment
predict
prognosi
except
angiographi
scintigraphi
detect
portosystem
shunt
recent
advanc
biopsi
method
noninvas
imag
liver
made
hepat
biopsi
routin
essenti
tool
diagnosi
manag
patient
hepat
diseas
mani
type
hepat
diseas
treatabl
definit
diagnosi
allow
clinician
make
appropri
clinic
decis
regard
specif
treatment
rather
support
care
hepat
biopsi
specimen
analysi
help
determin
whether
abnorm
revers
irrevers
progress
static
primari
hepat
secondari
treat
specif
therapi
support
therapi
whether
need
followup
biopsi
posttreat
common
indic
perform
hepat
biopsi
abnorm
hepat
function
andor
increas
serum
hepat
enzym
activ
unknown
origin
usual
identifi
hepat
function
test
serum
bile
acid
blood
ammonia
measur
serum
biochem
profil
find
obtain
patient
show
sign
compat
hepat
diseas
routin
preanesthet
blood
work
clinic
ill
attribut
hepat
diseas
biopsi
warrant
patient
persist
abnorm
serum
hepat
enzym
activ
effort
rule
nonhepat
caus
enzym
elev
made
first
hyperadrenocortic
diabet
mellitu
congest
heart
failur
felin
hyperthyroid
asymptomat
patient
increas
hepat
enzym
activ
detect
routin
biochem
profil
gener
assess
hepat
function
serum
bile
acid
measur
grossli
elev
biochemistri
profil
repeat
week
persist
increas
hepat
enzym
activ
time
hepat
biopsi
justifi
abnorm
hepat
size
unknown
caus
either
microhepatica
hepatomegali
anoth
indic
hepat
biopsi
hepatomegali
present
effort
must
made
rule
nonhepat
caus
hyperadrenocortic
diabet
mellitu
congest
heart
failur
even
presenc
disord
might
clinic
indic
assess
hepat
involv
multisystem
diseas
hepat
biopsi
specimen
analysi
mani
case
hepatomegali
either
diffus
focal
enlarg
purpos
biopsi
confirm
suspect
neoplasia
recent
advanc
chemotherapi
made
import
step
proper
manag
final
hepat
biopsi
specimen
analysi
import
document
progress
diseas
often
multipl
serial
biopsi
necessari
document
remiss
certain
case
chronic
activ
hepat
cah
hepat
malign
lymphoma
therefor
determin
appropri
treatment
contraind
hepat
biopsi
rel
contraind
depend
biopsi
methodwhen
factor
present
clinician
must
weigh
potenti
benefit
obtain
biopsi
ie
definit
diagnosi
opportun
begin
ration
specif
therapi
risk
complic
could
potenti
occur
howev
experi
knowledg
variou
method
hepat
biopsi
risk
minim
common
contraind
hepat
biopsi
coagulopathi
determin
natur
coagulopathi
import
minim
influenc
common
coagulopathi
associ
hepat
diseas
dic
dic
present
knowledg
underli
diseas
essenti
longterm
manag
thu
obtain
biopsi
essenti
set
recommend
high
volum
intraven
fluid
maintain
tissu
perfus
face
microthrombi
platelet
function
inhibit
aspirin
minim
hypercoagul
state
transfus
fresh
crossmatch
whole
blood
collect
plastic
collect
bag
glass
activ
factor
xii
unit
heparin
ad
per
ml
blood
activ
antithrombin
iii
minim
hypercoagul
state
method
obtain
biopsi
requir
minim
incis
yet
allow
control
bleed
laparoscopyguid
keyhol
method
prefer
prolong
clot
time
unaccompani
dic
may
decreas
clot
factor
synthesi
vitamin
k
defici
vitamin
k
administr
may
help
certain
situat
one
report
vitamin
k
administr
improv
pivka
time
dog
hepat
diseas
normal
pivka
time
cat
experi
bleed
follow
hepat
biopsi
correl
coagul
test
includ
pivka
test
patient
coagulopathi
like
bleed
patient
without
coagulopathi
case
signific
bleed
follow
hepat
biopsi
technic
problem
experi
rapid
bleed
andor
necropsi
examin
suggest
larg
vessel
damag
rather
hemorrhag
due
persist
ooz
needl
biopsi
site
except
patient
dic
often
signific
hemorrhag
regardless
techniqu
control
studi
veterinari
patient
necessari
make
final
conclus
regard
postbiopsi
hemorrhag
patient
coagulopathi
unstabl
patient
safe
anesthet
anoth
rel
contraind
perform
liver
biopsi
patient
blind
percutan
ultrasoundguid
biopsi
method
may
consid
often
done
minim
sedat
complet
biliari
obstruct
dilat
intrahepat
bile
duct
contraind
describ
human
potenti
bile
periton
theoret
occur
increas
intraduct
pressur
therefor
inadvert
duct
ruptur
follow
biopsi
result
bile
leak
abdomin
caviti
experi
howev
complic
recogn
case
percutan
biopsi
perform
anim
biliari
obstruct
final
hepat
abscess
cyst
vascular
tumor
contraind
percutan
biopsi
method
unfortun
usual
known
present
late
unless
imag
modal
ultrasonographi
laparoscopi
avail
appropri
biochem
hepat
function
test
must
perform
assess
need
biopsi
identifi
concurr
diseas
need
hepat
biopsi
determin
sever
consider
must
made
histori
physic
examin
laboratori
ancillari
find
determin
overal
health
statu
patient
import
decid
appropri
anesthet
regim
certain
biopsi
method
requir
minim
sedat
blind
percutan
ultrasoundguid
requir
short
gener
anesthet
keyhol
laparoscopyguid
wherea
other
requir
long
gener
anesthet
laparotomi
addit
patient
extrem
low
serum
albumin
concentr
greater
risk
wound
dehisc
therefor
biopsi
appropri
perform
percutan
method
abdomin
radiograph
help
assess
hepat
size
inform
use
narrow
list
differenti
diagnos
also
help
plan
biopsi
approach
exampl
microhepatica
transthorac
percutan
approach
may
prefer
transabdomin
percutan
approach
laparoscopyguid
biopsi
may
prefer
ultrasoundguid
biopsi
revers
true
hepatomegali
thorac
radiograph
help
rule
metastat
neoplasia
coagul
profil
perform
hepat
biopsi
multitud
abnorm
possibl
hepat
diseas
discuss
detail
section
pathophysiolog
derang
occur
hepat
diseas
ideal
pivka
time
prothrombin
time
partial
thromboplastin
time
platelet
count
fibrin
degrad
product
determin
made
hepat
biopsi
signific
cost
time
concern
less
accept
altern
measur
activ
clot
time
toenail
bleed
time
former
test
assess
intrins
common
clot
pathway
abnorm
clot
factor
activ
drop
normal
wherea
partial
thromboplastin
time
abnorm
clot
factor
activ
drop
normal
manag
coagulopathi
obtain
hepat
biopsi
discuss
section
precaut
hepat
biopsi
chemic
restraint
sometim
necessari
insur
safe
procedur
patient
clip
sedat
gener
anesthesia
prefer
isofluran
sevofluran
induct
face
mask
induct
chamber
inject
anesthet
desir
prefer
combin
ketamin
diazepam
although
oxymorphon
provid
adequ
restraint
revers
necessari
excess
pant
often
occur
interfer
biopsi
procedur
therefor
recommend
five
basic
method
obtain
hepat
biopsi
blind
percutan
keyhol
techniqu
ultrasoundguid
laparoscopyguid
laparotomi
biopsi
method
certain
advantag
disadvantag
knowledg
well
practic
expertis
respect
method
allow
clinician
select
appropri
safest
method
obtain
hepat
tissu
blind
percutan
biopsi
advantag
blind
percutan
biopsi
rapid
requir
minim
sedat
low
cost
disadvantag
method
potenti
inadvert
trauma
organ
focal
lesion
may
miss
detect
bleed
may
delay
equip
variou
biopsi
needl
use
percutan
biopsi
gener
newer
autom
needl
prefer
springload
needl
similar
style
manual
trucut
baxter
abc
monoject
needl
autom
needl
complet
automat
semiautomat
autom
cut
needl
includ
monopti
bard
asap
microvas
biopti
bard
needl
complet
automat
needl
thrust
inner
obtur
contain
biopsi
tray
specimen
notch
follow
outer
cut
sheath
organ
fraction
second
needl
easili
oper
one
hand
action
quick
minim
displac
organ
shorter
intraparenchym
phase
much
reliabl
yield
tissu
allow
biopsi
organ
perform
minim
manual
mobil
allow
smaller
diamet
needl
use
allow
lighter
degre
sedat
semiautom
cut
needl
includ
vetcor
needl
cook
semiautomat
needl
requir
manual
thrust
intern
obtur
contain
biopsi
tray
specimen
notch
organ
follow
automat
thrust
outer
cut
sheath
springload
mechan
needl
advantag
complet
automat
needl
addit
advantag
control
final
needl
posit
lighter
smaller
handl
characterist
also
make
needl
well
suit
comput
tomographi
ct
guidanc
handl
let
free
oper
intraprocedur
scan
without
weight
handl
caus
needl
move
addit
tip
needl
precis
local
outer
cut
sheath
fire
older
manual
cut
needl
trucut
abc
needl
offer
advantag
newer
needl
aspir
needl
gener
use
obtain
smaller
sampl
would
suitabl
cytolog
prepar
rather
histopatholog
prepar
menghini
westcott
needl
use
obtain
small
sampl
histopatholog
examin
see
needl
also
well
suit
obtain
sampl
fluid
intraparenchym
cyst
gallbladd
punctur
usual
smallergaug
needl
gaug
therefor
tend
less
traumat
aspir
needl
employ
suction
obtain
fluid
cut
core
tissu
menghini
needl
especi
suit
transthorac
hepat
biopsi
use
transabdomin
techniqu
well
tip
needl
slightli
obliqu
convex
cut
core
tissu
suction
appli
needl
rapidli
thrust
liver
immedi
withdrawn
intrahepat
phase
last
fraction
second
slide
screw
act
depth
gaug
prevent
needl
enter
deepli
parenchyma
westcott
needl
suction
use
draw
tissu
specimen
notch
distal
end
gentl
backandforth
movement
allow
core
tissu
cut
transthorac
techniqu
short
intrahepat
phase
transthorac
techniqu
especi
suitabl
patient
sedat
riski
undesir
patient
microhepatica
transabdomin
techniqu
may
difficult
patient
given
corn
oil
oral
mllb
bodi
weight
caus
gallbladd
contract
thu
minim
risk
inadvert
punctur
menghini
needl
use
obtain
biopsi
specimen
patient
place
left
later
recumb
right
hemithorax
clip
surgic
prepar
local
anesthet
inject
subcutan
needl
punctur
site
dorsal
costochondr
junction
fifth
seventh
intercost
space
depend
size
patient
distanc
diaphragm
use
blade
skin
incis
made
prevent
dull
biopsi
needlewith
stylet
menghini
needl
place
needl
pop
pleural
space
direct
caudal
parallel
rib
cage
contact
diaphragm
respiratori
movement
felt
care
taken
avoid
lacer
intercost
vessel
lie
along
caudal
aspect
rib
upon
make
contact
diaphragm
needl
depth
gaug
slid
within
approxim
cm
skin
depth
penetr
liver
limit
distanceth
stylet
remov
quickli
replac
syring
fill
ml
steril
salin
neg
pressur
correspond
approxim
ml
fluid
volum
produc
draw
plunger
peak
expir
needl
rapidli
thrust
liver
distanc
limit
depth
gaug
immedi
withdrawn
patient
one
swift
motion
maintain
neg
pressur
throughout
entir
step
ie
intrahepat
phase
last
split
second
core
hepat
tissu
rest
within
fluid
syring
needl
plunger
remov
content
pour
cultur
broth
onto
slide
impress
cytology
studi
andor
jar
contain
formalin
patient
immedi
turn
onto
right
side
approxim
minut
allow
weight
liver
control
hemorrhag
possibl
complic
techniqu
includ
gallbladd
punctur
possibl
bile
periton
pleuriti
pneumothorax
excess
bleed
patient
firm
fibrot
liver
techniqu
may
yield
suitabl
sampl
situat
cut
type
needl
use
transabdomin
approach
may
success
transabdomin
techniqu
blind
transabdomin
techniqu
especi
use
size
liver
normal
larg
longer
intrahepat
phase
transthorac
techniqu
cut
type
needl
use
therefor
higher
degre
sedat
may
necessari
uncoop
patient
patient
given
corn
oil
oral
mlkg
bodi
weight
caus
gallbladd
contract
thu
reduc
risk
inadvert
punctur
prefer
use
autom
cut
type
needl
monopti
asap
needl
patient
place
right
dorsal
obliqu
recumb
angl
posit
stomach
fall
toward
right
side
larg
area
around
xiphoid
cartilag
clip
surgic
prepar
local
anesthet
inject
subcutan
needl
entri
site
caudal
left
xiphoid
cartilag
middl
v
form
xiphoid
cartilag
rib
cage
needl
enter
far
cranial
may
inadvert
enter
thorac
caviti
hepatomegali
entri
site
move
caudal
appropri
hepat
size
skin
incis
blade
prevent
dull
biopsi
needl
biopsi
needl
insert
advanc
bodi
wall
aim
craniolater
direct
toward
left
shoulder
needl
advanc
inspir
liver
close
bodi
wall
needl
need
advanc
far
penetr
liver
often
felt
common
error
use
techniqu
insert
needl
far
go
complet
liver
liver
enter
biopsi
needl
oper
cut
sampl
done
peak
inspir
needl
remov
attempt
core
hepat
tissu
rest
within
specimen
notch
needl
initi
attempt
fail
obtain
hepat
tissu
needl
redirect
base
perceiv
locat
liver
bodi
conform
ie
deep
chest
direct
previou
attempt
tissu
care
remov
needl
place
cultur
broth
onto
slide
impress
cytolog
studi
andor
formalin
patient
immedi
place
sternal
recumb
allow
weight
liver
control
hemorrhag
possibl
complic
techniqu
includ
punctur
stomach
gallbladd
ruptur
possibl
bile
periton
punctur
diaphragm
lung
possibl
pneumothorax
excess
bleed
keyhol
techniqu
keyhol
techniqu
offer
advantag
provid
guidanc
needl
blind
percutan
biopsi
rel
rapid
low
cost
disadvantag
method
includ
requir
sedat
compar
blind
percutan
biopsi
possibl
caus
inadvert
trauma
organ
possibl
focal
lesion
may
miss
possibl
detect
bleed
may
delay
techniqu
especi
suitabl
individu
lack
experi
perform
blind
percutan
biopsi
keyhol
techniqu
equip
similar
describ
blind
transabdomin
percutan
biopsi
gener
anesthet
small
incis
abdomin
caviti
made
caudal
site
needl
introduct
glove
finger
insert
abdomen
palpat
liver
stabil
biopsi
needl
insert
incis
separ
incis
cranial
first
incis
finger
guid
needl
liver
biopsi
specimen
cut
prefer
autom
cut
needl
techniqu
oper
one
hand
wherea
trucut
needl
would
requir
assist
oper
needl
complic
similar
describ
blind
percutan
biopsi
ultrasoundguid
biopsi
ultrasoundguid
biopsi
offer
advantag
provid
guidanc
needl
possibl
blind
percutan
biopsi
rel
rapid
requir
minim
sedat
intraparenchym
lesion
visual
biopsi
select
perform
addit
intrahepat
structur
gallbladd
portal
vessel
avoid
disadvantag
ultrasoundguid
biopsi
includ
requir
expens
equip
detect
bleed
may
delay
biopsi
method
success
operatordepend
ultrasoundguid
biopsi
easier
liver
normal
larg
size
microhepatica
overli
ga
stomach
often
make
visual
liver
difficult
set
laparoscopi
would
offer
appropri
imageguid
biopsi
method
techniqu
dog
requir
minim
sedat
ultrasoundguid
biopsi
use
low
dose
ketamin
cat
mg
intraven
isofluran
sevofluran
administ
face
mask
care
ultrasound
examin
perform
biopsi
allow
plan
procedur
base
type
echo
pattern
size
lesion
proxim
organ
proxim
blood
vessel
determin
cystic
solid
tissu
determin
needl
path
focal
liver
biopsi
locat
lesion
determin
posit
scan
head
needl
path
diffus
lesion
transduc
usual
place
caudal
left
xiphoid
aim
left
medial
later
lobe
patient
extrem
small
liver
may
difficult
adequ
visual
needl
without
stomach
ga
interf
case
place
patient
right
ventral
obliqu
posit
often
help
reduc
interfer
stomach
otherwis
patient
usual
place
dorsal
recumb
procedur
rubber
trough
v
tray
assist
posit
addit
patient
ga
gener
anesthesia
assist
compress
rebreath
bag
hold
patient
deep
inspir
move
diaphragm
liver
caudal
improv
visual
lesion
seen
due
overli
ga
bone
chang
patient
transduc
posit
usual
allow
adequ
visual
area
scan
includ
needl
entri
site
surgic
prepar
ultrasound
transduc
cover
steril
plastic
wrap
steril
glove
small
amount
coupl
gel
place
transduc
surfac
biopsi
guid
may
use
desir
allow
accur
placement
needl
plane
scan
howev
sometim
desir
needl
enter
differ
plane
due
overli
structur
plane
scan
case
biopsi
guid
use
biopsi
guid
also
limit
angl
insert
needl
entri
site
usual
cm
scan
head
therefor
superfici
lesion
center
scan
biopsi
guid
use
furthermor
needl
rigid
biopsi
guid
inadvert
trauma
organ
may
result
patient
move
take
deep
breath
small
amount
steril
coupl
gel
watersolubl
lubric
place
skin
ultrasound
examin
repeat
verifi
needl
path
small
stab
incis
made
skin
needl
insert
site
autom
needl
gener
prefer
easili
oper
one
hand
therefor
needl
must
load
entri
abdomen
one
hand
maneuv
transduc
hand
advanc
needl
organ
direct
ultrasound
visual
needl
tip
seen
gentl
movement
transduc
allow
visual
allow
distinct
needl
echogen
structur
imag
needl
gentli
move
ideal
minim
enough
move
organ
within
abdomin
caviti
rather
move
needl
within
organ
spinal
needl
use
move
stylet
stationari
needl
increas
echogen
visual
needl
tip
without
creat
tissu
trauma
occasion
needl
visual
indirect
evid
organ
punctur
use
includ
movement
organ
visual
motion
organ
border
needl
direct
trajectori
avoid
structur
fire
care
must
taken
prevent
go
deep
needl
seen
penetr
diaphragm
enter
thorac
caviti
biopsi
specimen
obtain
needl
remov
core
liver
rest
within
specimen
notch
needl
needl
care
use
transfer
tissu
cultur
broth
onto
slide
impress
cytolog
studi
andor
formalin
number
biopsi
specimen
obtain
depend
coagul
statu
patient
type
diagnost
test
plan
adequaci
tissu
retriev
complet
procedur
ultrasound
examin
perform
check
excess
hemorrhag
extern
digit
pressur
abdomin
compress
wrap
may
use
control
hemorrhag
possibl
complic
techniqu
similar
describ
blind
transabdomin
percutan
biopsi
laparoscopyguid
biopsi
main
advantag
laparoscopyguid
biopsi
abil
visual
liver
biliari
tree
abdomin
organ
experi
gallbladd
examin
palpat
blunt
probe
bile
duct
trace
entri
duodenum
manner
determin
whether
common
bile
duct
cystic
duct
obstruct
addit
focal
lesion
liver
directli
visual
appropri
biopsi
site
select
intrahepat
structur
gallbladd
portal
vessel
avoid
hemorrhag
observ
excess
control
direct
compress
blunt
probe
biopsi
site
electrocauteri
applic
gel
foam
compar
laparotomi
much
less
anesthet
timewith
experi
oper
perform
complet
laparoscop
examin
obtain
multipl
biopsi
specimen
minut
case
incis
much
less
risk
wound
dehisc
disadvantag
laparoscopi
requir
gener
anesthet
need
expens
equip
detail
equip
techniqu
perform
laparoscopi
found
chapter
potenti
complic
procedur
includ
relat
gener
anesthet
excess
bleed
overdistent
abdomen
ga
air
embol
tension
pneumothorax
diaphragm
inadvert
punctur
abdomin
ga
enter
thorac
caviti
experi
complic
extrem
rare
laparotomi
biopsi
advantag
laparotomi
biopsi
includ
abil
view
entir
abdomin
caviti
treat
diseas
surgic
correct
therefor
one
visual
select
biopsi
site
excess
hemorrhag
control
howev
known
coagulopathi
laparotomi
advis
size
incis
therefor
high
potenti
addit
bleed
set
laparoscopi
prefer
method
obtain
biopsi
specimen
laparotomi
offer
addit
advantag
abl
obtain
larg
biopsi
specimen
disadvantag
laparotomi
biopsi
includ
requir
long
gener
anesthet
therefor
risk
patient
addit
may
poor
wound
heal
sever
hypoalbuminemia
present
therefor
increas
risk
dehisc
techniqu
obtain
hepat
tissu
laparotomi
beyond
scope
chapter
reader
refer
surgic
textbook
inform
subject
import
complic
monitor
follow
hepat
biopsi
excess
hemorrhag
subsequ
hypovolem
shock
hematocrit
total
solid
measur
unreli
mean
identif
hemorrhag
sever
hour
necessari
extravascular
fluid
redistribut
occur
follow
acut
bleed
therefor
chang
hematocrit
delay
time
hematocrit
drop
might
late
begin
lifesav
blood
transfus
therefor
clinic
monitor
includ
assess
mucou
membran
color
capillari
refil
time
help
intraven
fluid
support
andor
blood
transfus
may
necessari
treat
hypovolem
shock
patient
known
coagulopathi
biopsi
crossmatch
perform
compat
blood
made
avail
possibl
blood
transfus
store
blood
avoid
contain
high
concentr
ammonia
result
elabor
red
blood
cell
therefor
fresh
blood
collect
plastic
collect
bag
platelet
stick
glass
glass
activ
factor
xii
therefor
worsen
dic
experi
complic
hemorrhag
within
hour
biopsi
procedur
patient
unlik
experi
bleed
problem
hepat
biopsi
sampl
often
quit
friabl
need
handl
care
avoid
excess
fragment
depend
biopsi
method
amount
tissu
submit
may
small
pathologist
must
familiar
interpret
small
sampl
therefor
repres
section
liver
must
submit
portion
hepat
biopsi
sampl
cultur
aerob
anaerob
bacteria
therefor
appropri
cultur
media
avail
bacteri
infect
liver
primari
event
secondari
abnorm
clearanc
portal
bacteria
associ
abnorm
hepat
reticuloendotheli
cell
function
portion
biopsi
sampl
place
glass
slide
obtain
impress
smear
cytolog
studi
place
sampl
formalin
sever
diseas
readili
diagnos
cytolog
examin
histopatholog
confirm
includ
felin
hepat
lipidosi
hepat
malign
lymphoma
hepat
carcinoma
fungal
hepat
addit
routin
hematoxylineosin
h
e
stain
copper
stain
may
help
includ
orcein
rhodamin
rubean
timm
stain
use
stain
indic
suspect
case
primari
copperstorag
diseas
occur
bedlington
terrier
west
highland
white
terrier
assess
whether
chelat
therapi
necessari
case
chronic
activ
hepat
especi
doberman
pinscher
recommend
copper
stain
request
anytim
hepat
biopsi
sampl
obtain
breed
controversi
exist
whether
fine
needl
aspir
needl
biopsi
specimen
laparoscop
spoon
biopsi
specimen
surgic
wedg
biopsi
sampl
give
similar
result
appear
strong
institut
bia
regard
question
usual
depend
expertis
experi
entir
team
clinician
involv
eg
internist
radiologist
pathologist
impress
fine
needl
aspir
help
certain
condit
confirm
diagnosi
hepat
lipidosi
certain
type
neoplasm
lymphoma
mast
cell
tumor
howev
fine
needl
aspir
usual
fail
defin
lobular
architectur
locat
inflamm
within
lobul
degre
fibrosi
degre
cholestasi
vascular
patholog
condit
fine
needl
aspir
also
often
unreli
mix
lesion
recent
studi
compar
fine
needl
aspir
cytolog
studi
surgic
biopsi
specimen
suggest
cytolog
examin
unreli
categori
hepat
diseas
dog
cat
needl
biopsi
may
also
limit
use
situat
well
depend
qualiti
quantiti
biopsi
sampl
obtain
occasion
receiv
result
needl
biopsi
specimen
analysi
adequ
explain
clinic
laboratori
featur
patient
like
case
simpli
sampl
error
needl
biopsi
specimen
procur
via
ultrasound
guidanc
typic
obtain
portion
liver
seen
best
usual
left
medial
lobe
minim
attempt
sampl
site
geograph
divers
limit
sampl
size
may
explain
failur
case
exampl
needl
biopsi
specimen
regen
nodul
often
suggest
metabol
disord
sever
portal
triad
need
includ
benefit
often
sever
areasa
recent
studi
show
concord
needl
biopsi
surgic
biopsi
specimen
analysi
clearli
laparoscop
surgic
wedg
biopsi
give
inform
size
biopsi
specimen
obtain
caution
must
use
obtain
biopsi
sampl
edg
lobe
often
increas
fibrou
tissu
surfac
due
blend
fibrou
tissu
capsul
portal
fibrou
tissu
therefor
center
lobe
includ
sampl
laparoscop
surgic
biopsi
procedur
addit
laparoscop
biopsi
allow
sampl
multipl
lobe
typic
obtain
least
seven
spoon
biopsi
specimen
laparoscop
examin
common
histopatholog
abnorm
encount
experi
mani
clinician
list
order
frequenc
box
clinic
perspect
biopsi
specimen
analysi
follow
purpos
categor
diseas
inflammatori
neoplast
degen
dysplast
metabol
abnorm
lipidosi
steroid
hepatopathi
establish
specif
caus
possibl
determin
prognosi
direct
institut
appropri
specif
therapi
inform
must
determin
hepat
biopsi
specimen
analysi
includ
follow
chronic
acut
chronic
sever
involv
structur
within
individu
lobular
unit
bile
canaliculi
blood
vessel
lymphat
hepatocyt
major
zone
lobul
hepat
capsul
distribut
sever
natur
inflammatori
cell
degre
degener
necrosi
distribut
sever
fibrosi
presenc
pigment
vacuolar
chang
fat
steroid
presenc
organ
need
special
stain
copper
amyloid
glycogen
fibrou
tissu
mani
diseas
liver
treatabl
definit
diagnosi
known
howev
proper
manag
requir
understand
etiolog
proper
interpret
diagnost
test
etiolog
diagnosi
base
hepat
biopsi
specimen
analysi
discuss
cover
commonli
encount
diseas
liver
review
specif
treatment
appropri
inflammatori
diseas
repres
one
common
manifest
hepat
diseas
liver
often
affect
infecti
toxic
inflammatori
diseas
activ
reticuloendotheli
cell
function
play
import
role
detoxifi
agent
absorb
bowel
liver
also
receiv
larg
portion
cardiac
output
therefor
potenti
system
hematogen
involv
liver
also
may
involv
noninfecti
immunemedi
reaction
noninfecti
inflammatori
diseas
among
common
hepat
diseas
seen
unfortun
caus
often
unclear
remain
idiopath
entiti
addit
primari
inflammatori
hepat
diseas
liver
involv
secondari
diseas
organ
innoc
bystand
liver
receiv
gi
product
toxin
portal
blood
primari
gi
diseas
result
mucos
damag
lead
increas
absorpt
agent
portal
circul
caus
direct
damag
liver
toxic
hepatopathi
incit
immunolog
reaction
lead
inflamm
liver
uncommon
find
elev
hepat
enzym
activ
associ
idiopath
inflammatori
bowel
diseas
lymphocyticplasmacyt
enter
coliti
viral
enter
parvoviru
coronaviru
sever
pancreat
set
absorpt
endotoxin
toxic
product
result
hepat
damag
inflamm
case
often
refer
reactiv
hepatopathi
gener
increas
serum
transaminas
activ
alt
ast
normal
concentr
serum
bile
acid
addit
hepat
abnorm
resolv
underli
diseas
treat
drug
also
caus
hepat
damag
result
inflamm
includ
anticonvuls
box
certain
antiparasit
drug
mebendazol
thiacetarsamid
final
metabol
abnorm
copperstorag
diseas
result
hepat
inflamm
histolog
appear
entiti
similar
therefor
clinician
must
awar
mani
factor
lead
hepat
inflamm
thoroughli
evalu
patient
manag
disord
appropri
cah
defin
idiopath
activ
inflammatori
diseas
liver
chronic
durat
term
appli
propos
specif
diseas
analog
diseas
human
name
descript
patholog
process
result
histolog
appear
character
chronic
ongo
inflamm
clinician
believ
disord
specif
diseas
rather
gener
reaction
liver
injuri
histolog
pattern
one
nonspecif
inflamm
respons
insult
other
believ
clinic
featur
histolog
pattern
respons
immunemodul
drug
similar
enough
diseas
human
warrant
name
true
diseas
entiti
sever
distinct
clinic
entiti
result
chronic
hepat
includ
copperstorag
diseas
bedlington
terrier
west
highland
white
terrier
skye
terrier
possibl
doberman
pinscher
infecti
diseas
viral
hepat
leptospirosi
drug
anticonvuls
idiopath
caus
discuss
focu
primarili
idiopath
caus
although
must
emphas
diseas
known
underli
caus
must
look
case
chronic
hepat
steroidrespons
autoimmun
underli
caus
chronic
hepat
identifi
pathogenesi
similar
describ
human
figur
may
merit
briefli
propos
immunolog
factor
lead
perpetu
inflamm
follow
hepatocyt
damag
caus
agent
follow
hepatocyt
injuri
releas
hepat
antigen
previous
expos
system
immun
system
hidden
immun
surveil
result
influx
inflammatori
cell
primarili
lymphocyt
plasma
cell
caus
antibodymedi
complementmedi
cytotox
result
hepatocyt
injuri
viciou
cycl
perpetu
immunolog
event
occur
long
initi
insult
gone
first
reaction
occur
near
portal
triad
eventu
extend
beyond
limit
plate
hepatocyt
singlecellthick
layer
hepatocyt
surround
portal
triad
hepat
lobul
eventu
result
necrosi
bridg
fibrosi
inflamm
fibrosi
extend
adjac
portal
area
normal
hepat
architectur
lost
fibrot
process
becom
diffus
term
cirrhosi
whether
event
occur
dog
propos
human
whether
syndrom
seen
dog
analog
cah
human
be
unknown
clinic
featur
chronic
activ
hepat
dog
cah
repres
approxim
dog
undergo
hepat
biopsi
one
studi
diseas
occur
primarili
middleag
dog
averag
year
major
greater
occur
femal
mark
predisposit
doberman
pinscher
virtual
case
greater
occur
femal
breed
find
mark
copper
accumul
liver
affect
doberman
pinscher
unclear
diseas
seen
breed
occur
breed
howev
copper
normal
excret
bile
accumul
hepatocyt
cholestat
disord
find
high
hepat
copper
concentr
two
doberman
pinscher
subacut
hepat
ie
without
evid
cholestasi
suggest
possibl
primari
copperstorag
diseas
purpos
discuss
howev
diseas
seen
doberman
pinscher
breed
consid
seen
idiopath
cah
breed
clinic
featur
similar
also
breed
predisposit
american
cocker
spaniel
clinic
sign
cah
includ
typic
chronic
hepat
diseas
polyuria
polydipsia
weight
loss
anorexia
icteru
ascit
abnorm
bleed
tendenc
depress
disorient
seizur
patient
short
fulmin
clinic
cours
die
within
short
period
show
clinic
sign
other
present
progress
sign
hepat
diseas
although
sign
often
wax
wane
third
group
dog
asymptomat
present
diseas
identifi
biochem
screen
subsequ
hepat
biopsi
specimen
analysi
abnorm
laboratori
find
includ
increas
serum
activ
hepat
enzym
includ
alt
ast
alp
ggt
virtual
dog
dog
approxim
increas
serum
total
bilirubin
concentr
mild
mark
mani
approxim
hypoalbuminem
abnorm
chemistri
valu
inconsist
hepat
function
test
serum
bile
acid
plasma
ammonia
concentr
usual
abnorm
clot
time
may
abnorm
test
result
gener
reflect
sever
diseas
stage
detect
one
larg
seri
dog
report
chronic
hepat
caus
low
serum
glucos
concentr
prolong
prothrombin
time
best
predictor
earli
death
within
week
present
dog
surviv
week
hypoalbuminemia
laboratori
chang
predict
shorter
surviv
time
degre
sever
necrosi
fibrosi
accur
predictor
earli
death
presenc
bridg
fibrosi
histolog
chang
predict
shorter
surviv
time
dog
surviv
week
radiograph
find
vari
sever
diseas
abnorm
find
includ
microhepatica
usual
associ
termin
cirrhosi
ascit
associ
portal
hypertens
hypoalbuminemia
case
undergo
angiograph
evalu
multipl
acquir
tortuou
portosystem
shunt
indic
chronic
portal
hypertens
histolog
appear
uniqu
cah
seen
inflammatori
hepat
diseas
therefor
inflammatori
diseas
must
elimin
suggest
diagnosi
cah
histolog
featur
includ
piecem
necrosi
bridg
necrosi
activ
cirrhosi
piecem
necrosi
refer
specif
pattern
typic
cah
character
periport
necrosi
inflamm
occur
irregular
fashion
surround
island
normal
hepatocyt
major
inflammatori
cell
lymphocyt
plasma
cell
although
lesser
number
neutrophil
macrophag
accompani
featur
includ
bile
duct
hyperplasia
bile
stasi
regen
nodul
eventu
deposit
fibrou
tissu
sequela
inflamm
necrosi
eventu
connect
adjac
portal
triad
bridg
necrosi
fibrosi
normal
hepat
architectur
lost
fibrot
process
becom
diffus
term
cirrhosi
doberman
pinscher
evalu
copper
stain
strongli
posit
quantit
measur
hepat
copper
concentr
high
breed
studi
extens
presenc
hepat
copper
howev
seen
sever
case
breed
high
hepat
copper
concentr
histolog
gross
appear
liver
normal
earli
case
diseas
progress
liver
becom
shrunken
lose
normal
lobular
pattern
becom
discolor
brown
red
yellow
mottl
surfac
becom
irregular
eventu
surfac
becom
coars
nodular
textur
reflect
regen
nodul
occur
set
termin
cirrhosi
treatment
cah
dog
remain
specul
control
clinic
trial
larg
number
dog
perform
necroinflammatori
respons
usual
progress
dog
go
spontan
remiss
cirrhosi
present
likelihood
success
manag
case
low
therefor
prognosi
poor
sever
case
dog
die
within
sever
week
month
despit
appropri
treatment
emphas
need
earli
detect
three
basic
goal
treat
dog
cah
arrest
inflamm
correct
nutrit
imbal
treat
hepat
encephalopathi
dietari
manag
resolv
fibrosi
though
control
trial
use
glucocorticoid
treat
dog
cah
mani
clinician
success
use
part
therapeut
regimen
larg
studi
doberman
pinscher
cah
howev
littl
benefit
seen
prednison
alon
anoth
studi
chronic
hepat
variou
breed
dog
surviv
week
treat
prednison
improv
surviv
compar
dog
treat
prednison
howev
varieti
hepat
diseas
treat
lack
prospect
control
group
limit
valid
conclus
studi
studi
human
show
combin
lowdos
glucocorticoid
azathioprin
imuran
efficaci
highdos
glucocorticoid
alon
fewer
side
effect
observ
combin
may
justifi
dog
success
use
combin
prednison
azathioprin
prednison
alon
theoret
basi
prednisolon
prefer
prednison
treat
dog
hepat
diseas
latter
drug
requir
hepat
convers
former
activ
drug
howev
studi
human
cah
shown
two
drug
equal
efficaci
reach
similar
blood
level
activ
form
similar
studi
perform
dog
although
found
differ
prednisolon
prednison
treat
dog
hepat
diseas
recommend
start
dosag
prednison
mglb
bodi
weight
per
day
start
dosag
azathioprin
mgm
bodi
surfac
area
daili
clinic
remiss
achiev
usual
week
dose
prednison
gradual
taper
low
mainten
dose
approxim
mglb
bodi
weight
likewis
azathioprin
taper
alternateday
dosag
schedul
origin
dose
gener
taper
prednison
first
taper
azathioprin
dose
prednison
low
azathioprin
gener
associ
fewer
side
effect
better
toler
complet
blood
count
cbc
platelet
count
obtain
week
start
azathioprin
everi
month
thereaft
look
potenti
myelosuppress
detect
azathioprin
either
taper
discontinu
depend
magnitud
cytopenia
taper
process
patient
monitor
serum
biochemistri
profil
relaps
often
difficult
differenti
effect
prednison
serum
hepat
enzym
activ
especi
alp
activ
effect
diseas
process
serum
enzym
activ
set
clinic
judgment
use
determin
prednison
continu
taper
serial
bile
acid
assay
serum
bilirubin
albumin
concentr
also
use
monitor
patient
hepat
inflamm
adequ
control
azathioprin
enzym
activ
decreas
prednison
taper
eventu
prednison
discontinu
later
azathioprin
discontinu
case
cholestasi
use
hydrocholeret
drug
ursodeoxychol
acid
ursodiol
actigal
urso
may
help
ursodeoxychol
acid
natur
occur
dihydroxyl
hydrophil
bile
acid
found
small
quantiti
normal
human
bile
larger
quantiti
bile
certain
speci
bear
one
use
dissolut
radioluc
gallston
propos
mechan
action
alter
composit
bile
chang
cholesterolprecipit
cholesterolsolubil
dispers
cholesterol
liquid
crystal
bile
thu
solubil
gallston
human
ursodiol
dissolv
gallston
rate
approxim
mmmonth
work
best
radioluc
noncalcifi
gallston
less
mm
diamet
side
effect
rare
diarrhea
influenc
either
serum
total
cholesterol
triglycerid
concentr
exact
mechan
benefici
effect
inflammatori
hepat
diseas
remain
controversi
believ
favor
chang
bile
acid
pool
render
retain
endogen
bile
acid
less
toxic
chang
bile
acid
pool
toxic
hydrophob
bile
acid
less
toxic
hydrophil
bile
acid
also
thought
ursodeoxychol
acid
antiinflammatori
immunomodulatori
choleret
effect
promot
bile
flow
decreas
viscos
bile
latter
mechan
believ
mediat
cholehepat
shunt
hypothesi
propos
ursodeoxychol
convert
ursodeoxychol
acid
addit
hydrogen
ion
origin
carbon
acid
leav
bicarbon
ion
act
osmot
draw
water
decreas
viscos
promot
bile
flow
ursodeoxychol
acid
use
manag
chronic
hepat
diseas
human
includ
cah
primari
biliari
cirrhosi
primari
scleros
cholang
signific
improv
symptom
laboratori
paramet
surviv
report
mani
patient
undergo
treatment
diseas
use
ursodeoxychol
acid
either
alon
combin
drug
patient
variou
cholestat
diseas
includ
dog
cah
cat
cholangiohepat
drug
well
toler
case
respons
dramat
use
ursodeoxychol
acid
consid
either
primari
adjunct
combin
immunosuppress
antiinflammatori
drug
treatment
patient
chronic
liver
diseas
may
effect
drug
patient
glucocorticoid
therapi
immunosuppress
drug
therapi
contraind
ineffect
ursodeoxychol
acid
also
power
choleret
agent
use
treat
sludg
bile
cholelithiasi
drug
suppli
capsul
recent
tablet
safe
effect
dose
mglbday
administ
either
daili
divid
twice
day
drug
given
food
studi
need
perform
substanti
efficaci
dosag
dog
cat
vitamin
e
therapi
also
recommend
mani
type
hepat
diseas
includ
cah
oxid
injuri
liver
well
recogn
sever
type
inflammatori
process
free
radic
gener
chronic
hepat
injuri
effect
certain
drug
toxin
immunolog
injuri
free
radic
damag
cellular
macromolecul
via
lipid
peroxid
thu
particip
cellular
injuri
play
import
role
initi
andor
perpetu
hepat
injuryvitamin
e
reduc
oxid
injuri
hepat
tissu
provid
protect
free
radicalsvitamin
e
use
dosag
unitslb
twice
day
bile
acid
requir
fatsolubl
vitamin
e
absorpt
may
reduc
liver
diseas
watersolubl
formul
use
type
formul
avail
health
food
store
sadenosylmethionin
molecul
synthes
cell
critic
intermediari
metabol
especi
import
liver
much
bodi
intermediari
metabol
occur
deriv
amino
acid
methionin
initi
three
major
biochem
pathway
transmethyl
transsulfur
aminopropyl
pathway
involv
major
anabol
catabol
reaction
influenc
steroid
hormon
effect
carnitin
synthesi
drug
metabol
detoxif
hepatocyt
red
blood
cell
membran
function
addit
involv
detoxif
toxin
protect
oxid
injuri
latter
effect
larg
part
mediat
glutathion
metabolit
transsulfur
pathway
metabol
glutathion
deplet
document
approxim
canin
felin
hepatopathieswith
glutathion
deplet
oxid
injuri
like
result
membran
damag
toxin
accumul
result
hepatocellular
injuri
death
specul
could
minim
supplement
furthermor
aminopropyl
metabolit
contribut
antiinflammatori
effect
avail
nutraceut
studi
experiment
clinic
varieti
speci
oral
use
becam
possibl
stabl
oral
salt
entericco
tablet
develop
nutramax
laboratori
inc
current
market
trade
name
denosyl
sever
studi
shown
product
safe
varieti
speci
includ
dog
cat
potenti
indic
usag
dog
cat
includ
hepat
necrosi
inflammatori
disord
cholestasi
druginduc
hepatotox
copper
storag
hepatopathi
metabol
disord
glucocorticoidinduc
hepatopathi
idiopath
felin
hepat
lipidosi
disord
administr
meant
help
minim
oxid
injuri
protect
free
radic
damag
protect
deleteri
effect
retain
bile
acid
enhanc
bile
flow
stabil
hepatocellular
membran
decreas
inflamm
aid
detoxif
endotoxin
substanc
absorb
portal
circul
sinc
divers
spectrum
effect
may
help
divers
group
hepatopathi
current
recommend
dose
mglb
divid
twice
daili
dog
mg
per
cat
daili
cat
rapidli
absorb
best
administ
empti
stomach
maxim
absorpt
drug
safe
administ
drug
use
treat
hepat
diseas
without
toxic
compromis
effect
drug
includ
ursodeoxychol
acid
control
studi
need
substanti
recommend
determin
disord
like
benefit
administr
optim
durat
treatment
unknown
quit
variabl
decis
discontinu
medic
ideal
base
followup
hepat
biopsi
specimen
analysi
evid
ongo
inflamm
therapi
continu
absenc
followup
hepat
biopsi
specimen
analysi
decis
discontinu
treatment
may
arbitrari
base
clinic
biochem
inform
patient
monitor
least
monthli
relaps
first
patient
requir
longterm
year
lowdos
therapi
eg
prednison
everi
hour
maintain
remiss
possibl
sourc
sepsi
examin
immunosuppress
drug
administ
includ
cultur
origin
hepat
biopsi
specimen
uncommon
grow
bacteria
secondari
event
case
hepat
failur
due
abnorm
hepat
reticuloendotheli
cell
function
urinari
tract
infect
also
common
dog
receiv
prednison
azathioprin
must
emphas
longterm
control
studi
support
recommend
treat
dog
cah
studi
need
help
clarifi
appropri
treatment
doberman
pinscher
increas
risk
develop
cah
recommend
serum
chemistri
profil
perform
everi
month
screen
cah
breed
treatment
institut
develop
clinic
sign
certainli
owner
wish
provid
best
care
given
option
earli
pet
life
dietari
treatment
correct
nutrit
imbal
goal
dietari
therapi
minim
hyperammonemia
correct
amino
acid
imbal
correct
vitamin
miner
defici
feed
control
diet
also
reduc
product
absorpt
toxin
small
intestin
potenti
antigen
worsen
cah
therapeut
effort
similar
use
manag
case
hepat
diseas
symptomat
discuss
detail
section
manag
hepat
diseas
case
excess
hepat
copper
document
special
copper
stain
quantit
hepat
copper
measur
effort
must
made
minim
hepat
copper
concentr
drug
penicillamin
cuprimin
trientin
syprin
use
chelat
hepat
copper
enhanc
urinari
excret
supplement
vitamin
c
ascorb
acid
also
increas
copper
excret
urin
supplement
zinc
acet
glucon
sulfat
limit
intestin
copper
absorpt
deposit
liver
well
remov
copper
liver
drug
discuss
detail
section
copperstorag
diseas
resolv
fibrosi
fibrosi
common
sequela
cah
sever
accur
predictor
earli
death
shorter
surviv
time
surviv
initi
week
postdiagnosi
period
manag
import
part
manag
case
cah
drug
choic
decreas
fibrot
deposit
dissolv
exist
fibrou
tissu
liver
colchicin
sever
studi
human
alcohol
posthepatit
primari
biliari
cirrhosi
show
colchicin
benefici
effect
clinic
biochem
histolog
surviv
colchicin
use
success
case
chronic
hepat
fibrosi
cirrhosi
dog
control
trial
need
substanti
clinic
observ
mechan
colchicin
benefit
patient
chronic
hepat
cirrhosi
unclear
although
antifibrot
antiinflammatori
effect
antifibrot
effect
primarili
due
inhibit
microtubul
assembl
within
cell
bind
protein
tubulin
thu
interf
collagen
synthesi
secret
stimul
collagenas
activ
thu
enhanc
breakdown
exist
collagen
colchicin
also
interfer
transcellular
movement
collagen
reduc
activ
hepat
collagenprocess
enzym
inhibit
prolifer
fibroblast
thu
colchicin
inhibit
collagen
product
increas
collagenasemedi
remov
fibrou
tissu
colchicin
also
mani
antiinflammatori
properti
long
use
antiinflammatori
agent
treat
gout
human
be
antiinflammatori
effect
includ
inhibit
leukocyt
migrat
degranul
decreas
level
mani
effect
colchicin
may
indic
mani
diseas
inflamm
fibrosi
promin
recommend
dosag
colchicin
dog
mglb
bodi
weight
daili
gener
use
drug
conjunct
prednison
azathioprin
ursodeoxychol
acid
vitamin
e
side
effect
dog
minim
dose
depend
includ
primarili
diarrhea
rare
vomit
side
effect
occur
dose
decreas
improv
dose
often
increas
week
subsequ
well
toler
side
effect
human
also
uncommon
usual
revers
includ
nausea
diarrhea
abdomin
pain
alopecia
bone
marrow
depress
myopathi
neuropathi
epistaxi
control
studi
need
defin
role
colchicin
manag
cah
dog
dpenicillamin
cuprimin
limit
use
antifibrot
agent
human
interfer
collagen
crosslink
matur
addit
antiinflammatori
effect
may
also
effect
lower
hepat
copper
concentr
doberman
pinscher
cah
dosag
dog
mglb
three
time
day
unfortun
drug
high
incid
side
effect
especi
vomit
anorexia
often
preclud
use
term
cholangiohepat
refer
complex
diseas
includ
inflammatori
chang
hepatobiliari
system
cholangiohepat
one
common
hepatobiliari
diseas
cat
diseas
name
predomin
inflammatori
cell
involv
common
form
lymphocyticplasmacyt
cholangiohepat
form
includ
predominantli
neutrophil
infiltr
suppur
cholangiohepat
lymphocyt
infiltr
biliari
cirrhosi
diffus
fibrosi
biliari
system
thought
end
stage
primari
inflammatori
diseas
despit
one
common
felin
hepatobiliari
diseas
etiolog
remain
unknown
predomin
inflammatori
cell
usual
lymphocyt
plasma
cell
immunemedi
etiolog
suspect
also
histolog
similar
primari
biliari
cirrhosi
human
believ
immunemedi
basi
human
abnorm
cellmedi
humor
immun
circul
immun
complex
antimitochondri
antibodi
document
cat
limit
laboratori
techniqu
detect
addit
evid
immunemedi
etiolog
mark
improv
seen
glucocorticoid
treatment
mani
cat
although
immunemedi
mechan
may
occur
mani
cat
concurr
diseas
identifi
case
includ
pancreat
inflammatori
bowel
diseas
bile
duct
obstruct
system
infect
toxin
cholelithiasi
case
suppur
cholangiohepat
suspect
bacteri
infect
may
underli
caus
escherichia
coli
bacteria
occasion
grown
cultur
hepat
biopsi
sampl
case
either
neutrophil
lymphocyticplasmacyt
cholangiohepat
support
theori
unclear
whether
bacteri
growth
caus
effect
hepat
diseas
caus
hepat
failur
decreas
clearanc
portal
bacteria
e
coli
ascend
bowel
secondari
abnorm
hepat
reticuloendotheli
cell
function
occurwhen
evalu
suspect
case
cholangiohepat
clinician
make
effort
rule
predispos
caus
mention
caus
identifi
immunemedi
mechan
suspect
clinic
featur
cat
may
affect
cholangiohepat
age
suppur
form
commonli
found
male
cat
younger
cat
wherea
nonsuppur
form
commonli
found
older
cat
seem
breed
predisposit
although
tendenc
seen
persian
cat
one
report
clinic
sign
typic
seen
hepat
failur
cat
includ
anorexia
vomit
depress
weight
loss
affect
cat
icter
affect
cat
minim
depress
anorexia
icteru
main
sign
mani
cat
febril
clinic
sign
often
acut
onset
although
cat
nonsuppur
form
chronic
ill
despit
trend
present
none
featur
reliabl
distinguish
suppur
nonsuppur
form
cholangiohepat
laboratori
find
includ
mark
increas
salt
activ
moder
increas
serum
alp
ggt
activ
usual
hyperbilirubinemia
concurr
bilirubinuria
also
seen
cat
mild
nonregen
anemia
consist
anemia
chronic
diseas
ultrasound
find
nonspecif
may
identifi
underli
diseas
pancreat
extrahepat
bile
duct
obstruct
definit
diagnosi
depend
histolog
examin
hepat
biopsi
tissu
cytolog
examin
usual
reliabl
establish
diagnosi
diseas
character
diffus
involv
liver
randomloc
hepat
biopsi
adequ
obtain
repres
tissu
usual
promin
infiltr
lymphocyt
plasma
cell
lymphocyt
alon
predominantli
neutrophil
portal
triad
depend
form
diseas
portal
triad
fibrosi
bile
duct
prolifer
centrilobular
accumul
bile
bile
cast
canalicular
area
also
frequent
present
septa
fibrou
tissu
variabl
lymphocyt
infiltr
often
link
portal
tract
form
circumscrib
nodul
hepatocyt
suggest
diseas
progress
biliari
cirrhosi
character
bridg
portal
fibrosi
bile
duct
prolifer
hyperplasia
nodular
regener
minim
inflamm
aerob
anaerob
cultur
hepat
tissu
without
bile
obtain
via
cholecystocentesi
obtain
cultur
often
posit
although
alway
clear
primari
secondari
event
cat
suppur
cholangiohepat
common
organ
cultur
descend
order
preval
e
coli
staphylococcu
streptococcu
bacillu
actinomyc
bacteroid
enterococcu
enterobact
clostridia
prior
treatment
antibiot
may
result
falseneg
cultur
liver
cat
cholangiohepat
may
appear
larg
round
margin
surfac
often
irregular
nodular
although
may
also
smooth
depend
degre
nodular
regener
color
often
mottl
red
brown
normal
lobular
pattern
complet
lost
reflect
distort
normal
lobular
architectur
may
accentu
lobular
mark
give
reticul
appear
reflect
promin
portal
infiltr
treatment
underli
associ
diseas
identifi
aggress
treat
exampl
case
bile
duct
obstruct
surgic
correct
usual
necessari
may
involv
biliari
decompress
obstruct
reliev
rerout
bile
duct
cholecystoenterostomi
concurr
inflammatori
bowel
diseas
pancreat
also
consid
case
lymphocyticplasmacyt
cholangiohepat
glucocorticoid
drug
choic
prednisolon
prefer
prednison
cat
due
possibl
improv
bioavail
prednisolon
cat
institut
dosag
mglb
bodi
weight
twice
day
least
month
subsequ
taper
month
biochem
clinic
remiss
posit
growth
cultur
hepat
biopsi
tissu
appropri
antibiot
given
concurr
metronidazol
flagyl
may
also
use
adjunct
treatment
due
immun
modulatori
effect
administ
slightli
reduc
dosag
mglb
two
three
time
day
undergo
hepat
metabol
cat
refractori
immunosuppress
regimen
scleros
form
biliari
cirrhosi
lowdos
puls
oral
methotrex
combin
prednisolon
metronidazol
ursodeoxychol
acid
use
total
dose
mg
methotrex
given
interv
total
three
dose
period
dose
well
toler
interv
base
hematolog
clinic
evalu
biochem
improv
first
morn
dose
doubl
mg
cat
need
dosag
interv
extend
everi
day
gi
side
effect
treatment
suppur
form
felin
cholangiohepat
involv
use
appropri
antibiot
base
cultur
result
hepat
biopsi
specimen
cultur
result
neg
amoxicillinclavulan
acid
mglb
bodi
weight
three
time
day
quinolon
antibiot
usual
good
choic
metronidazol
effect
anaerob
combin
antibiot
mention
dosag
mglb
bodi
weight
two
three
time
day
durat
therapi
often
rang
month
mani
case
transient
respons
antibiot
administr
subsequ
concurr
glucocorticoid
administr
often
necessari
clinic
judgment
use
situat
determin
glucocorticoid
start
case
howev
worsen
glucocorticoid
administr
emphas
need
hepat
biopsi
glucocorticoid
therefor
given
suppur
form
last
resort
antibiot
fail
virtual
case
without
extrahepat
bile
duct
obstruct
use
hydrocholeret
drug
ursodeoxychol
acid
ursodiol
actigal
urso
may
help
see
discuss
ursodeoxychol
acid
section
chronic
activ
hepat
ursodeoxychol
acid
natur
occur
dihydroxyl
hydrophil
bile
acid
found
small
quantiti
normal
human
bile
larger
quantiti
bile
certain
speci
bear
exact
mechan
benefici
effect
inflammatori
hepat
diseas
remain
controversi
believ
favor
chang
bile
acid
pool
render
retain
endogen
bile
acid
less
toxic
chang
bile
acid
pool
toxic
hydrophob
bile
acid
less
toxic
hydrophil
bile
acid
also
believ
ursodeoxychol
acid
antiinflammatori
immunomodulatori
effect
ursodeoxychol
acid
use
manag
chronic
hepat
diseas
human
includ
cah
primari
biliari
cirrhosi
primari
scleros
cholang
signific
improv
symptom
laboratori
paramet
report
mani
patient
undergo
treatment
diseas
use
ursodeoxychol
acid
either
alon
combin
drug
patient
variou
cholestat
diseas
includ
dog
cah
cat
cholangiohepat
drug
well
toler
case
respons
dramat
use
ursodeoxychol
acid
felin
cholangiohepat
complex
consid
adjunct
combin
immunosuppress
antiinflammatori
drug
antibiot
histolog
form
diseas
ursodeoxychol
acid
also
power
choleret
agent
use
treat
sludg
bile
cholelithiasi
recommend
dose
mglbday
administ
either
daili
divid
twice
day
newer
tablet
form
drug
urso
made
dose
conveni
drug
minim
side
effect
experi
may
dramat
improv
therapeut
benefit
studi
need
perform
substanti
efficaci
dosag
dog
cat
use
also
appear
help
diseas
see
section
cah
detail
descript
drug
specif
dietari
manag
gener
critic
success
outcom
howev
nutrit
support
may
necessari
import
affect
cat
eat
balanc
diet
specif
diet
proteinrestrict
diet
rare
necessari
cat
case
respons
therapi
rapid
tube
feed
necessari
prolong
anorexia
nutrit
support
provid
use
enter
feed
tube
percutan
endoscop
gastrostomi
peg
tube
esophagostomi
tube
nasoesophag
tube
use
feed
tube
describ
chapter
vitamin
e
therapi
also
recommend
mani
type
hepat
diseas
includ
felin
cholangiohepat
oxid
injuri
liver
well
recogn
sever
type
inflammatori
process
free
radic
gener
chronic
hepat
injuri
effect
certain
drug
toxin
immunolog
injuri
free
radic
damag
cellular
macromolecul
via
lipid
peroxid
thu
particip
cellular
injuri
play
import
role
initi
andor
perpetu
hepat
injuri
vitamin
e
reduc
oxid
injuri
hepat
tissu
provid
protect
free
radicalsvitamin
e
use
dosag
unitsday
bile
acid
requir
fatsolubl
vitamin
e
absorpt
may
reduc
liver
diseas
watersolubl
formul
use
type
formul
avail
health
food
store
prognosi
fair
good
unless
diseas
histolog
advanc
mani
patient
respond
dramat
glucocorticoid
administr
eventu
wean
medic
howev
cat
relaps
need
ongo
intermitt
treatment
cat
requir
prednisolon
dosag
mglbday
longterm
basi
month
year
success
control
diseas
process
fortun
longterm
side
effect
glucocorticoid
administr
minim
cat
hepat
necrosi
often
lead
acut
hepat
failur
hepatocyt
expos
extens
portal
system
venou
circul
suscept
injuri
varieti
etiolog
agent
hepat
necrosi
occur
secondari
hepat
process
inflamm
neoplasia
associ
known
hepatotoxin
occur
caus
known
caus
hepat
necrosi
list
box
clinic
featur
clinic
sign
hepat
necrosi
depend
degre
sever
mani
patient
asymptomat
diseas
detect
biochem
screen
mani
case
hepat
trauma
wherea
case
acut
fulmin
hepat
failur
latter
instanc
affect
patient
rang
profoundli
depress
comatos
degre
hepat
encephalopathi
depend
caus
sever
vomit
anorexia
fever
often
seen
icteru
often
seen
periport
involv
presenc
coagulopathi
dic
reflect
degre
sever
usual
manifest
gi
bleed
hematemesi
ecchymos
excess
bleed
venipunctur
site
laboratori
find
includ
profound
increas
salt
sast
activ
increas
salt
activ
correl
histolog
find
initi
period
hepatocellular
injuri
serum
enzym
activ
may
persist
declin
follow
day
despit
persist
extens
necrosi
activ
serum
alp
ggt
serum
bilirubin
concentr
variabl
reflect
degre
cholestasi
degre
clinic
sever
often
poorli
correl
measur
variabl
abnorm
includ
hypoglycemia
abnorm
clot
paramet
hepat
function
test
serum
bile
acid
plasma
ammonia
concentr
often
normal
unless
massiv
hepat
necrosi
hyperbilirubinemia
laboratori
abnorm
usual
overlap
diseas
cah
primari
hepat
neoplasia
histolog
find
reflect
degre
hepat
necrosi
pattern
necrosi
differenti
seen
cah
locat
within
lobul
appear
neutrophil
enter
phagocyt
cellular
debri
absenc
lymphocyt
plasma
cell
predomin
inflammatori
cell
treatment
involv
withdraw
known
hepatotoxin
treatment
underli
condit
list
box
associ
hepat
necrosi
effort
must
made
look
disord
associ
hepat
necrosi
addit
treatment
measur
aim
provid
optimum
condit
hepat
regener
prevent
secondari
complic
hepat
diseas
measur
discuss
detail
section
manag
hepat
diseas
mani
patient
detect
increas
serum
activ
hepat
enzym
routin
biochem
screen
present
clinic
ill
clinician
must
tri
determin
underli
nonhepat
caus
present
includ
endocrinopathi
hyperadrenocortic
diabet
mellitu
hyperthyroid
disord
list
box
obviou
underli
caus
exist
clinician
must
determin
whether
clinic
sign
attribut
hepat
diseas
sign
seriou
enough
caus
ill
workup
hepat
function
test
bile
acid
blood
ammonia
concentr
ultrasound
examin
andor
hepat
biopsi
warrant
clinic
sign
absent
mild
baselin
hepat
function
test
gener
serum
bile
acid
assay
run
use
monitor
paramet
unless
hepat
function
significantli
abnorm
repeat
chemistri
profil
hepat
function
test
run
week
test
persist
abnorm
hepat
imag
biopsi
warrant
even
patient
remain
clinic
normal
cah
chronic
activ
hepat
mani
drug
report
caus
hepat
diseas
patient
common
one
list
box
sever
type
hepatopathi
associ
drug
administr
includ
hepatocellular
necrosi
cholestasi
cah
vacuolar
chang
includ
steroid
hepatopathi
combin
process
hepatotox
drug
classifi
caus
predict
hepat
damag
intrins
toxicos
idiosyncrat
potenti
caus
hepat
damag
drug
caus
predict
hepat
damag
high
incid
hepatotox
usual
dose
depend
effect
reproduc
experiment
anim
hand
idiosyncrat
reaction
character
occur
small
percentag
patient
usual
dose
depend
experiment
reproduc
idiosyncrat
toxicosi
result
unusu
suscept
affect
patient
advers
reaction
result
metabol
aberr
hypersensit
immunemedi
event
specif
mechan
injuri
usual
unknown
idiosyncrat
toxicosi
occur
gener
treatment
druginduc
hepat
diseas
involv
withdraw
drug
support
care
discuss
concentr
import
druginduc
hepatopathi
anticonvuls
druginduc
hepat
injuri
hepatobiliari
diseas
associ
administr
mani
anticonvuls
drug
describ
includ
phenytoin
primidon
phenobarbit
either
alon
combin
drug
often
result
elev
hepat
enzym
activ
patient
asymptomat
test
hepat
function
includ
serum
bile
acid
plasma
ammonia
concentr
often
normal
howev
signific
hepatobiliari
diseas
occasion
develop
patient
given
seemingli
safe
dose
drug
dose
increas
toxic
level
maintain
seizur
control
toxic
blood
level
also
develop
patient
receiv
appropri
dose
hepat
failur
caus
occur
drug
metabol
clear
liver
primidon
hepatotox
phenobarbit
clinic
sign
includ
typic
hepat
diseas
includ
depress
anorexia
weight
loss
subsequ
develop
jaundic
featur
typic
hepatoencephalopathi
endstag
hepat
diseas
termin
event
often
includ
excel
seizur
control
anticonvuls
drug
poorli
metabol
thu
achiev
high
blood
level
time
clinic
sign
notic
hepat
diseas
usual
advanc
often
presenc
cirrhosi
prognosi
poor
howev
estim
clinic
sign
develop
dog
receiv
anticonvuls
drug
long
term
laboratori
abnorm
includ
variabl
increas
salt
sast
serum
alp
ggt
activ
chang
mark
dog
receiv
primidon
andor
phenobarbit
increas
salt
activ
usual
revers
upon
withdraw
drug
alway
correl
morpholog
evid
hepatocellular
necrosi
increas
serum
alp
activ
relat
increas
hepat
synthesi
enzym
abnorm
occur
mani
asymptomat
dog
without
signific
hepat
injuri
test
hepat
function
use
determin
whether
impend
hepat
failur
includ
serum
bile
acid
albumin
plasma
ammonia
concentr
increas
total
bilirubin
concentr
decreas
albumin
bun
glucos
cholesterol
concentr
although
specif
common
indic
two
distinct
form
hepatotox
injuri
relat
anticonvuls
drug
treatment
one
form
character
develop
clinic
sign
extend
period
treatment
histolog
find
includ
diffus
fibrosi
nodular
regener
variou
amount
necrosi
lipidosi
inflamm
eventu
lead
macronodular
cirrhosi
second
form
hepatotox
injuri
metabol
hepat
failur
intrahepat
cholestasi
distinct
histor
clinic
histolog
featur
associ
cirrhosi
conspicu
absenc
necroinflammatori
respons
versu
form
drug
toxic
acquir
canin
hepat
diseas
unrel
drug
administr
prognosi
poor
histolog
lesion
sever
hepat
failur
occur
treatment
involv
withdraw
anticonvuls
drug
possibl
use
altern
anticonvuls
drug
potassium
bromid
hepatotox
effect
associ
potassium
bromid
indic
use
glucocorticoid
unless
activ
inflammatori
compon
use
colchicin
might
indic
fibrosi
promin
featur
see
section
chronic
activ
hepat
use
ursodeoxychol
acid
may
also
indic
due
presenc
signific
cholestat
compon
case
use
may
also
help
emphas
caution
use
attribut
abnorm
hepat
function
hepat
failur
anticonvuls
administr
incid
problem
low
laboratori
ancillari
test
includ
hepat
biopsi
specimen
analysi
may
well
justifi
patient
carprofen
toxic
carprofen
rimadyl
commonli
use
nonsteroid
antiinflammatori
drug
nsaid
treat
canin
osteoarthr
degen
joint
diseas
estim
incid
sever
hepatotox
reaction
carprofen
dog
per
one
report
dog
describ
hepatocellular
toxicosi
associ
administr
carprofen
time
report
dog
receiv
carprofen
dog
report
evid
previou
signific
hepatopathi
medic
problem
predispos
hepatopathi
variou
drug
given
dog
appar
relationship
develop
hepat
toxicosi
dog
labrador
retriev
dog
rang
year
old
mean
year
carprofen
administ
allevi
sign
musculoskelet
pain
dog
amount
carprofen
administ
rang
mglb
bodi
weight
mean
mglb
oral
everi
hour
durat
treatment
rang
day
mean
day
clinic
sign
toxicosi
notic
dog
day
mean
median
day
initi
carprofen
two
dog
receiv
carprofen
day
develop
clinic
sign
one
dog
receiv
drug
day
clinic
sign
toxicosi
drug
discontinu
discoveri
hepat
necrosi
biopsi
specimen
obtain
evalu
possibl
metastat
cancer
dog
labrador
retriev
develop
clinic
sign
interv
day
initi
carprofen
administr
mean
median
day
one
dog
receiv
carprofen
day
clinic
abnorm
develop
day
first
dose
clinic
sign
associ
toxicosi
predominantli
anorexia
dog
vomit
dog
sign
notic
less
frequent
lethargi
diarrhea
polyuria
polydipsia
hematuria
physic
examin
reveal
icteru
dog
ascit
dog
common
laboratori
abnorm
increas
serum
activ
alt
dog
ast
dog
alp
dog
serum
bilirubin
concentr
dog
hypoalbuminemia
seen
dog
addit
urinalys
perform
dog
dog
evid
renal
diseas
present
includ
isosthenuria
azotemia
glucosuria
proteinuria
evid
epitheli
cell
granular
cast
hemogram
radiograph
ultrasonograph
abnorm
minim
histopatholog
evalu
perform
dog
reveal
vari
degre
vacuolar
chang
balloon
degener
necrosi
hepatocyt
bridg
fibrosi
mixedcellular
inflamm
accumul
bile
pigment
fifteen
dog
treat
dog
hospit
dog
receiv
intraven
fluid
antibiot
drug
use
manag
gi
sign
includ
histamin
h
receptor
antagonist
metoclopramid
sucralf
misoprostol
three
dog
given
ursodeoxychol
acid
day
four
dog
die
euthan
within
day
initi
examin
one
dog
sever
hepat
renal
failur
also
perfor
gi
tract
diffus
intestin
ulcer
document
necropsi
unknown
whether
gi
tract
ulcer
subsequ
perfor
directli
attribut
carprofen
use
indirectli
attribut
hypoperfus
ischemia
uremia
dog
fulli
recov
druginduc
hepat
diseas
labrador
retriev
recov
hepat
injuri
mortal
rate
breed
surviv
dog
vomit
resolv
day
support
care
institut
carprofen
discontinu
inappet
primari
persist
clinic
sign
resolv
day
carprofen
discontinu
carprofen
administr
discontinu
repeatedli
reinstitut
discontinu
period
dog
clinic
sign
resolv
discontinu
reappear
associ
drug
administr
laboratori
evalu
perform
surviv
dog
week
onset
clinic
sign
dog
markedli
improv
regard
hepat
variabl
valu
determin
month
diagnosi
toxic
condit
dog
within
refer
rang
slightli
increas
fifteen
surviv
dog
healthi
day
episod
toxicosi
dog
unrel
problem
result
studi
suggest
drug
reaction
carprofen
idiosyncrat
hostdepend
natur
progress
condit
appear
correl
dose
carprofen
magnitud
hepat
enzym
activ
histopatholog
sever
hepat
lesion
also
noteworthi
renal
lesion
detect
number
dog
welldocu
side
effect
nsaid
although
prescreen
hematolog
serum
biochem
analys
may
yield
result
use
predict
dog
advers
reaction
carprofen
evalu
renal
hepat
function
administr
drug
recommend
dog
renal
hepatobiliari
abnorm
may
poor
candid
receiv
drug
extra
caution
use
carprofen
use
dog
addit
serum
biochemistri
analysi
obtain
approxim
week
start
carprofen
detect
patient
develop
hepat
renal
diseas
owner
inform
clinic
sign
drug
intoler
instruct
immedi
discontinu
drug
sign
develop
mebendazoleinduc
hepat
diseas
mebendazol
telmint
anthelmint
drug
use
effect
ascarid
hookworm
whipworm
though
gener
consid
safe
drug
acut
hepat
necrosi
associ
mebendazol
administr
dog
report
addit
report
addit
case
advers
drug
reaction
associ
mebendazol
administr
report
us
food
drug
administr
base
report
extens
safeti
studi
normal
anim
induc
hepat
diseas
unclear
whether
mebendazol
intrins
predict
idiosyncrat
hepatotoxin
fact
toxic
low
incid
difficult
reproduc
experiment
appar
dose
relat
suggest
mebendazol
idiosyncrat
toxin
wherea
presenc
toxic
sever
member
one
kennel
suggest
mebendazol
intrins
hepatotoxin
regardless
mechan
toxic
recommend
mebendazol
use
safer
effect
anthelmint
similar
antiparasit
spectrum
fenbendazol
panacur
febantel
drontol
plu
recommend
abnorm
accumul
copper
hepatocyt
result
metabol
defect
copper
metabol
document
bedlington
terrier
west
highland
white
terrier
skye
terrier
possibl
doberman
pinscher
breed
disord
similar
ident
wilson
diseas
human
excess
copper
accumul
hepatocyt
result
progress
hepatocyt
destruct
diseas
breed
must
distinguish
caus
secondari
hepat
copper
accumul
copper
normal
excret
biliari
tract
therefor
copper
accumul
liver
cholestat
disord
includ
cah
cirrhosi
dog
primari
copperstorag
diseas
copper
accumul
liver
develop
hepat
damag
cholestasi
copper
ingest
passiv
absorb
proxim
small
intestin
remaind
lost
fece
ingest
copper
bound
copper
transport
protein
metallothionein
portion
lost
fece
unbound
copper
absorb
intestin
enter
portal
circul
bound
albumin
anoth
copper
transport
protein
transcuprein
copper
transport
liver
within
hepatocyt
copper
bound
cytosol
metallothionein
store
lysosom
copper
undergo
two
fate
excret
bile
bound
copper
transport
protein
ceruloplasmin
transport
peripher
tissu
step
import
step
regul
copper
homeostasi
biliari
excret
dog
abnorm
copper
storag
copper
accumul
within
lysosom
hepatocyt
lysosom
copper
innocu
lysosom
storag
capac
exhaust
copper
break
cytoplasm
toxic
hepatocyt
excess
hepat
copper
alter
hepat
membran
permeabl
interfer
normal
hepatocyt
transport
protein
triglycerid
eventu
hepatocyt
undergo
cellular
lysi
necrosi
result
massiv
releas
copper
damag
hepatocyt
taken
circul
lead
hemolyt
crisi
bedlington
terrier
diseas
autosom
recess
disord
specif
defect
copper
metabol
thought
excess
copper
bind
abnorm
metallothionein
liver
sequest
copper
liver
lysosom
reduc
biliari
excret
excess
copper
accumul
detect
earli
month
age
progress
time
unclear
whether
subset
doberman
pinscher
cah
primari
copperstorag
diseas
whether
abnorm
hepat
copper
concentr
secondari
cholestasi
associ
activ
hepat
one
report
howev
document
increas
hepat
copper
concentr
two
doberman
pinscher
subacut
hepat
cholestasi
present
histolog
lead
specul
genet
defect
copper
metabol
might
primari
caus
hepat
inflammatori
diseas
doberman
pinscher
diseas
west
highland
white
terrier
differ
copperstorag
diseas
bedlington
terrier
compar
lower
concentr
hepat
copperwest
highland
white
terrier
gener
toler
ppm
copper
west
highland
white
terrier
rare
accumul
excess
copper
throughout
lifetim
month
age
west
highland
white
terrier
reach
upper
limit
excess
copper
dog
excess
hepat
copper
return
normal
year
age
skye
terrier
excess
copper
accumul
liver
appear
relat
cholestasi
thought
result
disord
intracellular
bile
metabol
abnorm
bile
secret
although
wilson
diseas
human
similar
diseas
affect
bedlington
terrier
sever
import
differ
wilson
diseas
often
lead
copper
accumul
subsequ
damag
tissu
includ
brain
manifest
seen
dog
addit
concentr
ceruloplasmin
human
wilson
diseas
low
wherea
concentr
unbound
copper
variabl
may
high
affect
bedlington
terrier
serum
copper
ceruloplasmin
concentr
normal
diseas
autosom
recess
inherit
defect
studi
larg
number
bedlington
terrier
screen
liver
biopsi
abnorm
copper
storag
approxim
dog
affect
recent
genet
studi
vetgen
llc
suggest
bedlington
terrier
test
homozyg
clear
diseas
homozyg
affect
remaind
heterozyg
carrier
copperstorag
diseas
bedlington
terrier
categor
three
gener
group
first
group
affect
dog
usual
young
adult
short
fulmin
cours
acut
hepat
necrosi
failur
high
mortal
rate
dog
usual
icter
anorect
vomit
may
undergo
hemolyt
crisi
copper
toxic
rapid
lysi
hepatocyt
dog
die
despit
support
measur
sometim
stress
event
whelp
show
precipit
onset
sign
second
group
affect
dog
usual
middleag
older
usual
insidi
deterior
gener
condit
character
chronic
weight
loss
anorexia
intermitt
vomit
gener
unthrifti
present
mani
dog
hallmark
chronic
endstag
hepat
diseas
includ
icteru
ascit
third
group
affect
dog
asymptomat
diseas
detect
biochem
screen
usual
increas
salt
activ
document
hepat
biopsi
specimen
analysi
thought
dog
group
repres
prestag
first
two
group
affect
dog
group
hepat
copper
concentr
elev
earli
month
age
progress
increas
copper
concentr
usual
occur
year
age
patient
surviv
time
level
slowli
declin
although
never
complet
return
normal
consist
laboratori
abnorm
increas
salt
activ
usual
occur
hepat
injuri
taken
place
salt
activ
usual
correl
sever
diseas
histolog
although
enzym
deplet
may
occur
termin
cirrhosi
serum
alp
activ
serum
bilirubin
concentr
variabl
reflect
degre
cholestasi
presumpt
diagnosi
consid
bedlington
terrier
increas
salt
activ
although
diseas
need
confirm
hepat
biopsi
specimen
analysi
must
point
normal
salt
level
rule
diseas
bedlington
terrier
get
form
hepat
diseas
diagnosi
confirm
quantit
measur
hepat
copper
hepat
biopsi
specimen
normal
hepat
copper
concentr
rang
ppm
liver
dri
weight
basi
although
mark
variabl
among
dog
variou
breed
formalinfix
hepat
tissu
suitabl
quantit
measur
dog
valu
rang
consid
affect
affect
dog
hepat
concentr
time
normal
diseas
also
document
histochem
stain
copper
rubean
acid
timm
rhodanin
orcein
stain
pathologist
use
rubean
acid
affect
liver
granul
copper
seen
stain
qualit
estim
measur
excret
stool
follow
intraven
inject
also
advoc
noninvas
method
detect
affect
dog
histolog
find
vari
normal
except
excess
copper
accumul
vari
sever
chronic
hepat
diseas
progress
focal
hepat
necrosi
featur
ident
describ
cah
eventu
diseas
progress
micronodular
macronodular
cirrhosi
gross
appear
liver
reflect
histolog
sever
rang
normal
fine
coars
nodular
surfac
regen
nodul
reflect
endstag
liver
diseas
recent
vetgen
llc
began
offer
genet
test
copper
toxicosi
bedlington
terrier
breed
test
use
link
marker
two
allel
marker
type
call
found
dog
marker
type
homozyg
normal
clear
diseas
dog
affect
diseas
marker
type
dog
carrier
allel
usual
associ
copper
toxicosi
diseas
allel
find
strong
genet
disequilibrium
allow
potenti
valuabl
test
interpret
result
dog
like
homozyg
normal
clear
diseas
dog
like
affect
affect
dog
affect
carrier
dog
vetgen
data
indic
dog
chanc
carrier
test
may
help
make
recommend
breeder
dog
chosen
breed
gene
could
elimin
subsequ
gener
howev
breeder
still
allow
liver
biopsi
specimen
obtain
dog
use
breed
near
intermedi
futur
current
way
detect
small
number
affect
dog
associ
allel
vetgen
provid
collect
kit
dna
use
soft
cheek
brush
test
complet
puppi
purchas
earli
age
treatment
earli
detect
essenti
therefor
high
incid
breed
strongli
recommend
bedlington
terrier
undergo
biochem
screen
two
three
time
per
year
ideal
liver
biopsi
perform
year
age
posit
diagnosi
establish
treatment
depend
stage
diseas
affect
dog
specif
therapi
involv
administr
drug
chelat
copper
increas
urinari
excret
well
effort
decreas
copper
absorpt
tradit
drug
choic
dpenicillamin
cuprimin
recommend
dosag
dog
mglb
two
time
day
drug
ideal
given
meal
maxim
effect
manner
penicillamin
remov
approxim
ppm
copper
per
year
given
meal
efficaci
decreas
approxim
half
common
side
effect
includ
anorexia
vomit
divid
dosag
three
four
daili
dose
andor
administ
food
often
minim
sign
unfortun
side
effect
may
intoler
dog
necessit
discontinu
drug
usual
take
sever
year
hepat
copper
concentr
decreas
normal
therapi
must
continu
life
addit
chelat
copper
dpenicillamin
antifibrot
properti
stabil
lysosom
immunemodul
effect
might
also
benefit
manag
diseas
recent
tetramin
cupruret
agent
evalu
shown
effect
decopp
agent
lower
hepat
copper
increas
urinari
excret
drug
also
better
toler
dpenicillamin
trientin
syprin
drug
choic
cupruret
effect
similar
dpenicillamin
ie
remov
approxim
ppm
copper
per
year
although
may
attack
differ
copper
pool
recommend
dose
mglb
two
time
day
side
effect
minim
dog
compar
caus
dpenicillamin
trientin
often
use
first
patient
experi
side
effect
dpenicillamin
trientin
alway
readili
avail
mani
pharmacist
order
order
directli
manufactur
merck
experiment
drug
shown
potent
copper
chelat
yet
commerci
avail
addit
measur
reduc
hepat
copper
concentr
includ
supplement
diet
zinc
mglb
zinc
glucon
three
time
day
mglb
zinc
sulfat
three
time
day
mg
element
zinc
zinc
acet
two
time
day
zinc
induc
increas
concentr
intestin
metallothionein
bind
ingest
copper
intestin
epitheli
cell
thu
prevent
copper
absorpt
cell
slough
copper
subsequ
lost
fece
addit
zinc
enhanc
remov
copper
hepatocyt
zinc
lower
hepat
copper
indirectli
affect
multipl
area
copper
equilibria
displac
copper
target
tissu
zinc
also
induc
hepat
metallothionein
bind
sequest
excess
copper
innocu
form
compar
free
copper
rate
remov
hepat
copper
rel
slow
reason
dog
sever
fulmin
hepat
secondari
copper
accumul
candid
zinc
therapi
alon
patient
zinc
commonli
combin
chelat
agent
trientin
one
studi
demonstr
mark
improv
hepat
hepat
copper
concentr
three
bedlington
terrier
three
west
highland
white
terrier
treat
zinc
acet
sole
decopp
agent
advantag
zinc
treatment
includ
efficaci
low
cost
minim
side
effect
type
zinc
supplement
import
measur
serum
zinc
level
goal
achiev
plasma
zinc
concentr
load
period
dose
decreas
approxim
half
origin
dose
serum
zinc
level
measur
everi
month
serum
concentr
drop
dose
increas
origin
dose
effect
zinc
must
given
separ
food
least
hour
food
constitu
phytat
bind
zinc
diminish
efficaci
zinc
caus
vomit
may
mix
tablespoon
tuna
fish
oil
minim
nausea
vitamin
c
also
might
use
decreas
copper
absorpt
increas
copper
excret
urin
addit
dog
hepat
insuffici
defici
ascorb
acid
ideal
vitamin
c
given
meal
recommend
dosag
mglbday
dog
also
fed
diet
low
copper
concentr
commerci
diet
low
copper
includ
hill
prescript
diet
ld
purina
fit
trim
purina
hipro
wayn
anf
pedigre
nutro
natur
choic
precis
diet
high
copper
includ
iam
eukanuba
scienc
diet
blue
seal
natur
homemad
diet
contain
excess
copper
includ
meat
poultri
fish
dairi
product
food
excess
copper
exclud
diet
includ
egg
liver
shellfish
organ
meat
beanslegum
mushroom
chocol
nut
cereal
miner
supplement
contain
copper
also
avoid
treatment
measur
support
symptomat
discuss
detail
section
manag
hepat
diseas
primari
infect
involv
liver
rare
caus
hepat
dog
cat
uncommon
howev
cultur
bacteria
secondari
event
noninfecti
hepat
diseas
due
decreas
hepat
reticuloendotheli
cell
function
addit
bacteri
pathogen
parasit
fungal
infect
involv
liver
liver
play
central
role
process
portal
product
receiv
extens
arteri
blood
suppli
import
reticuloendotheli
cell
function
direct
connect
intestin
via
biliari
tract
subject
infect
sever
rout
includ
hematogen
portal
arteri
ascend
via
biliari
system
howev
bacteri
infect
liver
occur
unusu
circumst
includ
patient
receiv
immunosuppress
drug
patient
hyperadrenocortic
diabet
mellitu
sever
enter
biliari
stasi
septicemia
decreas
hepat
blood
suppli
devit
necrosi
hepat
tissu
sourc
infect
origin
bowel
treatment
aim
bacteria
normal
found
gut
one
studi
cat
suppur
cholangiohepat
bacteria
cultur
hepat
biopsi
specimen
descend
order
preval
e
coli
staphylococcu
streptococcu
bacillu
actinomyc
bacteroid
enterococcu
enterobact
clostridia
anoth
studi
dog
hepat
abscess
e
coli
clostridium
sp
klebsiella
pneumonia
enterococcu
sp
staphylococcu
epidermidi
staphylococcu
intermediu
common
bacteria
isol
mani
patient
polymicrobi
infect
clinic
find
bacteri
cholangiohepat
hepat
abscess
usual
caus
persist
fever
anorexia
hepatomegali
variabl
abdomin
pain
sign
periton
may
sign
system
infect
includ
lymphadenopathi
sign
infect
organ
pneumonia
endocard
urinari
tract
involv
enter
risk
factor
includ
biliari
obstruct
inflammatori
bowel
diseas
pancreat
laboratori
find
usual
includ
increas
activ
salt
sast
involv
biliari
system
increas
activ
serum
alp
ggt
possibl
increas
bilirubin
concentr
may
neutrophil
leukocytosi
hyperglobulinemia
especi
chronic
infect
coagulopathi
may
present
radiograph
find
usual
normal
howev
radioluc
area
within
liver
biliari
system
andor
gallbladd
may
seen
secondari
gasform
bacteria
radiopaqu
cholelith
may
also
seen
ultrasound
imag
may
detect
discret
abscess
present
seen
multipl
hypoecho
hyperecho
heterogen
anecho
area
within
liver
case
cholecyst
ultrasonograph
find
includ
thicken
gallbladd
wall
sludg
within
lumen
definit
diagnosi
made
hepat
biopsi
discret
abscess
suspect
radiograph
ultrasonograph
find
blind
percutan
biopsi
method
contraind
aerob
anaerob
cultur
liver
obtain
whenev
hepat
biopsi
perform
falseneg
cultur
obtain
prior
antibiot
treatment
treatment
involv
appropri
antibiot
base
hepat
biopsi
specimen
cultur
cultur
result
neg
despit
gross
histopatholog
find
suggest
bacteri
infect
antibiot
choic
depend
suspect
rout
infect
gi
tract
origin
antibiot
use
includ
coverag
anaerob
gramneg
organ
good
combin
includ
fluoroquinolon
ampicillin
metronidazol
fluoroquinolon
excel
gramneg
activ
effect
oral
administ
drug
treatment
hepatobiliari
bacteri
infect
ampicillin
metronidazol
indic
anaerob
infect
singleag
amoxicillinclavulan
acid
clavamox
also
good
choic
due
agent
broad
spectrum
activ
clindamycin
also
activ
anaerob
enter
liver
high
concentr
howev
use
bile
duct
obstruct
sever
impair
hepat
function
antibiot
must
administ
sever
month
discret
abscess
present
ultrasound
imag
guid
end
point
therapi
antibiot
given
least
month
follow
resolut
ultrasound
lesion
discret
abscess
present
surgic
intervent
drainag
resect
may
necessari
likewis
sever
cholecyst
present
cholecystectomi
may
indic
concurr
medic
treatment
appropri
antibiot
also
indic
one
studi
case
high
surviv
rate
dog
underw
surgic
treatment
hepat
abscess
cholestasi
also
associ
extrahepat
bacteri
infect
dog
cat
typic
find
includ
hyperbilirubinemia
variabl
increas
serum
hepat
enzym
activ
histolog
bile
pigment
accumul
hepatocyt
variabl
inflammatori
chang
parasit
infect
liver
biliari
tract
rare
common
certain
geograph
area
southeastern
unit
state
cat
frequent
infect
trematod
parasit
propens
ingest
intermedi
host
land
snail
fish
reptil
amphibian
parasit
report
infect
liver
biliari
system
includ
platynosomum
heterobilharzia
cytauxzoon
opisthorchi
amphimeru
metorchi
clonorchi
clinic
sign
fluke
infest
usual
associ
extrahepat
biliari
obstruct
mani
cat
fluke
infest
asymptomat
thu
detect
presenc
fluke
may
mean
caus
agent
observ
sign
diagnosi
establish
detect
egg
fece
histolog
examin
hepat
biopsi
tissu
drug
choic
treatment
fluke
praziquantel
droncit
dosag
mglb
bodi
weight
two
time
day
day
nitroscan
lopatol
singl
dose
mglb
may
also
effect
cat
requir
corticosteroid
treatment
concurr
eosinophil
cholangiohepat
system
mycos
includ
histoplasmosi
blastomycosi
coccidioidomycosi
affect
liver
hepat
involv
usual
reflect
system
involv
one
mani
tissu
affect
signific
hepat
involv
often
repres
easi
mean
detect
offend
organ
hepat
enzym
elev
suggest
hepat
involv
may
justifi
hepat
biopsi
often
least
invas
mean
establish
definit
diagnosi
histopatholog
examin
reveal
granulomat
hepat
offend
organ
usual
seen
special
stain
fungal
cultur
hepat
tissu
usual
necessari
may
help
import
noninflammatori
diseas
liver
includ
vascular
anomali
portosystem
shunt
portal
vein
hypoplasia
metabol
derang
felin
hepat
lipidosi
steroid
hepatopathi
glycogenstorag
diseas
hepat
amyloidosi
urea
cycl
enzym
defici
abnorm
iron
storag
hepat
neoplasia
discuss
review
common
diseas
entiti
portosystem
shunt
portal
vascular
anomali
portacav
shunt
portosystem
vascular
anastomos
occur
congenit
anomali
acquir
entiti
secondari
chronic
portal
hypertens
latter
circumst
elev
portal
blood
pressur
lead
open
fetal
blood
vessel
shunt
portal
blood
away
liver
system
circul
vessel
normal
close
birth
act
reservoir
handl
increas
pressur
load
unlik
congenit
portosystem
shunt
shunt
usual
multipl
extrem
tortuou
variabl
extrahepat
locat
common
caus
acquir
portosystem
shunt
cirrhosi
remaind
discuss
concern
congenit
portosystem
shunt
etiolog
congenit
portosystem
shunt
normal
blood
leav
stomach
intestin
spleen
pancrea
enter
portal
vein
flow
liver
enter
hepat
vein
system
venou
circul
portal
blood
thu
contain
absorb
nutrient
intestin
hormon
tropic
liver
bacteri
product
toxin
fetu
function
liver
process
product
minim
thu
vessel
shunt
blood
away
liver
system
venou
circul
normal
vessel
close
shortli
birth
allow
establish
hepat
circul
vessel
remain
patent
birth
portosystem
shunt
occur
caus
anomali
unknownwhen
blood
divert
away
liver
hepat
atrophi
result
lack
tropic
factor
present
portal
blood
especi
insulin
glucagon
sever
type
congenit
portosystem
shunt
seen
dog
cat
includ
limit
follow
approxim
one
fourth
congenit
portosystem
shunt
intrahepat
dog
cat
associ
patent
ductu
venosu
singl
extrahepat
shunt
major
solitari
portalcaud
vena
caval
shunt
common
constitut
portosystem
shunt
intrahepat
shunt
found
largebre
dog
doberman
pinscher
golden
retriev
labrador
retriev
irish
setter
samoy
irish
wolfhound
wherea
extrahepat
shunt
seen
smallbre
dog
miniatur
schnauzer
yorkshir
terrier
miniatur
poodl
dachshund
dog
intrahepat
shunt
may
develop
clinic
sign
earlier
age
dog
extrahepat
shunt
possibl
due
larger
volum
blood
flow
intrahepat
shunt
approxim
portosystem
shunt
seen
small
anim
occur
cat
sever
clinic
sign
depend
volum
locat
shunt
clinic
sign
result
impair
hepat
function
lead
hepat
encephalopathi
import
factor
lead
encephalopathi
accumul
blood
ammonia
gutassoci
encephalopath
toxin
normal
metabol
clear
liver
portosystem
shunt
ammonia
toxin
increas
blood
lead
encephalopathi
addit
increas
benzodiazepinelik
substanc
amino
acid
derang
increas
aromat
amino
acid
occur
portosystem
shunt
contribut
encephalopath
sign
clinic
sign
case
diagnos
patient
less
year
age
howev
case
patient
old
year
time
diagnosi
sex
predilect
clinic
sign
patient
portosystem
shunt
highli
variabl
divers
natur
sign
clinician
must
maintain
high
index
suspicion
young
patient
unexplain
sign
compat
shunt
avoid
miss
diagnosi
clinic
sign
often
chang
throughout
day
week
may
exacerb
sign
feed
reflect
ammonia
gener
dietari
substrat
howev
find
seldom
occur
case
common
clinic
sign
chronic
depress
retard
growth
weight
loss
dog
stunt
appear
poor
doer
addit
clinic
sign
includ
chronic
gi
sign
vomit
diarrhea
anorexia
polydipsiapolyuria
neurolog
sign
often
neurolog
sign
suggest
shunt
approxim
case
degre
neurolog
dysfunct
relat
hepat
encephalopathi
neurolog
sign
often
variabl
wax
wane
time
includ
depress
incoordin
behavior
chang
often
aggress
amaurot
blind
seizur
dementia
stupor
addit
abnorm
intoler
anesthet
agent
often
seen
routin
neuter
first
year
life
young
patient
persist
sign
especi
neurolog
behavior
chang
suspect
portosystem
shunt
cat
ptyalism
common
sign
central
nervou
system
cn
gi
sign
young
cat
ptyalism
andor
cn
sign
evalu
presenc
portosystem
shunt
laboratori
find
routin
hemogram
serum
chemistri
profil
may
normal
often
mild
nonregen
microcyt
anemia
target
cell
may
seen
patient
conspicu
normal
mildli
increas
serum
hepat
enzym
activ
despit
hepat
failur
princip
lesion
one
atrophi
lack
portal
blood
suppli
cholestasi
hepatocellular
necrosi
leakag
featur
diseas
approxim
patient
mild
hypoalbuminemia
reflect
decreas
albumin
synthesi
increas
volum
albumin
distribut
ascit
present
mani
patient
decreas
bun
concentr
reflect
decreas
synthesi
ammonia
virtual
patient
normal
serum
bilirubin
concentr
fast
hypoglycemia
may
seen
mani
chang
nonspecif
hepat
function
test
must
perform
document
hepat
failur
serum
bile
acid
measur
ammonia
toler
test
sensit
test
detect
presenc
portosystem
shunt
abnorm
virtual
time
approxim
one
third
half
dog
portosystem
shunt
ammonium
biurat
crystal
urin
form
chapter
increas
concentr
uric
acid
urin
result
decreas
hepat
convers
allantoin
increas
urin
concentr
ammonia
associ
hyperammonemia
urin
acid
supersatur
substrat
crystal
precipit
occur
addit
crystal
urin
calculi
form
kidney
less
commonli
bladder
stone
usual
compos
ammonium
acid
urat
uric
acid
often
presenc
renal
calculi
import
clue
portosystem
shunt
present
young
patient
calculi
remov
crystallograph
analysi
identifi
uric
acid
stone
present
patient
evalu
presenc
portosystem
shunt
reliabl
method
confirm
presenc
portosystem
shunt
contrast
radiographi
nuclear
scintigraphi
plain
radiograph
find
usual
indic
microhepatica
best
determin
upright
angul
stomach
later
project
puppi
kitten
normal
larg
liver
rel
bodi
size
find
increas
index
suspicion
portosystem
shunt
diagnosi
confirm
evalu
hepat
blood
flow
contrast
radiographi
nuclear
scintigraphi
sever
techniqu
evalu
hepat
blood
flow
includ
intraop
mesenter
portographi
percutan
splenoportographi
cranial
mesenter
arteri
portographi
intraop
mesenter
portographi
practic
techniqu
appli
gener
practic
addit
identifi
shunt
mesenter
portographi
also
assess
residu
portoven
flow
liver
prognost
import
follow
inject
mesenter
jejun
vein
radiograph
contrast
medium
normal
flow
portal
vein
arbor
liver
patient
portosystem
shunt
contrast
medium
bypass
liver
seen
caudal
vena
cava
azyg
vein
caudal
extent
shunt
cranial
probabl
intrahepat
shunt
wherea
caudal
extent
shunt
caudal
probabl
extrahepat
shunt
shunt
identifi
angiograph
studi
one
proceed
surgic
correct
surgic
procedur
altern
patient
allow
recov
anesthet
procedur
use
obtain
angiogram
second
procedur
perform
later
week
longer
correct
shunt
prefer
latter
approach
small
patient
anesthesia
long
time
angiogram
potenti
hypothermia
prolong
anesthet
recoveri
portosystem
shunt
also
identifi
ultrasonograph
guidanc
nuclear
scintigraphi
see
section
nuclear
scintigraphi
evalu
liver
latter
diagnost
method
use
mesenter
portographi
may
still
necessari
locat
shunt
readili
seen
exploratori
laparotomi
patholog
find
histopatholog
find
patient
portosystem
shunt
includ
diffus
hepat
atrophi
lobular
collaps
prolifer
small
hepat
arteriol
atrophi
character
close
proxim
portal
triad
compress
hepat
cord
inconspicu
portal
vein
find
usual
diagnost
congenit
vascular
anomali
hepat
biopsi
specimen
analysi
repres
anoth
method
addit
radiograph
find
obtain
diagnosi
howev
chang
may
difficult
distinguish
portal
vein
hypoplasia
without
macroscop
shunt
formerli
known
hepat
microvascular
dysplasia
see
section
start
p
latter
disord
clinic
histopatholog
featur
portosystem
shunt
normal
find
mesenter
portographi
andor
nuclear
scintigraphi
degen
chang
brain
suggest
hepat
encephalopathi
includ
leukopolymicrocavit
graywhit
matter
junction
spongiform
degener
cortic
necrosi
surgic
treatment
treatment
choic
singl
portosystem
shunt
surgic
ligat
longterm
medic
manag
palli
rather
cur
surgic
intervent
medic
manag
may
necessari
stabil
patient
emerg
treatment
hepat
encephalopathi
includ
cleans
enema
oral
antibiot
lactulos
administr
see
section
manag
acut
hepat
failur
surgic
correct
multipl
portosystem
shunt
usual
success
underli
portal
hypertens
hepat
patholog
abnorm
persist
see
refer
surgic
textbook
detail
descript
surgic
techniqu
gener
rule
smallbre
dog
extrahepat
shunt
largebre
dog
intrahepat
shunt
singl
extrahepat
shunt
usual
readili
identifi
surgeri
thu
isol
attenu
occlud
depend
portal
pressur
surgic
manipul
intrahepat
shunt
much
difficult
wherea
extrahepat
shunt
ligat
adapt
gener
practic
extrahepat
shunt
found
termin
caudal
vena
cava
left
phrenicoabdomin
renal
vein
shunt
vessel
isol
correct
made
gradual
occlus
use
ameroid
constrictor
see
occlus
cellophan
band
sutur
materi
sutur
use
portal
pressur
must
measur
determin
whether
complet
occlus
possibl
readili
done
place
fr
feed
tube
mesenter
vein
thread
portal
vein
connect
salin
manomet
measur
pressur
zero
level
standard
level
femor
triangl
heart
normal
portal
pressur
cm
h
mm
hg
patient
normal
decreas
portal
pressur
shunt
manipul
shunt
complet
ligat
fatal
acut
portal
hypertens
develop
result
splanchnic
congest
stasi
blood
rapid
develop
endotox
shock
shunt
attenu
silk
sutur
portal
pressur
exceed
cm
h
mm
hg
cm
h
mm
hg
baselin
silk
ligatur
place
close
vena
cava
possibl
gradual
tighten
measur
portal
pressur
observ
splanchnic
viscera
sign
stasi
includ
blanch
bowel
hypermotil
small
bowel
distend
pulsat
jejun
arteri
also
import
monitor
central
venou
pressur
may
also
help
predict
presenc
portal
hypertens
increas
portal
resist
decreas
portal
venou
flow
central
venou
pressur
drop
decreas
venou
return
splanchnic
venou
pool
avoid
need
measur
portal
venou
pressur
still
allow
complet
occlus
shunt
attenu
accomplish
ameroid
constrictor
devic
shape
like
miniatur
donut
small
open
allow
place
around
shunt
subsequ
lock
prevent
remov
placement
around
shunt
vessel
constrictor
come
variou
inner
diamet
mm
use
variouss
shunt
vessel
constrictor
made
hygroscop
casein
materi
porou
surround
metal
outer
ring
porou
materi
gradual
satur
periton
fluid
expand
outer
metal
ring
prevent
outward
expans
inward
expans
gradual
occlud
central
hole
shunt
vessel
manner
shunt
gradual
occlud
usual
period
week
gradual
occlus
need
measur
portal
pressur
shunt
occlud
hepat
vasculatur
becom
perfus
thu
act
prevent
portal
hypertens
gener
complet
occlus
singl
extrahepat
shunt
use
ameroid
constrictor
approxim
case
manipul
intrahepat
shunt
technic
difficult
sever
techniqu
describ
attenu
intrahepat
shunt
see
refer
surgic
literatur
detail
possibl
shunt
isol
entri
liver
leav
liver
enter
caudal
vena
cava
otherwis
shunt
look
incis
prehepat
vena
cava
occlud
hepat
vena
caval
blood
flow
locat
note
abnorm
irregular
margin
shunt
vessel
enter
vena
cava
insid
altern
shunt
locat
transport
approach
follow
vascular
occlus
shunt
occlud
complet
without
caus
portal
hypertens
novel
approach
describ
involv
complet
intrahepat
shunt
closur
along
surgic
creation
portacav
shunt
use
extern
jugular
vein
graft
ameroid
constrictor
place
around
graft
permit
gradual
closur
dog
mild
moder
portal
hypertens
cm
h
follow
shunt
manipul
usual
normal
portal
pressur
within
sever
week
surgeri
dog
often
ascit
secondari
transient
portal
hypertens
disappear
week
portal
pressur
drop
often
silk
ligatur
use
partial
occlud
shunt
caus
reaction
result
gradual
complet
occlus
shunt
time
biopsi
liver
alway
perform
histopatholog
evalu
occasion
bacteri
cultur
cystic
renal
calculi
concurr
portosystem
shunt
remov
procedur
shunt
correct
patient
stabl
anesthet
time
excess
otherwis
second
surgeri
perform
sever
week
later
remov
urinari
calculi
followup
mesenter
portogram
hepat
biopsi
perform
time
evalu
shunt
correct
postop
monitor
import
detect
sign
sever
portal
hypertens
includ
abdomin
pain
hemorrhag
diarrhea
endotox
shock
lead
death
fortun
use
ameroid
constrictor
intraop
monitor
portal
pressur
make
unusu
complic
hypoglycemia
may
occur
patient
eat
necessit
intraven
glucos
supplement
intraven
crystalloid
colloid
signific
hypoalbuminemia
essenti
immedi
postop
period
statu
epilepticu
gener
motor
seizur
occur
follow
shunt
attenu
usual
first
observ
day
postop
etiolog
seizur
unknown
one
theori
may
stimul
brain
receptor
benzodiazepin
associ
presenc
shunt
follow
ligat
shunt
seizur
may
result
withdraw
benzodiazepinelik
substanc
document
present
portal
blood
dog
portosystem
shunt
follow
shunt
ligat
prognosi
poor
experi
despit
control
statu
epilepticu
role
prophylact
anticonvuls
drug
potassium
bromid
need
defin
medic
manag
chronic
hepat
diseas
continu
need
manag
sign
encephalopathi
howev
patient
asymptomat
shortli
surgic
shunt
correct
patient
evalu
month
surgeri
serum
biochem
hepat
function
test
eg
bile
acid
assay
persist
abnorm
function
suggest
incomplet
shunt
closur
concurr
portal
vein
hypoplasia
develop
multipl
extrahepat
shunt
portal
hypertens
result
ameroid
constrictor
partial
ligat
use
attenu
shunt
nuclear
scintigraphi
mesenter
portographi
perform
month
surgeri
evalu
complet
closur
evid
incomplet
shunt
closur
nuclear
scintigraphi
repeat
month
follow
surgeri
still
evid
incomplet
closur
patient
still
symptomat
second
surgeri
could
perform
complet
shunt
closur
one
studi
dog
undergo
partial
shunt
closur
develop
complic
associ
continu
renew
portosystem
shunt
followup
period
despit
excel
shortterm
result
suggest
second
surgeri
consid
dog
prognosi
prognosi
medic
manag
congenit
portosystem
shunt
poor
patient
progress
hepat
atrophi
eventu
sign
hepat
encephalopathi
becom
refractori
medic
manag
occasion
patient
live
old
age
without
medic
therapi
although
later
life
patient
often
urat
urinari
calculi
sign
hepat
encephalopathi
case
uncommon
howev
prognosi
singl
extrahepat
shunt
surgic
correct
excel
unless
sever
portal
hypertens
persist
unusu
clinic
improv
often
seen
shortli
surgic
correct
hepat
biopsi
specimen
analysi
obtain
sever
month
surgic
correct
may
normal
concurr
portal
vein
hypoplasia
result
surgic
ligat
extrahepat
portosystem
shunt
cat
seem
wors
dog
approxim
cat
favor
outcom
prognosi
intrahepat
shunt
guard
due
technic
difficulti
surgic
correct
inabl
complet
attenu
shunt
without
develop
portal
hypertens
success
depend
larg
part
skill
experi
surgeon
portal
vein
hypoplasia
without
macroscop
shunt
formerli
refer
hmd
refer
microscop
patholog
malform
hepat
microvasculatur
character
small
intrahepat
portal
vessel
portal
endotheli
hyperplasia
portal
vein
dilat
random
juvenil
intralobular
blood
vessel
central
venou
mural
hypertrophi
fibrosi
thought
lesion
allow
abnorm
commun
portal
system
circul
import
note
portal
vein
hypoplasia
occur
isol
diseas
conjunct
macroscop
portosystem
shunt
one
larg
studi
dog
cat
portal
vein
hypoplasia
also
concurr
congenit
portosystem
shunt
dog
cat
portal
vein
hypoplasia
clinic
sign
similar
portosystem
shunt
includ
neurolog
gi
abnorm
well
urat
urolithiasi
portal
hypertens
usual
develop
dog
cat
portal
vein
hypoplasia
breed
dog
affect
portal
vein
hypoplasia
similar
congenit
portosystem
shunt
includ
yorkshir
cairn
terrier
hereditari
mechan
describ
breed
report
dog
portal
vein
hypoplasia
suggest
clinic
sign
clinicopatholog
featur
similar
portosystem
shunt
although
often
sever
recent
studi
case
compar
dog
portal
vein
hypoplasia
alon
dog
portal
vein
hypoplasia
concurr
portosystem
shunt
reveal
dog
portal
vein
hypoplasia
alon
older
higher
valu
mean
corpuscular
volum
mcv
serum
total
protein
albumin
creatinin
cholesterol
bun
blood
glucos
concentr
addit
dog
portal
vein
hypoplasia
alon
lower
preprandi
postprandi
bile
acid
concentr
discrimin
variabl
two
group
postprandi
bile
acid
concentr
mcv
serum
albumin
cholesterol
concentr
howev
larg
overlap
valu
suggest
patient
present
clinic
find
congenit
vascular
anomali
must
undergo
imag
studi
nuclear
scintigraphi
mesenter
portographi
detect
patient
macroscop
portosystem
shunt
amen
surgic
therapi
definit
portal
vein
hypoplasia
requir
hepat
biopsi
surgic
wedg
biopsi
laparoscop
spoon
biopsi
prefer
provid
hepat
lobul
evalu
treatment
portal
vein
hypoplasia
support
macroscop
shunt
attenu
dietari
measur
agent
use
treat
hepat
encephalopathi
describ
section
manag
chronic
hepat
diseas
mani
dog
remain
asymptomat
dietari
therapi
alon
although
prognosi
variabl
steroid
hepatopathi
result
excess
endogen
hyperadrenocortic
exogen
iatrogen
administr
amount
glucocorticoid
repres
one
common
caus
increas
serum
hepat
enzym
activ
common
diagnosi
hepat
biopsi
specimen
analysi
dog
steroid
hepatopathi
occur
rare
cat
etiolog
chang
liver
induc
glucocorticoid
unknown
likelihood
individu
patient
develop
steroid
hepatopathi
follow
glucocorticoid
administr
variabl
depend
individu
sensit
type
rout
durat
administr
glucocorticoid
patient
show
minim
chang
serum
hepat
enzym
activ
morpholog
chang
liver
even
chronic
glucocorticoid
administr
wherea
patient
increas
serum
hepat
enzym
activ
morpholog
chang
persist
week
singl
dose
glucocorticoid
chang
persist
sever
month
singl
inject
longact
glucocorticoid
chronic
administr
oral
glucocorticoid
chang
also
occur
topic
ocular
administr
glucocorticoid
clinic
find
clinic
sign
steroid
hepatopathi
rang
asymptomat
associ
glucocorticoid
excess
sign
includ
polyuria
polydipsia
polyphagia
endocrin
alopecia
distend
abdomen
lethargi
usual
sign
specif
relat
hepat
failur
except
lethargi
sever
case
hepatomegali
often
identifi
abdomin
palpat
abdomin
radiograph
laboratori
find
usual
mild
moder
increas
salt
sast
activ
mark
increas
serum
alp
ggt
activ
dog
steroid
hepatopathi
increas
variabl
occasion
magnitud
elev
serum
activ
transaminas
alt
ast
exce
magnitud
elev
serum
alp
ggt
activ
serum
albumin
bilirubin
concentr
usual
normal
abnorm
caus
look
often
laboratori
abnorm
seen
primari
nonhyperbilirubinem
hepatobiliari
diseas
steroid
hepatopathi
similar
presenc
increas
serum
bilirubin
concentr
virtual
elimin
steroid
hepatopathi
differenti
diagnosi
primari
hepatobiliari
diseas
increas
serum
alp
activ
attribut
isoenzym
differ
induc
biliari
stasi
isoenzym
also
produc
liver
refer
steroidinduc
isoenzym
alp
laboratori
method
avail
distinguish
steroidinduc
isoenzym
induc
biliari
stasi
howev
steroidinduc
isoenzym
alp
variabl
elev
mani
primari
hepatobiliari
diseas
therefor
measur
activ
use
test
determin
presenc
steroid
hepatopathi
though
specif
isoenzym
ggt
induc
glucocorticoid
import
note
magnitud
increas
serum
ggt
activ
induc
glucocorticoid
often
parallel
alp
serum
ggt
activ
use
distinguish
steroid
hepatopathi
primari
hepatobiliari
diseas
result
hepat
function
test
includ
serum
bile
acid
blood
ammonia
concentr
variabl
steroid
hepatopathi
serum
bile
acid
normal
slightli
moder
elev
less
mark
increas
serum
bile
acid
unlik
result
steroid
hepatopathi
hepatobiliari
diseas
consid
blood
ammonia
concentr
ammonia
toler
test
result
usual
normal
steroid
hepatopathi
histopatholog
find
histopatholog
abnorm
usual
highli
suggest
steroid
hepatopathi
usual
mark
vacuol
balloon
hepatocyt
centrilobular
diffus
distribut
vacuol
thought
due
glycogen
deposit
might
also
variabl
degre
hepat
necrosi
diagnosi
laboratori
clinic
sign
compat
steroid
hepatopathi
patient
asymptomat
steroid
hepatopathi
rule
hepat
biopsi
done
histori
glucocorticoid
administr
appropri
laboratori
test
adrenocorticotrop
hormon
acth
stimul
lowdos
dexamethason
suppress
test
diagnosi
still
uncertain
hepat
imag
ultrasound
usual
reveal
hyperecho
sometim
mottl
parenchyma
biopsi
warrant
biopsi
specimen
analysi
usual
readili
distinguish
steroid
hepatopathi
hepat
diseas
hepat
biopsi
specimen
analysi
anoth
method
diagnos
hyperadrenocortic
laboratori
test
inconclus
treatment
includ
elimin
sourc
excess
glucocorticoid
sourc
exogen
administr
corticosteroid
discontinu
administr
necessari
decreas
least
ongo
use
consid
import
clinic
sign
lethargi
present
persist
altern
immunemodul
drug
may
substitut
appropri
azathioprin
cyclophosphamid
cyclosporin
hyperadrenocortic
treat
clinic
indic
laboratori
morpholog
chang
liver
seen
steroid
hepatopathi
complet
revers
sourc
excess
glucocorticoid
remov
felin
hepat
lipidosi
common
condit
cat
result
intrahepatocyt
accumul
triglycerid
abnorm
lipid
metabol
associ
sever
hepat
dysfunct
dog
cat
accumul
fat
hepatocyt
associ
number
caus
includ
endocrin
nutrit
metabol
toxic
abnorm
caus
list
box
instanc
known
underli
caus
syndrom
refer
felin
hepat
lipidosi
known
underli
caus
diseas
occur
idiopath
entiti
discuss
confin
syndrom
etiolog
case
underli
diseas
associ
felin
hepat
lipidosi
although
major
case
idiopath
common
underli
diseas
identifi
pancreat
inflammatori
bowel
diseas
cholangiohepat
etiolog
idiopath
felin
hepat
lipidosi
unknown
theori
propos
base
liver
role
triglycerid
metabol
triglycerid
accumul
liver
rate
hepat
uptak
synthesi
exce
rate
remov
sourc
triglycerid
includ
de
novo
synthesi
liver
fatti
acid
system
circul
deriv
dietari
sourc
adipos
store
hepatocyt
fatti
acid
esterifi
triglycerid
phospholipid
oxid
within
liver
triglycerid
releas
hepatocyt
primarili
verylowdens
lipoprotein
vldl
abil
liver
excret
oxid
triglycerid
exceed
triglycerid
suppli
triglycerid
accumul
hepatocyt
therefor
hepat
lipid
accumul
result
excess
hepat
triglycerid
synthesi
impair
fatti
acid
oxid
within
hepatocyt
impair
fatti
acid
transport
liver
vldl
chang
nutrit
hormon
statu
toxic
influenc
hepatocellular
function
advers
affect
triglycerid
metabol
addit
possibl
excess
triglycerid
storag
damag
hepatocyt
excess
hepat
triglycerid
accumul
may
indic
abnorm
cellular
metabol
may
also
affect
cell
function
known
mechan
involv
pathogenesi
felin
hepat
lipidosi
anorexia
previous
obes
cat
import
featur
disord
may
initi
fatti
deposit
liver
starvat
free
fatti
acid
increas
releas
adipos
tissu
obes
probabl
predispos
process
excess
mobil
fatti
acid
subsequ
incomplet
metabol
liver
lead
accumul
within
hepatocyt
cat
underli
system
diseas
initi
anorexia
concurr
hepat
lipidosi
although
case
underli
disord
identifi
also
propos
cat
hepat
lipidosi
diabet
prediabet
although
specul
littl
evid
possibl
insulinresist
state
would
result
continu
releas
fatti
acid
adipos
tissu
subsequ
accumul
liver
known
metabol
hepatocellular
derang
prevent
triglycerid
remov
liver
although
metabol
ultrastructur
abnorm
identifi
ultrastructur
studi
cat
hepat
lipidosi
hepatocellular
organel
nuclei
displac
cell
peripheri
result
compress
lumen
bile
canaliculi
contribut
cholestasi
bile
acid
retent
also
uniqu
abnorm
rel
pauciti
peroxisom
rather
upregul
expect
circumst
increas
fatti
acid
oxid
organel
import
preprocess
longchain
fatti
acid
present
mitochondri
oxid
peroxisom
take
increas
role
circumst
mitochondri
dysfunct
unlik
mitochondria
depend
carnitin
peroxisom
fatti
acid
oxid
transport
facilit
depend
carnitin
peroxisom
also
involv
bile
acid
synthesi
subsequ
peroxisom
dysfunct
lead
abnorm
bile
acid
profil
cat
hepat
lipidosi
thu
defect
peroxisom
increas
depend
peroxisom
oxid
may
increas
oxid
stress
hepatocyt
also
specul
rel
carnitin
defici
result
hepatocellular
triglycerid
accumul
cat
hepat
lipidosi
shown
plasma
urin
hepat
tissu
carnitin
concentr
normal
elev
cat
hepat
lipidosi
howev
possibl
may
inadequ
carnitin
quantiti
rate
mitochondri
oxid
dispos
accumul
acetyl
coa
furthermor
increas
urin
concentr
shortchain
acylcarnitin
cat
hepat
lipidosi
reflect
increas
product
carnitinefacilit
remov
liver
could
allow
rout
elimin
excess
fatti
acid
liver
final
evid
carnitin
supplement
cat
hepat
lipidosi
improv
recoveri
rate
previou
theori
disput
well
orot
acid
toxin
capabl
induc
hepat
lipidosi
speci
impair
phospholipid
synthesi
vldl
transport
liver
arginin
defici
seen
cat
hepat
lipidosi
lead
orot
acid
accumul
arginin
essenti
normal
urea
cycl
function
impair
urea
cycl
function
associ
product
orot
acid
precursor
howev
attempt
produc
hepat
lipidosi
cat
orot
acid
administr
unsuccess
urin
orot
acid
concentr
normal
cat
hepat
lipidosisvitamin
b
defici
also
specul
associ
hepat
lipidosi
one
descript
cat
hepat
lipidosi
vitamin
b
defici
document
seri
inspect
plasma
urin
unusu
fatti
acid
reflect
sitespecif
impair
mitochondri
oxid
reveal
uniqu
moieti
suggest
obviou
defect
particular
mitochondri
enzym
clinic
featur
mention
earlier
cat
hepat
lipidosi
obes
usual
period
anorexia
follow
sign
typic
hepat
failur
case
known
ill
stress
event
eg
board
travel
diet
chang
may
caus
initi
period
anorexia
case
howev
initi
caus
known
hepat
lipidosi
occur
clinic
sign
includ
inappet
weight
loss
vomit
jaundic
physic
examin
find
includ
obes
evid
dorsal
muscl
wast
jaundic
possibl
hepatomegali
laboratori
radiograph
find
laboratori
find
includ
mark
elev
serum
hepat
enzym
activ
especi
alp
lesser
extent
transaminas
salt
sast
halflif
alp
short
cat
hour
activ
enzym
increas
serum
sever
hepatobiliari
diseas
hepat
lipidosi
activ
alp
usual
markedli
elev
often
higher
form
hepat
diseas
cat
hepat
lipidosi
also
common
hepatobiliari
diseas
cat
result
magnitud
increas
alp
activ
exceed
serum
ggt
activ
serum
total
bilirubin
concentr
usual
increas
reflect
degre
intrahepat
cholestasi
coagul
abnorm
especi
elev
pivka
time
also
common
occur
almost
cat
one
studi
howev
overt
bleed
includ
hepat
biopsi
site
rare
experi
hypokalemia
present
affect
cat
found
neg
prognost
factor
postprandi
serum
bile
acid
concentr
almost
alway
abnorm
elev
hypophosphatemia
present
cat
one
report
oral
aliment
may
result
declin
serum
phosphoru
concentr
result
clinic
manifest
hemolyt
anemia
radiograph
usual
reveal
normal
hepat
size
hepatomegali
ultrasonograph
find
ultrasonograph
find
almost
alway
abnorm
felin
hepat
lipidosi
find
includ
overal
increas
echogen
hepat
parenchyma
compar
falciform
fat
one
studi
find
seen
cat
hepat
lipidosi
howev
studi
also
found
relationship
diseas
hepat
lipidosi
make
nonspecif
find
addit
increas
beam
attenu
liver
border
hepat
vessel
difficult
visual
underli
disord
pancreat
may
also
detect
ultrasound
examin
patholog
find
diagnosi
felin
idiopath
hepat
lipidosi
base
histolog
find
absenc
concurr
diseas
known
caus
lipid
accumul
liver
see
box
typic
histopatholog
featur
diffus
lobular
fatti
infiltr
within
individu
hepatocyt
lipid
accumul
usual
macrovesicular
natur
although
microvesicular
cat
usual
evid
intrahepat
cholestasi
diagnosi
often
made
analysi
fine
needl
aspir
liver
impress
smear
made
hepat
biopsi
specimen
cytolog
featur
includ
vacuol
hepatocyt
minim
inflamm
howev
cytolog
examin
exclud
presenc
concurr
diseas
cholangiohepat
lymphoma
grossli
liver
cat
hepat
lipidosi
usual
larg
friabl
slightli
round
margin
smooth
surfac
color
usual
yellow
accentu
lobular
pattern
treatment
precipit
caus
anorexia
identifi
address
includ
environment
influenc
diet
chang
board
concurr
diseas
identifi
cholangiohepat
inflammatori
bowel
diseas
pancreat
treat
goal
treatment
revers
metabol
chang
result
mobil
free
fatti
acid
occur
starvat
usual
accomplish
aggress
forcefeed
mild
case
method
stimul
voluntari
oral
intak
may
effect
heat
food
ad
season
salt
substitut
food
may
help
howev
tube
feed
seem
necessari
case
best
accomplish
peg
tube
fr
esophagostomi
tube
fr
nasoesophag
tube
fr
prefer
place
peg
tube
case
often
cat
gener
anesthesia
hepat
biopsi
procedur
analysi
impress
smear
biopsi
sampl
suggest
hepat
lipidosi
avoid
stress
second
anesthet
procedur
howev
cat
clearli
stabl
enough
undergo
anesthet
procedur
placement
feed
tube
case
cat
often
never
recov
complet
procedur
patient
usual
much
safer
obtain
biopsi
specimen
local
anesthesia
reli
cytolog
analysi
fine
needl
aspir
follow
placement
nasoesophag
tube
cat
awak
allow
administr
liquid
nutrit
formula
clinicar
petag
temporari
basi
constant
administr
infus
pump
graviti
flow
versu
bolu
feed
also
help
vomit
problem
initi
day
treatment
cat
often
electrolyt
disturb
hypokalemia
also
stabil
appropri
intraven
fluid
nonlactatecontain
fluid
supplement
potassium
chlorid
potassium
phosphat
cat
stabl
peg
esophagostomi
tube
place
longterm
use
home
largebor
tube
prefer
comfort
cat
nasoesophag
tube
allow
owner
feed
blend
cat
food
home
total
calori
intak
kcallb
bodi
weight
per
day
largebor
tube
use
balanc
commerci
cat
food
gruel
eg
hill
felin
pd
kcal
per
cd
kcal
per
use
feed
solut
gener
dilut
water
make
gruel
contain
approxim
kcalml
also
dilut
water
make
gruel
contain
approxim
kcalml
restrict
protein
diet
indic
unless
overt
sign
hepat
encephalopathi
present
ptyalism
initi
feed
start
one
half
calcul
amount
first
hour
calcul
daili
requir
divid
four
six
feed
per
day
initi
eventu
cat
toler
necessari
volum
three
four
feed
per
day
volum
exceed
mllb
bodi
weight
feed
attempt
made
gradual
increas
feed
volum
mainten
first
day
antiemet
may
necessari
prevent
vomit
first
day
longer
treatment
mani
case
drug
choic
metoclopramid
reglan
given
dosag
mg
minut
feed
case
work
given
feed
tube
liquid
form
avail
purpos
occasion
subcutan
administr
constant
intraven
infus
may
necessari
strategi
control
vomit
includ
addit
antiemet
prochlorperazin
compazin
chlorpromazin
ondansetron
strategi
administ
liquid
enter
formula
clinicar
constant
infus
decreas
amount
water
ad
cat
food
gruel
decreas
volum
administ
still
provid
amount
calori
dilut
one
part
water
two
part
food
gruel
contain
kcalml
variou
dietari
supplement
propos
help
treat
cat
idiopath
hepat
lipidosi
carnitin
supplement
seem
improv
surviv
rate
shorten
recoveri
time
one
report
n
supplement
lcarnitin
mgday
advoc
base
possibl
rel
carnitin
defici
compar
histor
control
cat
receiv
lcarnitin
recoveri
rate
compar
recoveri
rate
cat
receiv
lcarnitin
cat
receiv
lcarnitin
gastrostomi
tube
feed
recoveri
rate
cat
receiv
lcarnitin
gastrostomi
tube
feed
recoveri
rate
report
taurin
supplement
mgday
also
advoc
mani
cat
hepat
lipidosi
decreas
serum
taurin
concentr
taurin
import
amino
acid
use
obligatori
bile
acid
conjug
cat
may
modifi
injuri
potenti
retain
bile
acid
increas
renal
excret
thiamin
also
provid
mg
inject
oral
two
time
day
day
evid
thiamin
defici
ventral
neck
flexion
vitamin
e
may
help
minim
oxid
hepat
injuri
administr
mglbday
may
also
help
speed
recoveri
vitamin
k
supplement
use
overt
bleed
detect
suspect
prolong
recoveri
rare
ursodeoxychol
acid
may
benefici
help
stabil
peroxisom
cholestasi
usual
present
see
earlier
section
use
ursodeoxychol
acid
cat
cholangiohepat
case
ursodeoxychol
acid
necessari
cat
recov
die
drug
alter
outcom
provid
hepatoprotect
supplement
lcitrullin
promot
ureagenesi
minim
synthesi
orot
acid
cholin
requir
phospholipid
synthesi
vldl
product
also
empir
recommend
lowdos
insulin
therapi
indic
cat
overtli
diabet
evid
arginin
supplement
help
diseas
lipotrop
agent
contain
methionin
therapeut
benefit
contraind
result
product
encephalopath
toxin
mercaptan
use
glucocorticoid
anabol
steroid
likewis
avoid
prognosi
prognosi
fair
good
case
success
treat
approxim
cat
recoveri
rate
depend
stabl
cat
time
present
aggress
forcefeed
abil
control
vomit
virtual
cat
recov
surviv
beyond
first
day
earlier
treat
higher
recoveri
rate
spontan
recoveri
rare
forcefeed
may
need
prolong
week
owner
abl
manag
gastrostomi
esophagostomi
tube
feed
home
period
normal
biochem
paramet
tube
feed
gradual
decreas
cat
coax
eat
cat
eat
complet
without
tube
feed
week
tube
pull
evid
affect
cat
prone
recurr
follow
initi
recoveri
residu
hepat
damag
prevent
hepat
lipidosi
nutrit
support
provid
obes
cat
stop
eat
diseas
intrahepat
diseas
follow
inject
tcdiisopropyl
iminodiacet
acid
disofenin
patient
unobstruct
biliari
tract
nuclear
activ
intestin
within
hour
failur
visual
intestin
nuclear
imag
hour
patient
biliari
obstruct
one
studi
method
sensit
specif
accur
diagnos
extrahepat
biliari
obstruct
final
hepat
biopsi
often
suggest
presenc
extrahepat
biliari
obstruct
treatment
treatment
bile
duct
obstruct
depend
underli
etiolog
see
box
case
specif
medic
therapi
possibl
symptomat
care
surgeri
necessari
approxim
patient
pancreat
result
bile
duct
obstruct
eventu
resum
normal
bile
flow
without
surgic
intervent
given
appropri
support
care
enough
time
case
obstruct
probabl
associ
acut
edema
inflamm
around
bile
ductwhen
resolv
bile
duct
patenc
return
therefor
pancreat
suspect
caus
biliari
obstruct
support
care
warrant
initi
period
biochem
clinic
improv
within
week
patenc
unlik
spontan
occur
surgic
intervent
warrant
period
nutrit
support
jejunostomi
tube
feed
total
parenter
nutrit
tpn
may
requir
specif
medic
therapi
bile
duct
obstruct
caus
pancreat
surgic
treatment
usual
necessari
caus
bile
duct
obstruct
surgeri
intend
establish
patenc
extrahepat
biliari
system
intestin
procedur
use
depend
locat
obstruct
degre
distent
common
bile
duct
gallbladd
presenc
concurr
cholecyst
underli
diseas
common
procedur
perform
cholecystojejunostomi
cholecystoduodenostomi
gallbladd
infect
common
bile
duct
larg
enough
cholecystectomi
choledochoenterostomi
indic
detail
descript
procedur
beyond
scope
chapter
reader
refer
surgic
literatur
inform
recurr
cholang
andor
cholecyst
sequela
biliaryenter
anastomos
howev
seldom
clinic
problem
larg
enough
stoma
creat
clinic
sign
includ
depress
fever
vomit
empir
antibiot
administr
usual
effect
control
episod
etiolog
cholelith
rare
dog
cat
etiolog
unknown
theori
implic
bile
stasi
infect
chang
bile
composit
cholelith
dog
cat
report
contain
primarili
cholesterol
bilirubin
rel
percentag
compon
variabl
mix
stone
often
occur
addit
compon
includ
calcium
magnesium
oxal
cholelith
analyz
method
use
cystic
calculi
cholesterol
bilirubin
content
determin
clinic
find
cholelithiasi
usual
asymptomat
unless
associ
cholecyst
obstruct
bile
flow
one
report
approxim
cholelith
discov
necropsi
associ
clinic
sign
clinic
sign
present
often
intermittentwhen
cholecyst
present
often
fever
abdomin
pain
vomit
bile
duct
cystic
duct
obstruct
occur
jaundic
sign
extrahepat
biliari
obstruct
seen
physic
examin
find
usual
reflect
degre
abdomin
pain
jaundic
laboratori
find
may
normal
similar
seen
extrahepat
biliari
obstruct
includ
increas
serum
activ
hepat
enzym
bilirubin
concentr
radiograph
find
depend
whether
cholelith
calcifi
case
enough
calcium
stone
make
radiopaqu
howev
calcifi
seen
area
gallbladd
rare
area
common
bile
duct
ultrasonographi
modal
choic
detect
cholelith
gallbladd
readili
seen
ultrasonograph
examin
cholelith
appear
hyperecho
area
hypoecho
acoust
shadow
also
determin
ultrasonographi
whether
gallbladd
biliari
duct
distent
thicken
gallbladd
wall
inspiss
bile
suggest
presenc
cholecyst
treatment
surgic
intervent
usual
treatment
choic
unless
patient
asymptomat
usual
procedur
choic
cholecystectomi
especi
concurr
cholecyst
altern
cholecystotomi
stone
remov
common
bile
duct
obstruct
reliev
cholecystoenterostomi
choledochoenterostomi
necessari
surgeri
bile
cultur
aerob
anaerob
appropri
antibiot
administ
manag
concurr
cholang
cholecyst
addit
therapeut
method
use
manag
cholelith
human
includ
endoscop
remov
chemic
dissolut
extracorpor
shock
wave
lithotripsi
method
evalu
small
anim
highprotein
lowcholesterol
diet
might
help
prevent
recurr
cholecyst
rare
dog
cat
predispos
factor
includ
cholelithiasi
bile
stasi
ascend
biliari
tract
infect
bacteremia
secondari
cholang
cholecyst
cholecyst
commonli
associ
complet
partial
bile
duct
obstruct
necrot
cholecyst
often
result
either
chronic
acut
gallbladd
ruptur
secondari
bile
periton
clinic
find
mild
case
sign
may
intermitt
includ
vomit
fever
abdomin
pain
acut
necrot
cholecyst
sign
includ
vomit
anorexia
abdomin
pain
fever
mani
patient
show
sign
shock
includ
increas
heart
rate
pale
mucou
membran
poor
capillari
refil
weak
puls
gallbladd
ruptur
occur
sign
bile
septic
periton
result
laboratori
find
sever
case
includ
neutrophil
leukocytosi
left
shift
hypoproteinemia
hypoglycemia
increas
bun
concentr
chang
associ
sepsi
endotox
shock
addit
usual
increas
serum
hepat
enzym
activ
increas
serum
bilirubin
concentr
biliari
obstruct
abdomin
paracentesi
may
reveal
evid
septic
bile
periton
radiograph
find
includ
decreas
abdomin
detail
leakag
bile
periton
cholelith
present
may
seen
radiograph
calcifi
case
ga
gallbladd
emphysemat
cholecyst
gasform
organ
involv
usual
clostridium
spp
e
coli
ultrasonograph
find
includ
gallbladd
biliari
duct
distent
cholelithiasi
thicken
gallbladd
wall
inspiss
bile
treatment
mild
case
treatment
involv
appropri
antibiot
base
result
bile
cultur
patient
prognosi
fair
sever
case
includ
necrot
emphysemat
cholecyst
treatment
choic
cholecystectomi
mani
case
gallbladd
ruptur
time
surgeri
situat
cholecystectomi
explor
abdomen
stone
escap
gallbladd
requir
patenc
bile
duct
must
establish
treat
appropri
divers
procedur
necessari
case
without
gallbladd
ruptur
still
advis
remov
gallbladd
easier
treat
infect
sourc
remov
aerob
anaerob
cultur
bile
calculi
gallbladd
wall
mandatori
determin
appropri
antimicrobi
therapi
pend
cultur
result
combin
aminoglycosid
quinolon
ampicillin
recommend
one
larg
studi
common
bacteria
isol
e
coli
bacteria
cultur
includ
klebsiella
sp
clostridium
sp
pseudomona
sp
aggress
fluid
support
also
mandatori
prognosi
prognosi
guard
poor
sever
case
earli
diagnosi
surgic
intervent
key
success
therapi
death
usual
attribut
sepsi
shock
periton
stress
anesthesia
therefor
patient
show
sign
compat
cholecyst
diagnosi
aggress
pursu
serial
abdomin
paracentesi
ultrasonographi
periton
lavag
abdomin
radiographi
serial
hemogram
diagnosi
suggest
surgic
explor
delay
liver
frequent
affect
primari
metastat
neoplasia
primari
tumor
account
neoplasm
dog
metastat
tumor
occur
least
twice
frequent
primari
tumor
hepat
neoplasia
occur
less
frequent
cat
except
malign
lymphoma
myeloprolif
diseas
preval
hepat
neoplasia
cat
common
primari
hepat
neoplasm
dog
order
frequenc
hepatoma
hepatocellular
carcinoma
cholangiocarcinoma
bile
duct
carcinoma
fibroma
fibrosarcoma
hemangiomahemangiosarcoma
leiomyoma
osteosarcoma
hamartoma
common
metastat
tumor
dog
involv
liver
lymphoma
hemangiosarcoma
import
primari
site
mammari
gland
adren
gland
pancrea
bowel
bone
lung
thyroid
gland
metastasi
liver
occur
via
portal
vein
hepat
arteri
lymphat
direct
extens
spread
portal
circul
common
cat
malign
lymphoma
myeloprolif
diseas
common
metastat
tumor
nonhematopoiet
hepat
neoplasm
cat
includ
benign
bile
duct
adenoma
bile
duct
adenocarcinoma
hepatocellular
carcinoma
hepat
tumor
except
lymphoma
seen
older
patient
hepat
neoplasia
review
detail
chapter
clinic
sign
hepat
neoplasia
depend
extent
involv
mani
case
primari
neoplasia
especi
hepat
adenoma
adenocarcinoma
sign
seen
tumor
advanc
symptomat
patient
show
sign
typic
hepat
diseas
includ
anorexia
lethargi
vomit
polyuria
polydipsia
involv
biliari
system
direct
involv
cholangiocarcinoma
imping
extrahepat
bile
duct
jaundic
may
seen
mani
case
hepatomegali
detect
physic
examin
clinic
sign
metastat
neoplasia
involv
liver
tend
sever
earlier
diseas
liver
usual
affect
addit
sign
typic
hepat
failur
patient
may
also
show
sign
typic
primari
tumor
locat
treatment
hepat
neoplasia
depend
type
tumor
extent
involv
hepatoma
hepatocellular
carcinoma
grow
slowli
often
local
singl
lobe
liver
often
amen
surgic
resect
good
longterm
prognosi
liver
resect
without
signific
hepat
dysfunct
regener
usual
occur
within
week
less
commonli
hepatocellular
carcinoma
nodular
diffus
case
prognosi
poor
cholangiocarcinoma
usual
widespread
either
massiv
diffus
current
untreat
usual
rapidli
progress
highli
metastat
grave
prognosi
metastat
tumor
treatabl
chemotherapi
lymphoma
respons
tumor
chemotherapi
variou
protocol
describ
consist
variou
combin
prednison
cyclophosphamid
cytoxan
vincristin
oncovin
doxorubicin
adriamycin
lasparaginas
elspar
reader
refer
veterinari
oncolog
literatur
detail
protocol
prognosi
hepat
involv
similar
multicentr
involv
cat
welldifferenti
lymphocyt
lymphoma
liver
prognosi
better
experi
surviv
time
usual
year
longer
treat
combin
prednison
chlorambucil
leukeran
hemangiosarcoma
also
palliat
chemotherapi
use
doxorubicin
plu
dacarbazin
combin
vincristin
doxorubicin
cyclophosphamid
human
hepat
arteri
infus
chemotherapeut
agent
embol
agent
iodin
poppyse
oil
use
pump
deliveri
system
via
angiographi
procedur
efficaci
system
administr
certain
tumor
allow
higher
region
drug
concentr
method
evalu
extens
small
anim
mani
type
hepat
diseas
manag
specif
treatment
modal
exampl
disord
specif
treatment
list
tabl
addit
specif
treatment
mani
patient
hepat
diseas
requir
gener
support
care
manag
acut
chronic
aspect
derang
seen
hepat
failur
discuss
concern
therapeut
effort
common
manag
hepat
diseas
gener
refer
discuss
specif
hepat
diseas
appropri
specif
therapi
cornerston
treat
acut
hepat
failur
includ
elimin
incit
caus
drug
toxin
provid
optim
condit
hepat
regener
prevent
complic
revers
derang
occur
hepat
failur
import
derang
may
seen
includ
dehydr
hypovolemia
hepat
encephalopathi
hypoglycemia
acidbas
electrolyt
abnorm
coagulopathi
gastric
ulcer
sepsi
endotoxemia
mani
patient
sever
hepat
diseas
vomit
diarrhea
anorexia
therefor
dehydr
readili
occur
addit
patient
ascit
alreadi
use
circulatori
reserv
function
maintain
intravascular
volum
tissu
perfusionwhen
addit
fluid
loss
vomit
diarrhea
occur
hypovolem
shock
result
addit
volum
deplet
patient
frequent
electrolyt
acidbas
disturb
patient
hepat
diseas
frequent
hypokalemia
addit
total
bodi
potassium
deplet
addit
deleteri
effect
hypokalemia
contribut
greatli
sever
hepat
encephalopathi
often
potassium
supplement
make
enorm
differ
treatment
patient
common
acidbas
disturb
hepat
diseas
alkalosi
although
disturb
seen
preren
azotemia
occur
excess
urea
diffus
colon
becom
substrat
ammonia
product
thu
worsen
encephalopathi
appropri
fluid
therapi
minim
deleteri
effect
manag
derang
aggress
intraven
fluid
therapi
often
need
fluid
choic
may
determin
measur
serum
electrolyt
arteri
blood
ga
level
arteri
blood
test
avail
serum
bicarbon
concentr
estim
serum
total
co
concentr
howev
valu
usual
avail
immedi
gener
fluid
choic
halfstrength
salin
dextros
supplement
potassium
chlorid
potassium
chlorid
ad
rate
meql
fluid
serum
potassium
concentr
known
time
concentr
adjust
ringer
solut
normal
salin
accept
altern
higher
sodium
content
make
less
desir
mani
patient
hepat
diseas
excess
sodium
retent
administr
exacerb
ascit
lactat
ringer
solut
avoid
lactat
must
convert
bicarbon
liver
care
must
also
taken
administ
fluid
aggress
patient
hepat
diseas
effici
excret
salt
water
load
respons
volum
expans
thu
exacerb
ascit
portal
hypertens
diuret
furosemid
given
caution
exacerb
hypovolemia
preren
azotemia
hypokalemia
metabol
alkalosi
approach
manag
acut
hepat
encephalopathi
involv
reduc
format
absorpt
encephalopath
toxin
intestin
tract
avoid
drug
exacerb
encephalopathi
eg
tranquil
anticonvuls
anesthet
control
gi
hemorrhag
appropri
dietari
manag
factor
precipit
metabol
chang
lead
encephalopathi
list
box
factor
must
avoid
treat
possibl
decreas
encephalopath
toxin
therapeut
effort
design
reduc
format
absorpt
encephalopath
toxin
primarili
direct
toward
reduc
ammonia
absorpt
although
encephalopath
toxin
also
import
includ
benzodiazepinelik
chapter
diseas
liver
hepatobiliari
system
substanc
mercaptan
shortchain
fatti
acid
aromat
amino
acid
ammonia
produc
primarili
colon
bacteri
action
dietari
amin
protein
urea
diffus
system
circul
colon
effort
lower
blood
ammonia
concentr
aim
interrupt
process
done
sever
way
first
food
withheld
initi
prevent
dietari
protein
reach
colon
addit
largevolum
mllb
bodi
weight
cleans
enema
use
decreas
bacteri
number
enema
solut
compos
normal
salin
solut
betadin
solut
ad
make
solut
decreas
colon
bacteri
number
altern
gentamicin
ad
mglb
bodi
weight
salin
solut
kill
ureaseproduc
bacteria
salin
also
advantag
lower
colon
ph
effect
convert
freeli
absorb
ammonia
nh
nonabsorb
ammonium
ion
nh
enema
retain
long
possibl
repeat
often
everi
hour
necessari
manag
neurolog
manifest
encephalopathi
hepat
coma
lactulos
cephulac
administr
anoth
use
adjunct
decreas
ammonia
absorpt
lactulos
disaccharid
undergo
minim
absorpt
stomach
small
intestin
reach
colon
unchang
metabol
bacteria
result
format
low
molecular
weight
acid
acidifi
colon
content
effect
convert
ammonia
nh
ammonium
ion
nh
thu
trap
colon
prevent
absorpt
addit
metabol
byproduct
lactulos
induc
osmot
catharsi
therefor
lower
colon
bacteri
number
initi
dose
lactulos
mllb
bodi
weight
given
sever
rout
oral
rout
prefer
stupor
patient
administ
via
orogastr
tube
altern
given
mix
salin
enema
consciou
patient
liquid
given
oral
syring
acut
situat
given
everi
hour
longterm
manag
chronic
hepat
encephalopathi
given
dose
oral
three
time
day
dose
titrat
note
consist
fece
excess
amount
lactulos
caus
diarrhea
ideal
fece
loos
slightli
liquid
oral
administ
antibiot
also
help
decreas
colon
bacteri
number
ammoniagener
bacteria
colon
primarili
gramneg
anaerob
appropri
antibiot
includ
oral
fluoroquinolon
aminoglycosid
undergo
minim
intestin
absorpt
plu
metronidazol
flagyl
ampicillin
amoxicillinclavulan
clavamox
also
good
choic
singl
agent
first
choic
either
amoxicillinclavulan
alon
combin
fluoroquinolon
ampicillin
aminoglycosid
use
success
oral
administ
gentamicin
use
inject
product
given
oral
dosag
mglb
bodi
weight
three
time
day
neomycin
mglb
bodi
weight
three
time
day
although
latter
accept
altern
metronidazol
given
dosag
mglb
bodi
weight
two
three
time
day
drug
also
system
absorb
may
use
anaerob
sepsi
occur
hepat
failur
abnorm
hepat
reticuloendotheli
cell
function
result
decreas
clearanc
bacteria
absorb
portal
circul
drug
exacerb
encephalopathi
drug
depress
cn
avoid
potenti
exacerb
hepat
encephalopathi
patient
increas
cerebr
sensit
cn
depress
addit
drug
clear
liver
prolong
activ
result
decreas
hepat
clearanc
analges
tranquil
sed
anesthet
barbitur
avoid
possibl
sedat
necessari
drug
use
decreas
dosag
convuls
state
present
diazepam
safest
drug
use
control
seizur
activ
analgesia
requir
fewest
problem
meperidin
demerol
drug
use
lower
dose
patient
normal
hepat
function
control
gastrointestin
hemorrhag
gi
hemorrhag
must
also
control
patient
hepat
diseas
prone
gi
hemorrhag
gastrin
concentr
may
increas
due
decreas
hepat
clearanc
increas
secret
stimul
excess
bile
acid
result
gastric
hyperacid
microthrombi
mucos
microcircul
dic
present
result
inabl
handl
backdiffus
hydrogen
ion
addit
patient
hepat
diseas
often
coagulopathi
exacerb
bleed
tendenc
result
gi
hemorrhag
increas
ammonia
product
blood
substrat
bacteri
convers
ammonia
ml
blood
yield
g
protein
addit
gi
hemorrhag
lead
hypovolemia
shock
hypoxia
effect
also
exacerb
encephalopathi
discuss
bland
diet
minim
residu
help
minim
potenti
inflamm
bowel
addit
specif
drug
therapi
indic
includ
drug
inhibit
gastric
acid
secret
drug
choic
histamin
h
receptor
antagonist
drug
includ
ranitidin
zantac
famotidin
pepcid
cimetidin
tagamet
prefer
use
ranitidin
parenter
dosag
mglb
bodi
weight
two
time
day
subcutan
intramuscularli
acut
stage
wherea
drug
administ
oral
dosag
frequenc
chronic
mainten
cat
oral
famotidin
mg
one
two
time
day
best
choic
dose
cimetidin
mglb
bodi
weight
four
time
day
intraven
subcutan
intramuscularli
oral
also
frequent
combin
ranitidin
sucralf
caraf
latter
drug
local
protect
effect
site
gi
eros
ulcer
form
complex
protein
ulcer
crater
provid
barrier
penetr
gastric
acid
addit
recent
evid
demonstr
protect
effect
normal
gastric
mucosa
stimul
product
protect
prostaglandin
e
stimul
normal
epitheli
cell
turnov
protect
effect
sucralf
given
dosag
g
oral
three
four
time
day
wide
safeti
margin
absorb
dose
cat
g
oral
three
four
time
day
anoth
drug
might
potenti
manag
gi
ulcer
misoprostol
cytotec
synthet
prostaglandin
e
analogu
approv
use
human
also
undergon
clinic
evalu
veterinari
medicin
prophylact
agent
nsaidinduc
ulcer
act
stabil
protect
mucou
layer
stomach
increas
epitheli
cell
turnov
inhibit
gastric
acid
secret
use
limit
basi
dosag
bodi
weight
oral
three
four
time
day
dog
therapeut
trial
need
defin
role
manag
gi
hemorrhag
anim
hepat
diseas
import
note
blood
transfus
avoid
unless
absolut
necessari
red
blood
cell
high
ammonia
content
blood
store
ammonia
releas
storag
blood
day
result
elabor
ammonia
per
ml
blood
day
per
ml
day
per
ml
uncommon
see
clinic
deterior
shortli
blood
administ
patient
hepat
failur
blood
administr
necessari
freshli
collect
blood
must
use
ideal
plastic
blood
collect
bag
use
platelet
stick
glass
glass
activ
factor
xii
exacerb
dic
dietari
manag
dietari
manag
import
acut
chronic
stage
hepat
failur
acut
stage
food
restrict
import
minim
dietari
substrat
ammonia
product
colon
encephalopath
patient
anorect
problem
acut
encephalopathi
control
dietari
manag
import
involv
protein
restrict
small
frequent
meal
care
select
ingredi
diet
factor
discuss
detail
section
manag
chronic
hepat
diseas
mani
patient
sever
hepat
failur
hypoglycem
inadequ
gluconeogen
enzym
deplet
glycogen
store
hypoglycemia
significantli
worsen
hepat
encephalopathi
addit
deleteri
effect
shown
hypoglycemia
accur
predictor
earli
death
patient
hepat
glucos
supplement
correct
hypoglycemia
prevent
catabol
process
may
lower
cn
blood
ammonia
concentr
usual
easi
restor
normal
blood
glucos
concentr
intraven
glucos
supplement
patient
hepat
failur
wherea
difficult
maintain
euglycemia
caus
hypoglycemia
insulinproduc
tumor
glucos
suppli
intraven
fluid
concentr
rare
higher
glucos
concentr
necessari
maintain
euglycemia
caus
coagulopathi
associ
sever
hepat
diseas
numer
see
section
pathophysiolog
derang
occur
hepat
diseas
appropri
manag
depend
identifi
caus
common
coagulopathi
seen
dic
appropri
treatment
includ
aggress
intraven
fluid
maintain
tissu
perfus
treatment
underli
hepatopathi
possibl
addit
treatment
measur
includ
inhibit
platelet
function
aspirin
clot
factor
antithrombin
iii
replac
fresh
whole
blood
transfus
collect
plastic
collect
bag
prevent
activ
factor
xii
along
heparin
therapi
unitslb
bodi
weight
subcutan
three
time
day
heparin
also
ad
transfus
blood
concentr
ml
blood
activ
antithrombin
iii
antithrombin
iii
deplet
suppli
form
fresh
blood
transfus
heparin
therapi
deleteri
caus
coagulopathi
abnorm
clot
factor
product
fresh
whole
blood
plasma
transfus
indic
mention
store
blood
avoid
due
high
ammonia
content
instanc
vitamin
k
defici
caus
abnorm
clot
abil
correct
administ
vitamin
k
oral
subcutan
even
correct
abnorm
clot
time
therapeut
measur
littl
harm
sometim
worth
tri
patient
sever
hepat
diseas
prone
system
hepat
infect
due
abnorm
hepat
reticuloendotheli
cell
function
liver
respons
clear
bacteri
product
portal
blood
therapi
direct
primarili
intestin
flora
main
concern
gramneg
enter
bacteria
anaerob
well
endotoxin
sepsi
strongli
suspect
multipl
blood
cultur
aerob
anaerob
indic
hepat
biopsi
perform
cultur
specimen
alway
obtain
organ
cultur
appropri
antibiot
therapi
employ
otherwis
patient
place
antibiot
empir
patient
sever
hepat
diseas
prophylact
antibiot
indic
appropri
choic
empir
antibiot
use
base
activ
intestin
flora
degre
hepat
clearanc
toxic
drug
requir
hepat
inactiv
avoid
wherea
drug
excret
liver
benefici
although
must
use
caution
drug
good
activ
anaerob
includ
metronidazol
mglb
bodi
weight
two
three
time
day
penicillin
cephalosporin
often
drug
combin
quinolon
aminoglycosid
gentamicin
combat
gramneg
organ
drug
given
system
septicemia
oral
kill
intestin
bacteria
aminoglycosid
absorb
given
rout
oral
amoxicillinclavulan
clavamox
good
broadspectrum
singleag
antibiot
tetracyclin
concentr
bile
may
use
biliari
tract
infect
howev
use
caution
avoid
excess
blood
level
toxic
quinolon
antibiot
enrofloxacin
orbifloxacin
marbofloxacin
also
promis
use
hepat
diseas
excel
activ
aerob
intestin
flora
reach
high
concentr
liver
antibiot
avoid
includ
chloramphenicol
lincomycin
sulfonamid
erythromycin
clindamycin
chlortetracyclin
hetacillin
drug
either
inactiv
liver
requir
hepat
metabol
caus
hepatotox
method
use
control
endotoxin
absorpt
includ
nonabsorb
oral
administ
antibiot
aminoglycosid
cholestyramin
latter
drug
bind
bile
acid
endotoxin
prevent
absorpt
portal
circul
addit
therapeut
measur
treat
acut
hepat
coma
includ
intraven
administr
branchedchain
amino
acid
amino
acid
derang
mainli
increas
aromat
amino
acid
contribut
hepat
encephalopathi
normal
amino
acid
ratio
may
help
administ
branchedchain
amino
acid
fewer
aromat
amino
acid
enter
cn
compet
common
carrier
get
across
bloodbrain
barrier
howev
conflict
evid
effect
manag
hepat
coma
high
cost
solut
also
limit
use
use
convent
amino
acid
solut
protein
hydrolys
avoid
use
solut
lead
high
serum
ammonia
concentr
use
dopamin
agonist
ldopa
also
propos
treat
acut
hepat
coma
thought
similar
drug
act
favor
alter
neutrotransmitt
concentr
brain
use
benzodiazepinereceptor
antagonist
flumazenil
also
suggest
manag
patient
hepat
encephalopathi
elev
activ
inhibitori
neurotransmitt
gammaaminobutyr
acid
gaba
seem
mediat
increas
brain
concentr
benzodiazepinereceptor
agonist
patient
hepat
encephalopathi
clinic
trial
dog
hepat
coma
need
drug
recommend
routin
clinic
use
specif
diseas
identifi
hepat
biopsi
specif
therapi
institut
possibl
see
tabl
howev
support
care
necessari
treat
patient
acut
chronic
phase
hepat
diseas
often
ongo
care
essenti
mani
hepat
diseas
readili
revers
progress
addit
long
time
often
requir
definit
therapi
effect
goal
therapi
chronic
hepat
diseas
slow
progress
diseas
amelior
exist
clinic
sign
hepat
encephalopathi
support
hepat
regener
reduc
need
specif
hepat
function
nutrit
therapi
repres
cornerston
longterm
manag
chronic
hepat
diseas
effect
way
minim
sign
hepat
encephalopathi
basi
recommend
stem
knowledg
pathophysiolog
hepat
encephalopathi
limit
dietari
protein
concentr
one
import
aspect
appropri
diet
ammonia
produc
colon
bacteri
action
dietari
peptid
lowprotein
diet
decreas
substrat
ammonia
product
ideal
protein
sourc
high
biolog
valu
high
digest
featur
minim
amount
protein
reach
colon
allow
protein
absorb
use
bodi
synthet
function
recommend
g
protein
fed
per
kcal
littl
protein
fed
enough
nitrogen
liver
synthet
function
includ
synthesi
albumin
clot
factor
addit
protein
defici
caus
catabol
bodi
protein
lead
neg
nitrogen
balanc
cachect
state
also
result
excess
ammonia
product
also
necessari
suppli
adequ
amount
nonprotein
calori
support
protein
synthesi
decreas
gluconeogenesi
bodi
protein
catabol
addit
quantiti
protein
help
feed
protein
sourc
high
branchedchain
amino
acid
low
aromat
amino
acid
amino
acid
derang
especi
high
concentr
aromat
amino
acid
contribut
pathogenesi
hepat
encephalopathi
milk
protein
higher
branchedchain
amino
acid
lower
aromat
amino
acid
meat
sourc
thu
prefer
protein
sourc
fish
protein
intermedi
amino
acid
concentr
red
meat
avoid
protein
sourc
like
precipit
encephalopathi
result
term
meat
intox
hepat
encephalopathi
dog
experiment
produc
hepat
failur
better
fed
milk
protein
fed
protein
sourc
also
seen
clinic
improv
cottag
chees
main
protein
sourc
compar
commerci
lowprotein
diet
kd
ud
prescript
diet
hill
pet
product
research
describ
two
appropri
homemad
diet
addit
lowprotein
diet
cottag
chees
main
protein
sourc
list
box
commerci
diet
use
dri
prescript
diet
hill
pet
product
prefer
altern
variou
diet
intend
renal
failur
accept
easili
digest
carbohydr
major
sourc
energi
rice
highli
digest
carbohydr
sourc
therefor
prefer
nutrient
regard
potato
accept
altern
increas
intestin
bacteri
number
result
poorli
digest
carbohydr
sourc
bacteri
growth
colon
support
ferment
polysaccharid
foodstuff
absorb
small
intestin
result
increas
ammonia
product
feed
lowresidu
diet
see
box
also
minim
turnov
epitheli
cell
major
sourc
nitrogen
colon
mention
earlier
provid
adequ
calori
carbohydr
minim
catabol
bodi
protein
amino
acid
meet
energi
need
addit
profound
neg
energi
balanc
incit
factor
develop
felin
hepat
lipidosi
free
fatti
acid
encephalopath
toxin
dietari
effort
made
decreas
format
absorpt
dietari
fat
sourc
shortchain
fatti
acid
may
exacerb
encephalopathi
rather
microbi
ferment
bowel
carbohydr
lesser
extent
amino
acid
lead
product
shortchain
fatti
acid
underscor
need
highli
digest
diet
fat
need
diet
provid
essenti
fatti
acid
addit
valu
energi
sourc
nonprotein
calori
fat
enhanc
palat
diet
fat
malabsorpt
steatorrhea
fatsolubl
vitamin
malabsorpt
seldom
clinic
problem
except
case
prolong
bile
duct
obstructionvitamin
therapi
see
follow
discuss
often
help
howev
final
fast
mobil
fatti
acid
bodi
therefor
frequent
meal
help
certain
b
vitamin
convert
activ
form
store
liver
therefor
supplement
goodqual
multipl
vitamin
prepar
help
fatsolubl
vitamin
requir
normal
bile
secret
absorpt
howev
rare
get
malabsorpt
fatsolubl
vitamin
unless
prolong
bile
duct
obstruct
intestin
bacteria
produc
vitamin
k
prolong
antibiot
use
result
malabsorpt
vitamin
vitamin
c
ascorb
acid
supplement
also
recommend
liver
produc
import
part
dog
daili
requir
ascorb
acid
dog
experiment
induc
hepat
diseas
mark
decreas
ascorb
acid
concentr
low
normal
supplement
ascorb
acid
also
increas
copper
excret
urin
copper
accumul
hepatocyt
cholestat
disord
primari
copperstorag
diseas
presenc
toxic
hepatocyt
therefor
ascorb
acid
given
dosag
mglb
bodi
weight
per
day
maintain
normal
plasma
concentr
potassium
supplement
also
help
case
chronic
hepat
diseas
mani
patient
hypokalem
sign
hepat
encephalopathi
exacerb
hypokalemia
supplement
frequent
improv
clinic
sign
serum
potassium
concentr
measur
necessari
determin
whether
supplement
necessari
potassium
chlorid
tablet
granul
tumilk
given
elixir
meqml
given
dosag
mllb
bodi
weight
three
time
day
miner
harm
avoid
copper
hepatotox
accumul
liver
patient
hepat
diseas
therefor
copperfre
vitamin
prepar
use
zinc
inhibit
absorpt
copper
deposit
liver
therefor
supplement
zinc
recommend
certain
hepat
diseas
dosag
mglb
bodi
weight
three
time
day
zinc
glucon
mglb
bodi
weight
three
time
day
zinc
sulfat
sodium
retent
frequent
problem
chronic
hepat
diseas
lead
presenc
chapter
diseas
liver
hepatobiliari
system
oz
cottag
chees
cook
meat
cottag
chees
consum
cup
cook
rice
potato
cup
cook
green
bean
tbsp
corn
oil
tsp
calcium
phosphat
saltfre
copperfre
vitaminminer
suppl
ment
ascorb
acid
see
text
zinc
glucon
sulfat
see
text
flavor
salt
substitut
onion
garlic
powder
ascit
therefor
lowsodium
diet
recommend
see
box
lipotroph
agent
contain
methionin
administ
amino
acid
precursor
mercaptan
group
potent
encephalopath
toxin
methionin
administr
significantli
worsen
sign
encephalopathi
therefor
lipotroph
drug
contain
methionin
place
manag
hepat
diseas
contraind
summari
nutrit
manag
summari
nutrit
manag
chronic
hepat
diseas
includ
follow
consider
calori
protein
moder
restrict
ingredi
high
biolog
valu
highli
digest
use
protein
sourc
high
branchedchainaromat
amino
acid
ratio
prefer
cottag
chees
ideal
protein
sourc
regard
palat
energydens
diet
amount
suffici
meet
energi
need
necessari
avoid
neg
energi
balanc
carbohydr
suppli
nonprotein
calori
highli
digest
sourc
sodium
copper
restrict
supplement
zinc
ascorb
acid
saltand
copperfre
vitaminminer
supplement
may
help
consider
must
present
highli
digest
lowresidu
diet
fed
small
frequent
meal
previous
discuss
lactulos
effect
decreas
ammonia
absorpt
decreas
colon
bacteri
number
lower
colon
ph
chronic
administr
lactulos
given
initi
dosag
mllb
bodi
weight
three
time
day
dosag
titrat
yield
two
three
loos
slightli
liquid
bowel
movement
per
day
oral
antibiot
also
decreas
ammonia
absorpt
decreas
colon
bacteri
number
presenc
activ
inflamm
fibrosi
patient
hepat
diseas
may
justifi
use
glucocorticoid
antifibrot
drug
colchicin
dpenicillamin
see
section
treatment
chronic
activ
hepat
detail
discuss
drug
ascit
import
complic
chronic
hepat
diseas
see
section
pathophysiolog
derang
occur
hepat
diseas
detail
discuss
pathogenesi
ascit
emerg
treatment
ascit
rare
necessari
occasion
howev
volum
ascit
fluid
high
enough
result
respiratori
distress
compress
diaphragm
limit
inspiratori
effort
patient
paracentesi
may
help
reason
withdraw
fluid
abdomin
caviti
make
easier
perform
percutan
hepat
biopsi
laparoscopi
abdomin
radiograph
diagnost
fluid
analysi
cytolog
examin
otherwis
paracentesi
therapeut
valu
risk
paracentesi
hypovolem
shock
iatrogen
infect
protein
deplet
perfor
abdomin
viscera
patient
ascit
alreadi
use
maximum
cardiac
circulatori
reserv
maintain
tissu
perfus
larg
volum
fluid
rapidli
remov
fluid
shift
intravascular
extravascular
compart
precipit
hypovolem
shock
although
rare
experi
recommend
paracentesi
necessari
fluid
withdrawn
slowli
intraven
fluid
support
avail
necessari
dietari
salt
restrict
diuret
aldosteroneinhibit
drug
use
longterm
control
ascit
diuret
administ
caution
avoid
dehydr
patient
hepat
failur
alreadi
use
maximum
circulatori
cardiac
reserv
maintain
perfus
ascit
present
one
main
caus
sodium
retent
patient
hepat
diseas
excess
aldosteron
activ
aldosteroneinhibit
drug
use
first
recommend
spironolacton
dosag
mglb
bodi
weight
two
time
day
initi
dose
ineffect
doubl
mglb
bodi
weight
two
time
day
spironolacton
also
exacerb
hypokalemia
loop
diuret
furosemid
lasix
also
effect
furosemid
use
caution
caus
excess
urinari
fluid
loss
result
hypovolemia
improv
ascit
also
exacerb
hypokalemia
alkalosi
furosemid
use
dosag
mglb
bodi
weight
two
three
time
day
serum
electrolyt
must
measur
period
addit
clinic
assess
ascit
persist
enalapril
benazepril
ad
dosag
mglb
one
two
time
day
drug
angiotensinconvert
enzym
ace
inhibitor
decreas
activ
reninangiotensinaldosteron
system
dietari
salt
restrict
prime
import
minim
sodium
retent
appropri
lowsalt
diet
includ
list
box
refer
prescript
diet
hill
pet
product
